ketamine has been researched along with Refractory Depression in 539 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 9.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| " We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD)." | 9.69 | Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. ( Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F, 2023) |
| "Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression." | 9.69 | Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. ( Achtyes, E; Ahearn, E; Frye, M; Goes, FS; Greden, J; Lapidos, A; Lopez-Vives, D; Parikh, SV; Senic, I; Sera, CE; Vande Voort, JL; Vest, E, 2023) |
| "To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities." | 9.69 | Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. ( Ahmed, GK; Ali, MA; Elfadl, GMA; Elserogy, YM; Ghada Abdelsalam, K, 2023) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 9.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD)." | 9.69 | Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. ( Al-Sharif, NB; Espinoza, RT; Joshi, SH; Khalil, J; McClintock, SM; Narr, KL; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD)." | 9.69 | Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. ( Amarneh, D; Averill, LA; Iqbal, S; Lijffijt, M; Mathew, SJ; Murphy, N; O'Brien, B; Swann, A; Tamman, AJF, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 9.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 9.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8." | 9.69 | Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. ( Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH, 2023) |
| "Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD)." | 9.51 | Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| "The objective of this analysis was to determine if there are sex differences with esketamine for treatment-resistant depression (TRD)." | 9.51 | Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. ( Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 9.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "Derive and confirm factor structure of the Montgomery-Åsberg Depression Rating Scale (MADRS) in patients with treatment-resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment." | 9.51 | Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. ( Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 9.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| "Whether the antidepressant effects of low-dose ketamine infusion and the therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary across different depression symptom domains, namely affective, cognitive, and somatic, remains unclear." | 9.41 | Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 9.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| "A total of 78 patients with medication-resistant depression were allocated to receive two ketamine infusions (n = 30; days 1 and 4), a single ketamine infusion (n = 24; only day 1), or normal saline placebo infusion (n = 24; only day 1)." | 9.41 | Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Although results are still preliminary, ketamine and classical hallucinogens have shown promise in recent years as novel, fast-acting antidepressants, especially for the treatment of unipolar treatment-resistant depression (TRD)." | 9.41 | The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. ( Baker, G; Dos Santos, RG; Dursun, SM; Hallak, JEC; Rossi, GN, 2023) |
| "Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression." | 9.41 | Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. ( Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F, 2021) |
| "This study aimed to assess the effect of a single infusion of intravenous (IV) ketamine on suicidal ideation in patients with treatment-resistant depression (TRD)." | 9.41 | The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. ( Debattista, C; Fava, M; Feeney, A; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Sanacora, G; Trivedi, MH, 2021) |
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 9.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "Repeated administration of subanesthetic intravenous ketamine may prolong the rapid decrease in suicidal ideation (SI) elicited by single infusions." | 9.34 | Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. ( Batten, LA; Birmingham, M; Blier, P; Hatchard, T; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J, 2020) |
| "Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression." | 9.34 | Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. ( Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F, 2020) |
| "The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine." | 9.34 | A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, S; Wels, J, 2020) |
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 9.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "Twenty-six medicated outpatients with severe major depressive disorder with current, chronic suicidal ideation were randomized in a double-blind fashion to six ketamine infusions (0." | 9.30 | Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. ( Akeju, O; Alpert, JE; Baer, L; Bentley, KH; Brown, EN; Cusin, C; Dording, C; Eikermann, M; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Pavone, KJ; Petrie, SR; Swee, MB; Taylor, N, 2019) |
| "Compared to placebo, ketamine significantly improved fatigue (p = ." | 9.30 | Disentangling the association of depression on the anti-fatigue effects of ketamine. ( Ballard, ED; Farmer, C; Kadriu, B; Saligan, LN; Zarate, CA, 2019) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 9.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| "Adults meeting criteria for treatment-resistant depression undergoing index course ECT received either methohexital (1 to 2 mg/kg) or ketamine (1 to 2 mg/kg) anesthesia in this dual-arm double-blinded randomized clinical trial (NCT02752724)." | 9.27 | Ketamine Anesthesia Does Not Improve Depression Scores in Electroconvulsive Therapy: A Randomized Clinical Trial. ( Borisovskaya, A; Buchholz, J; Carspecken, CW; Heller, K; Lan, ST; Rozet, I; Ruskin, D, 2018) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 9.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| " Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019." | 9.22 | Long-term safety of ketamine and esketamine in treatment of depression. ( Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST, 2022) |
| "Ketamine is a promising therapeutic option in treatment-resistant depression (TRD)." | 9.22 | Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. ( Alnefeesi, Y; Cao, B; Ceban, F; Chen-Li, D; Di Vincenzo, JD; Gill, H; Ho, RCM; Jawad, MY; Krane, E; Lee, Y; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "Ketamine has demonstrated rapid and significant antidepressant effects in patients with treatment resistant depression (TRD)." | 9.22 | The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. ( Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment-psilocybin and esketamine." | 9.22 | Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. ( Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U, 2022) |
| "Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression." | 9.22 | Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. ( Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Spijker, J; Veraart, JK, 2022) |
| "A linear mixed model showed that ketamine significantly lowered fatigue scores compared to placebo from 40 min post-treatment to Day 14 with the exception of Day 7." | 9.22 | An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. ( Luckenbaugh, DA; Machado-Vieira, R; Saligan, LN; Slonena, EE; Zarate, CA, 2016) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 9.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| "Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration." | 9.12 | Ketamine for depression. ( Jelen, LA; Stone, JM, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 9.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD)." | 9.12 | The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. ( Cao, B; Di Vincenzo, JD; Gill, H; Ho, R; Lin, K; Lipsitz, O; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, A; Teopiz, KM, 2021) |
| "Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD)." | 9.12 | Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. ( Cao, B; Cha, DS; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Lui, LMW; McIntyre, RS; McMullen, EP; Rodrigues, NB; Rosenblat, JD; Teopiz, KM; Vinberg, M, 2021) |
| "In recent years, ketamine and esketamine treatment have demonstrated rapid antidepressant effects in adults with treatment-resistant depression (TRD)." | 9.12 | Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. ( Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service." | 9.12 | Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. ( Achtyes, E; Bobo, WV; Coryell, W; Drake, K; Frye, MA; Goddard, A; Goes, F; Greden, JF; Kaplin, A; Lopez, D; Maixner, D; Parikh, SV; Rico, J; Riva-Posse, P; Singh, B; Tarnal, V; Vande Voort, JL; Watson, B, 2021) |
| "Ketamine may reduce suicidal ideation in treatment-resistant depression." | 9.05 | Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. ( Cipriani, A; Grunebaum, MF; Hawton, K; Hubers, A; Loo, C; Murrough, JW; Potts, J; Witt, K, 2020) |
| "Ketamine is an anaesthetic and analgesic agent that demonstrates the antidepressive effect in major depression." | 9.01 | Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. ( Cubała, WJ; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression." | 8.95 | Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. ( Curran, V; McShane, R; Morgan, C; Nutt, D; Schlag, A; Singh, I, 2017) |
| "Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment." | 8.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| " This article examines the advantages and applications of INDD in neuropsychiatry; provides examples of test, experimental, and approved INDD treatments; and focuses especially on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression." | 8.91 | Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. ( Andrade, C, 2015) |
| "The antidepressant effects of ketamine in patients with anxious depression (AD) remain unclear." | 8.31 | Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 8.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| "Ketamine may work as an anti-inflammatory agent, and it increases the levels of vascular endothelial growth factor (VEGF) in patients with treatment-resistant depression." | 8.31 | Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Kao, CF; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 8.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 8.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 8.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| "Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality." | 8.31 | Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. ( Arekapudi, A; Chau, E; Chisamore, N; Danayan, K; Di Vincenzo, JD; Doyle, Z; Fancy, F; Kratiuk, K; Mansur, R; McIntyre, RS; Meshkat, S; Phan, L; Rodrigues, NB; Rosenblat, JD; Tabassum, A, 2023) |
| "Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression." | 8.31 | Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. ( Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E, 2023) |
| "We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs)." | 8.31 | Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. ( Dinh-Williams, LL; Garel, N; Greenway, KT; Jutras-Aswad, D; Rej, S; Richard-Devantoy, S; Thibault-Levesque, J; Turecki, G, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 8.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| "Whether a single low-dose ketamine infusion may have rapid antidepressant and antisuicidal effects in patients with treatment-resistant double depression remains unclear." | 8.12 | Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 8.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| "In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)-short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)-were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK." | 8.12 | Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. ( Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y, 2022) |
| "Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019." | 8.12 | Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. ( Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J, 2022) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 8.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated." | 8.12 | The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Zheng, W; Zhou, Y, 2022) |
| "Intranasal esketamine has been recently approved for the treatment of resistant depression." | 8.12 | Intranasal esketamine for depression: Not so special K. ( Rosenman, S, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 8.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 8.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 8.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 8.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 8.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 8.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 8.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine's antidepressant actions in rodent models at sub-therapeutic doses." | 8.02 | Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression. ( Butters, K; Frye, MA; McGee, SL; Morath, BA; Price, JB; Tye, SJ; Van De Wakker, SK; Yates, CG; Yates, NJ, 2021) |
| "Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry." | 8.02 | [Ketamine infusion therapy in treatment-resistant depression]. ( Christodoulakis, ΤΕ, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 8.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 8.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 8.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 8.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 8.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 8.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 8.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 8.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine is a novel, rapid-acting antidepressant for treatment refractory depression (TRD); however, clinical durability is poor and treatment response trajectories vary." | 8.02 | Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression. ( Badathala, A; Fryer, SL; Marton, TF; Mathalon, DH; Pennybaker, S; Roach, BJ; Wallace, AW, 2021) |
| "Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression." | 8.02 | Ketamine treatment for depression: A model of care. ( Alonzo, A; Bayes, A; Dong, V; Kabourakis, M; Loo, C; Martin, D, 2021) |
| "Some patients with refractory depression who fail to respond to rapid injection of standard-dose ketamine are injected with high doses, but the safety and efficacy of this practice are unclear." | 7.96 | Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement. ( Fang, J; Li, Z; Su, B; Wang, L; Wang, M; Xiong, Z; Yang, Y, 2020) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 7.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 7.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 7.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 7.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term." | 7.91 | Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic. ( Brand, F; Hawton, K; Lascelles, K; Marzano, L; McShane, R; Trueman, H, 2019) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 7.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults." | 7.91 | Esketamine for treatment resistant depression: a trick of smoke and mirrors? ( Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D, 2019) |
| " Fifteen patients (group 1) received only thiopental anesthesia, 15 patients (group 2) had their second and third ECT sessions with ketamine, and 15 patients (group 3) had ketamine for the second, fourth, sixth, eighth, and tenth sessions." | 7.83 | Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression. ( Bartkowska-Sniatkowska, A; Bodnar, A; Chlopocka-Wozniak, M; Krzywotulski, M; Michalak, M; Rosada-Kurasinska, J; Rybakowski, JK, 2016) |
| "In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients." | 7.83 | Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. ( Akeju, O; Alpert, JE; Baer, L; Brown, EN; Cassano, P; Cusin, C; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Nyer, M; Pavone, KJ; Swee, MB; Taylor, N, 2016) |
| "For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach." | 7.30 | Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. ( Desbeaumes Jodoin, V; Elkrief, L; Garel, N; Lespérance, P; Longpré-Poirier, C; Miron, JP; Payette, O; Richard, M, 2023) |
| "Forty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0." | 7.30 | Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain." | 7.01 | Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. ( Chao, Z; Lan, X; Li, H; Ning, Y; Wang, C; Zhou, Y, 2021) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 6.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia." | 6.82 | The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. ( Ceban, F; Ho, R; Jasrai, AK; Kim, H; Lui, LMW; McIntyre, RS; Nasri, F; Nogo, D; Rosenblat, JD; Vinberg, M, 2022) |
| " Finally, continuing to monitor research subjects and patients long-term for the emergence of adverse effects on cognition or other organ systems is critical." | 6.82 | Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. ( Kritzer, MD; Masand, PS; Pae, CU, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 6.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 6.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "Ketamine has demonstrated efficacy as a rapid-onset intervention for the treatment of depression." | 6.72 | The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. ( El-Halabi, S; Gill, B; Gill, H; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD, 2021) |
| "One third among them will suffer from treatment resistant depression (TRD) which does not respond to two accepted treatment protocols." | 6.72 | [ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. ( Marom, A; Rosca, P, 2021) |
| "Nasal esketamine spray produces the adverse effects of dizziness, vertigo, and blurred vision severe enough to cause discontinuation in 4% of patients; it also can produce transient elevation of blood pressure (SOR: A, meta-analyses)." | 6.72 | Is ketamine effective and safe for treatment-resistant depression? ( Jenkinson, M; Kelsberg, G; Linn, S; Neher, JO; Safranek, S; Zorn, A, 2021) |
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 5.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| "Ketamine PK/PD data were collected from 21 treatment-refractory depressed participants who received ketamine (dose titration 0." | 5.72 | Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression. ( Abuhelwa, AY; Barratt, DT; Foster, DJR; Glue, P; Loo, CK; Somogyi, AA, 2022) |
| "Ketamine was generally well tolerated, and we observed improvements in functional impairment, anhedonia, and psychiatric symptoms, with no increases in manic symptoms." | 5.72 | Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study. ( Kang, MJY; Vazquez, GH, 2022) |
| " We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD)." | 5.69 | Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. ( Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F, 2023) |
| "Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression." | 5.69 | Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. ( Achtyes, E; Ahearn, E; Frye, M; Goes, FS; Greden, J; Lapidos, A; Lopez-Vives, D; Parikh, SV; Senic, I; Sera, CE; Vande Voort, JL; Vest, E, 2023) |
| "To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities." | 5.69 | Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. ( Ahmed, GK; Ali, MA; Elfadl, GMA; Elserogy, YM; Ghada Abdelsalam, K, 2023) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 5.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD)." | 5.69 | Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. ( Al-Sharif, NB; Espinoza, RT; Joshi, SH; Khalil, J; McClintock, SM; Narr, KL; Taraku, B; Zavaliangos-Petropulu, A, 2023) |
| "Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD)." | 5.69 | Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. ( Amarneh, D; Averill, LA; Iqbal, S; Lijffijt, M; Mathew, SJ; Murphy, N; O'Brien, B; Swann, A; Tamman, AJF, 2023) |
| "Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear." | 5.69 | Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 5.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8." | 5.69 | Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. ( Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH, 2023) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 5.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 5.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 5.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 5.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 5.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Treatment resistant depression is a significant source of morbidity and mortality." | 5.56 | Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. ( Agapoff, JR; Goebert, D; Lu, BY; Olson, DJ; Roller, A; Williams, SR, 2020) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 5.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 5.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD)." | 5.51 | Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| "The objective of this analysis was to determine if there are sex differences with esketamine for treatment-resistant depression (TRD)." | 5.51 | Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. ( Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S, 2022) |
| "Using data from a randomized, double-blind (DB), placebo-controlled trial of esketamine (ESK) in patients with treatment-resistant depression (TRD), we conducted exploratory analyses." | 5.51 | Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. ( Kobayashi, H; Ohnishi, T; Wakamatsu, A, 2022) |
| "Derive and confirm factor structure of the Montgomery-Åsberg Depression Rating Scale (MADRS) in patients with treatment-resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment." | 5.51 | Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. ( Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D, 2022) |
| "This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD)." | 5.51 | Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies. ( Bai, YM; Chen, MH; Cheng, CM; Li, CT; Lin, WC; Su, TP; Tsai, SJ, 2022) |
| "Major depression is one of the most frequent psychiatric conditions." | 5.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "Whether the antidepressant effects of low-dose ketamine infusion and the therapeutic impact of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism vary across different depression symptom domains, namely affective, cognitive, and somatic, remains unclear." | 5.41 | Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD)." | 5.41 | Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. ( Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A, 2021) |
| "A total of 78 patients with medication-resistant depression were allocated to receive two ketamine infusions (n = 30; days 1 and 4), a single ketamine infusion (n = 24; only day 1), or normal saline placebo infusion (n = 24; only day 1)." | 5.41 | Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Although results are still preliminary, ketamine and classical hallucinogens have shown promise in recent years as novel, fast-acting antidepressants, especially for the treatment of unipolar treatment-resistant depression (TRD)." | 5.41 | The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. ( Baker, G; Dos Santos, RG; Dursun, SM; Hallak, JEC; Rossi, GN, 2023) |
| "Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e." | 5.41 | Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? ( d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M, 2023) |
| "Evidence suggests that clinical markers, such as comorbid anxiety, body weight, and others can assist in predicting response to low-dose ketamine infusion in treatment resistant depression patients." | 5.41 | Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Cheng, CM; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS)." | 5.41 | A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Shekotikhina, M; Subramaniapillai, M; Vinberg, M, 2021) |
| "Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression." | 5.41 | Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. ( Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F, 2021) |
| "This study aimed to assess the effect of a single infusion of intravenous (IV) ketamine on suicidal ideation in patients with treatment-resistant depression (TRD)." | 5.41 | The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. ( Debattista, C; Fava, M; Feeney, A; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Sanacora, G; Trivedi, MH, 2021) |
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 5.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "Repeated administration of subanesthetic intravenous ketamine may prolong the rapid decrease in suicidal ideation (SI) elicited by single infusions." | 5.34 | Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. ( Batten, LA; Birmingham, M; Blier, P; Hatchard, T; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J, 2020) |
| "Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression." | 5.34 | Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. ( Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F, 2020) |
| "The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine." | 5.34 | A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, S; Wels, J, 2020) |
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 5.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "Ketamine's effects on different dimensions of depressive symptomatology, including typical/melancholic and atypical depression, remain largely unknown." | 5.34 | The effects of ketamine on typical and atypical depressive symptoms. ( Ballard, ED; Henter, ID; Hopkins, MA; Kadriu, B; Lener, MS; Luckenbaugh, DA; Park, LT; Pennybaker, SJ; Zarate, CA, 2020) |
| "Twenty-six medicated outpatients with severe major depressive disorder with current, chronic suicidal ideation were randomized in a double-blind fashion to six ketamine infusions (0." | 5.30 | Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. ( Akeju, O; Alpert, JE; Baer, L; Bentley, KH; Brown, EN; Cusin, C; Dording, C; Eikermann, M; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Pavone, KJ; Petrie, SR; Swee, MB; Taylor, N, 2019) |
| "Compared to placebo, ketamine significantly improved fatigue (p = ." | 5.30 | Disentangling the association of depression on the anti-fatigue effects of ketamine. ( Ballard, ED; Farmer, C; Kadriu, B; Saligan, LN; Zarate, CA, 2019) |
| "To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD)." | 5.30 | Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2019) |
| "A single low-dose ketamine infusion was effective in reducing suicidal ideation among Taiwanese patients with TRD." | 5.30 | Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). ( Bai, YM; Chen, MH; Cheng, CM; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2019) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 5.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| "Adults meeting criteria for treatment-resistant depression undergoing index course ECT received either methohexital (1 to 2 mg/kg) or ketamine (1 to 2 mg/kg) anesthesia in this dual-arm double-blinded randomized clinical trial (NCT02752724)." | 5.27 | Ketamine Anesthesia Does Not Improve Depression Scores in Electroconvulsive Therapy: A Randomized Clinical Trial. ( Borisovskaya, A; Buchholz, J; Carspecken, CW; Heller, K; Lan, ST; Rozet, I; Ruskin, D, 2018) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 5.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| " Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019." | 5.22 | Long-term safety of ketamine and esketamine in treatment of depression. ( Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST, 2022) |
| "Ketamine is an established intervention for treatment-resistant depression (TRD)." | 5.22 | A review of potential neuropathological changes associated with ketamine. ( Ho, R; Lui, LMW; McIntyre, RS; Nazal, H; Nogo, D; Rosenblat, JD; Song, Y; Teopiz, KM, 2022) |
| "While ketamine has been used clinically over the past decades, it has only been recently shown to be a promising therapy for treatment-resistant depression (TRD)." | 5.22 | The abuse liability of ketamine: A scoping review of preclinical and clinical studies. ( Cordero, IP; Di Vincenzo, JD; Ho, R; Jaberi, S; Jawad, MY; Le, TT; Lui, LMW; McIntyre, RS; Phan, L; Rosenblat, JD; Swainson, J, 2022) |
| "Ketamine is a promising therapeutic option in treatment-resistant depression (TRD)." | 5.22 | Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. ( Alnefeesi, Y; Cao, B; Ceban, F; Chen-Li, D; Di Vincenzo, JD; Gill, H; Ho, RCM; Jawad, MY; Krane, E; Lee, Y; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "Ketamine has demonstrated rapid and significant antidepressant effects in patients with treatment resistant depression (TRD)." | 5.22 | The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. ( Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM, 2022) |
| "This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment-psilocybin and esketamine." | 5.22 | Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. ( Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U, 2022) |
| "Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression." | 5.22 | Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. ( Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Spijker, J; Veraart, JK, 2022) |
| "A linear mixed model showed that ketamine significantly lowered fatigue scores compared to placebo from 40 min post-treatment to Day 14 with the exception of Day 7." | 5.22 | An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. ( Luckenbaugh, DA; Machado-Vieira, R; Saligan, LN; Slonena, EE; Zarate, CA, 2016) |
| "Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression." | 5.22 | Continuation phase intravenous ketamine in adults with treatment-resistant depression. ( Bobo, WV; Frye, MA; Kung, S; Morgan, RJ; Palmer, BA; Rasmussen, KG; Rico, J; Ritter, MJ; Schak, KM; Tye, SJ; Vande Voort, JL, 2016) |
| "Ketamine in electroconvulsive therapy (ECT) anesthesia has been reported to be associated with better seizure quality and longer duration compared with methohexital anesthesia." | 5.17 | Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. ( Björkqvist, M; Chrapek, W; Häkkinen, H; Järventausta, K; Kampman, O; Leinonen, E; Tuohimaa, K; Yli-Hankala, A, 2013) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 5.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| "The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine, an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important breakthrough in depression research in the last 50 years." | 5.12 | Ketamine: A tale of two enantiomers. ( Jelen, LA; Stone, JM; Young, AH, 2021) |
| "Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects within hours of administration." | 5.12 | Ketamine for depression. ( Jelen, LA; Stone, JM, 2021) |
| "The approval of intranasal esketamine for treatment-resistant depression marks the next step in our understanding of and ability to treat treatment-resistant depression." | 5.12 | Intranasal esketamine: From origins to future implications in treatment-resistant depression. ( Brula, AQ; Sanders, B, 2021) |
| " Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD)." | 5.12 | The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. ( Cao, B; Di Vincenzo, JD; Gill, H; Ho, R; Lin, K; Lipsitz, O; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, A; Teopiz, KM, 2021) |
| "Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD)." | 5.12 | Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. ( Cao, B; Cha, DS; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Lui, LMW; McIntyre, RS; McMullen, EP; Rodrigues, NB; Rosenblat, JD; Teopiz, KM; Vinberg, M, 2021) |
| "In recent years, ketamine and esketamine treatment have demonstrated rapid antidepressant effects in adults with treatment-resistant depression (TRD)." | 5.12 | Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. ( Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service." | 5.12 | Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. ( Achtyes, E; Bobo, WV; Coryell, W; Drake, K; Frye, MA; Goddard, A; Goes, F; Greden, JF; Kaplin, A; Lopez, D; Maixner, D; Parikh, SV; Rico, J; Riva-Posse, P; Singh, B; Tarnal, V; Vande Voort, JL; Watson, B, 2021) |
| "Ketamine may reduce suicidal ideation in treatment-resistant depression." | 5.05 | Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. ( Cipriani, A; Grunebaum, MF; Hawton, K; Hubers, A; Loo, C; Murrough, JW; Potts, J; Witt, K, 2020) |
| "Ketamine is an anaesthetic and analgesic agent that demonstrates the antidepressive effect in major depression." | 5.01 | Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. ( Cubała, WJ; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "Large, multicenter randomized controlled trials are needed to further investigate the potential advantages of adding ketamine to ECT for patients with severe or refractory depression." | 4.98 | Ketamine and electroconvulsive therapy: so happy together? ( Cobb, K; Nanda, M, 2018) |
| "We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression." | 4.95 | Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. ( Curran, V; McShane, R; Morgan, C; Nutt, D; Schlag, A; Singh, I, 2017) |
| "Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment." | 4.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| "Available evidence indicates that a single, low-dose administration of ketamine is a robust, rapid-onset intervention capable of mitigating depressive symptoms in adults with treatment-resistant mood disorders." | 4.93 | A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. ( Cha, DS; Lee, Y; Mansur, RB; Maruschak, NA; McIntyre, RS; Rosenblat, JD; Syeda, K; Wium-Andersen, IK; Woldeyohannes, HO, 2016) |
| "Searches in PubMed with the terms 'oral ketamine', 'depression', 'chronic pain', 'neuropathic pain', 'intravenous ketamine', 'intranasal ketamine' and 'subcutaneous ketamine' yielded 88 articles." | 4.93 | Oral ketamine for the treatment of pain and treatment-resistant depression†. ( aan het Rot, M; Balukova, SM; Chaves, TV; Kortekaas, R; Schoevers, RA, 2016) |
| " After a brief description of the intracellular transduction pathways implicated in both GSK-3β and mood disorders, we reviewed the results demonstrating GSK-3β involvement in the effects of lithium and ketamine." | 4.93 | The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. ( Costemale-Lacoste, JF; Gaillard, R; Guilloux, JP, 2016) |
| " This article examines the advantages and applications of INDD in neuropsychiatry; provides examples of test, experimental, and approved INDD treatments; and focuses especially on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression." | 4.91 | Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. ( Andrade, C, 2015) |
| " ketamine; deep brain stimulation) that are reported to be effective in treatment-resistant depression and (iv) a parallel to a known clinical risk factor." | 4.91 | Treatment-resistant depression: are animal models of depression fit for purpose? ( Belzung, C; Willner, P, 2015) |
| "The electronic database Pubmed, Web of Science and sciencedirect were searched using the keywords: ketamine, N-methyl-d-aspartate receptor antagonist, rapid-acting antidepressant, depression, treatment-resistant depression, bipolar depression, suicidal ideation, electroconvulsive therapy, mechanism of action." | 4.90 | A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. ( Clarke, G; Cryan, JF; Dinan, TG; Naughton, M; O'Leary, OF, 2014) |
| "The antidepressant effects of ketamine in patients with anxious depression (AD) remain unclear." | 4.31 | Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions." | 4.31 | Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions. ( Gu, LM; Lan, XF; Ning, YP; Wang, CY; Yang, XH; Zhang, B; Zheng, W; Zhou, YL, 2023) |
| "Ketamine may work as an anti-inflammatory agent, and it increases the levels of vascular endothelial growth factor (VEGF) in patients with treatment-resistant depression." | 4.31 | Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression. ( Bai, YM; Chen, MH; Hong, CJ; Kao, CF; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC, 2023) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 4.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 4.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| "This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression." | 4.31 | A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression. ( Lan, XF; Ning, YP; Wang, CY; Zheng, W; Zhou, YL, 2023) |
| "Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality." | 4.31 | Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. ( Arekapudi, A; Chau, E; Chisamore, N; Danayan, K; Di Vincenzo, JD; Doyle, Z; Fancy, F; Kratiuk, K; Mansur, R; McIntyre, RS; Meshkat, S; Phan, L; Rodrigues, NB; Rosenblat, JD; Tabassum, A, 2023) |
| "Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression." | 4.31 | Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. ( Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E, 2023) |
| "We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs)." | 4.31 | Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. ( Dinh-Williams, LL; Garel, N; Greenway, KT; Jutras-Aswad, D; Rej, S; Richard-Devantoy, S; Thibault-Levesque, J; Turecki, G, 2023) |
| "This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD)." | 4.31 | Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? ( Anand, A; Jha, MK; Mathew, SJ, 2023) |
| "Whether a single low-dose ketamine infusion may have rapid antidepressant and antisuicidal effects in patients with treatment-resistant double depression remains unclear." | 4.12 | Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. ( Bai, YM; Chen, MH; Hong, CJ; Li, CT; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2022) |
| " We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period." | 4.12 | Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. ( Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G, 2022) |
| "In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)-short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)-were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK." | 4.12 | Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. ( Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y, 2022) |
| "Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019." | 4.12 | Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. ( Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J, 2022) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 4.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated." | 4.12 | The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Zheng, W; Zhou, Y, 2022) |
| "Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine." | 4.12 | Prospective association of psychological pain and hopelessness with suicidal thoughts. ( Ballard, ED; Bloomfield-Clagett, B; Farmer, CA; Gerner, J; Park, LT; Zarate, CA, 2022) |
| "Intranasal esketamine has been recently approved for the treatment of resistant depression." | 4.12 | Intranasal esketamine for depression: Not so special K. ( Rosenman, S, 2022) |
| "Interest in the use of parenteral ketamine has been increasing over the last 2 decades for the management of treatment-resistant depression (TRD)." | 4.12 | Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. ( Budd, GP; Do, A; Fridfinnson, J; Lam, RW; Rafizadeh, R; Siu, JTP; Tham, JCW, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 4.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 4.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression." | 4.12 | Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. ( Batten, LA; Blier, P; Burhunduli, P; Norris, S; Ortiz, A; Owoeye, O; Phillips, JL; Talbot, J; Van Geel, A; Vasudev, D, 2022) |
| "Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses." | 4.12 | Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. ( Bottemanne, H; Claret, A; Fossati, P; Morlaas, O; Schmidt, L; Sharot, T, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 4.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "IV ketamine was effective in reducing symptoms of depression, SI, anxiety, and anhedonia in both cohorts in this large, well-characterized community-based sample of adults with TRD." | 4.12 | Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Shekotikhina, M; Siegel, A; Simonson, K; Subramaniapillai, M, 2022) |
| "Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form." | 4.02 | Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. ( Garakani, A, 2021) |
| "Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine's antidepressant actions in rodent models at sub-therapeutic doses." | 4.02 | Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression. ( Butters, K; Frye, MA; McGee, SL; Morath, BA; Price, JB; Tye, SJ; Van De Wakker, SK; Yates, CG; Yates, NJ, 2021) |
| "Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry." | 4.02 | [Ketamine infusion therapy in treatment-resistant depression]. ( Christodoulakis, ΤΕ, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 4.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 4.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| " We present a case of treatment refractory depression with recent suicide attempt and active suicidal ideations who was on an Opioid partial agonist, Buprenorphine, for management of pain." | 4.02 | Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine. ( Hosanagar, A; LeBlanc, A; Schmale, A, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 4.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 4.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Adults with treatment-resistant depression (TRD) receiving intravenous (IV) ketamine had depressive symptoms measured with the 16-Item Quick Inventory Depressive Symptoms Self-Report (QIDS-SR-16) and MARRRS at baseline and as a repeated measure across an acute course of four infusions." | 4.02 | Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 4.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD)." | 4.02 | Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. ( Abrishami, A; Arekapudi, AK; Chau, EH; Di Vincenzo, JD; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Szpejda, W; Wong, L, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 4.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine is a novel, rapid-acting antidepressant for treatment refractory depression (TRD); however, clinical durability is poor and treatment response trajectories vary." | 4.02 | Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression. ( Badathala, A; Fryer, SL; Marton, TF; Mathalon, DH; Pennybaker, S; Roach, BJ; Wallace, AW, 2021) |
| "Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression." | 4.02 | Ketamine treatment for depression: A model of care. ( Alonzo, A; Bayes, A; Dong, V; Kabourakis, M; Loo, C; Martin, D, 2021) |
| "Some patients with refractory depression who fail to respond to rapid injection of standard-dose ketamine are injected with high doses, but the safety and efficacy of this practice are unclear." | 3.96 | Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement. ( Fang, J; Li, Z; Su, B; Wang, L; Wang, M; Xiong, Z; Yang, Y, 2020) |
| "Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects." | 3.96 | Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, LT; Zarate, CA, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 3.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 3.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD)." | 3.96 | Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. ( Congdon, E; Espinoza, R; Joshi, SH; Kubicki, A; Loureiro, JR; Narr, KL; Sahib, AK; Vasavada, MM; Wade, B; Woods, RP, 2020) |
| "It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term." | 3.91 | Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic. ( Brand, F; Hawton, K; Lascelles, K; Marzano, L; McShane, R; Trueman, H, 2019) |
| " There is a rising promise in a N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, which may be used in the treatment of resistant depression." | 3.91 | Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. ( Cubała, WJ; Małyszko, A; Szarmach, J; Wiglusz, MS; Włodarczyk, A, 2019) |
| "In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults." | 3.91 | Esketamine for treatment resistant depression: a trick of smoke and mirrors? ( Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D, 2019) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with depression although intranasal use of (R,S)-ketamine in ketamine abusers is popular." | 3.91 | Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. ( Chang, L; Dong, C; Fujita, Y; Hashimoto, K; Pu, Y; Qu, Y; Ren, Q; Wang, SM; Xiong, Z; Zhang, K, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| " Fifteen patients (group 1) received only thiopental anesthesia, 15 patients (group 2) had their second and third ECT sessions with ketamine, and 15 patients (group 3) had ketamine for the second, fourth, sixth, eighth, and tenth sessions." | 3.83 | Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression. ( Bartkowska-Sniatkowska, A; Bodnar, A; Chlopocka-Wozniak, M; Krzywotulski, M; Michalak, M; Rosada-Kurasinska, J; Rybakowski, JK, 2016) |
| "In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients." | 3.83 | Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. ( Akeju, O; Alpert, JE; Baer, L; Brown, EN; Cassano, P; Cusin, C; Fava, M; Ionescu, DF; Mischoulon, D; Nock, MK; Nyer, M; Pavone, KJ; Swee, MB; Taylor, N, 2016) |
| "It was previously hypothesized that dextromethorphan (DM) and dextrorphan (DX) may possess antidepressant properties, including rapid and conventional onsets of action and utility in treatment-refractory depression, based on pharmacodynamic similarities to ketamine." | 3.78 | An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. ( Lauterbach, EC, 2012) |
| "Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate (NMDA) receptors." | 3.54 | Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. ( Kavalali, ET; Krystal, JH; Monteggia, LM, 2024) |
| " Frequency of response to specific CADSS items was examined to investigate qualitative differences in the pattern of symptoms reported across investigator-reported levels of adverse event severity." | 3.30 | Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. ( Borentain, S; Drevets, WC; Singh, JB; Turkoz, I; Wajs, E; Williamson, D, 2023) |
| "For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach." | 3.30 | Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. ( Desbeaumes Jodoin, V; Elkrief, L; Garel, N; Lespérance, P; Longpré-Poirier, C; Miron, JP; Payette, O; Richard, M, 2023) |
| "Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis." | 3.30 | Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. ( Aloysi, AS; Altinay, M; Anand, A; Asghar-Ali, AA; Barnett, BS; Chang, LC; Collins, KA; Costi, S; Goes, FS; Hu, B; Iqbal, S; Jha, MK; Krishnan, K; Malone, DA; Mathew, SJ; Murrough, JW; Nikayin, S; Nissen, SE; Ostroff, RB; Reti, IM; Sanacora, G; Wilkinson, ST; Wolski, K, 2023) |
| "Forty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0." | 3.30 | Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| "Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression." | 3.11 | Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). ( Åkeson, J; Cheng, T; Ekstrand, J; Fattah, C; Lindström, MB; Movahed Rad, P; Nordanskog, P; Nordenskjöld, A; Persson, M; Tingström, A, 2022) |
| "Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain." | 3.01 | Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. ( Chao, Z; Lan, X; Li, H; Ning, Y; Wang, C; Zhou, Y, 2021) |
| "Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed." | 3.01 | Intravenous arketamine for treatment-resistant depression: open-label pilot study. ( Bandeira, ID; Bezerra, MLO; Caliman-Fontes, AT; Correia-Melo, FS; Dias-Neto, AL; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Lima, CS; Loo, C; Marback, RF; Marques, BLS; Mello, RP; Quarantini, LC; Sampaio, AS; Sanacora, G; Silva, SS; Telles, M; Turecki, G; Vieira, F, 2021) |
| "Patients with major depressive disorder who do not respond to ≥2 different pharmacological treatments within the current depressive episode are considered to have treatment resistant depression (TRD)." | 3.01 | Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr ( Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J, 2021) |
| "Ketamine was associated with transient, self-limited dissociative symptoms that affected participant blinding, but there were no serious adverse events." | 3.01 | Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. ( Bloch, MH; Couloures, K; Dwyer, JB; Flores, JM; Johnson, JA; Landeros-Weisenberger, A; Londono Tobon, A; Nasir, M; Sanacora, G, 2021) |
| "Intranasal drug delivery offers a non-invasive and convenient dosing option for patients and physicians, especially for conditions requiring chronic/repeated-treatment administration." | 3.01 | Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. ( Cooper, K; Daly, E; Doty, RL; Drevets, WC; Fedgchin, M; Jamieson, C; Janik, A; Lane, R; Lim, P; Melkote, R; Ochs-Ross, R; Popova, V; Singh, J; Wylie, C, 2021) |
| "This phase 3 double-blind study randomized patients with treatment-resistant depression (TRD) ≥65 years (1:1) to flexibly dosed esketamine nasal spray and new oral antidepressant (esketamine/antidepressant) or new oral antidepressant and placebo nasal spray (antidepressant/placebo)." | 2.94 | Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. ( Adler, C; Daly, EJ; Drevets, WC; Gaillard, R; Hough, D; Lane, R; Lim, P; Manji, H; McShane, R; Morrison, RL; Ochs-Ross, R; Sanacora, G; Singh, JB; Steffens, DC; Wilkinson, ST; Zhang, Y, 2020) |
| "Esketamine nasal spray was recently approved for treatment-resistant depression." | 2.94 | Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. ( Aluisio, L; Borentain, S; Daly, E; DiBernardo, A; Janik, A; Nijs, M; Singh, JB; Turkoz, I; Wajs, E; Wiegand, F, 2020) |
| " Common treatment-emergent adverse events (TEAEs) were dizziness (32." | 2.94 | Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). ( Aluisio, L; Daly, EJ; Drevets, WC; George, JE; Grunfeld, J; Holder, R; Hough, D; Jeon, HJ; Kasper, S; Lane, R; Li, CT; Lim, P; Manji, H; Morrison, RL; Paik, JW; Sanacora, G; Singh, JB; Sulaiman, AH; Wajs, E; Wilkinson, ST; Young, AH, 2020) |
| "Ketamine has been demonstrated to improve depressive symptoms." | 2.90 | Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. ( Bleich-Cohen, M; Bloch, M; Domany, Y; Hendler, T; Litvak-Lazar, O; Meidan, R; Schreiber, S; Sharon, H; Stoppleman, N; Tarrasch, R, 2019) |
| "Ketamine has emerged as the first rapid-acting antidepressant and shows robust short-term efficacy in clinical trials, but there are concerns about its long-term safety and efficacy." | 2.90 | ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. ( Altinay, M; Anand, A; Asghar-Ali, A; Chang, LC; Collins, KA; Dale, RM; Hu, B; Kellner, CH; Krishnan, K; Malone, DA; Mathew, SJ; Murrough, JW; Ostroff, RB; Sanacora, G; Shao, M; Wilkinson, ST, 2019) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 2.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| " The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0." | 2.90 | Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. ( Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019) |
| " The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache." | 2.90 | Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). ( Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D, 2019) |
| " Three of 56 (5%) esketamine-treated participants during the double-blind phase vs none receiving placebo and 1 of 57 participants (2%) during the open-label phase had adverse events that led to study discontinuation (1 event each of syncope, headache, dissociative syndrome, and ectopic pregnancy)." | 2.87 | Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. ( Cooper, K; Daly, EJ; Drevets, WC; Fedgchin, M; Lim, P; Manji, H; Shelton, RC; Singh, JB; Thase, ME; Van Nueten, L; Winokur, A, 2018) |
| "Ketamine has emerged as a rapid-acting antidepressant, though controversy remains whether sufficient data exist to justify its use outside of research protocols." | 2.87 | Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. ( Katz, RB; Ostroff, RB; Sanacora, G; Toprak, M; Webler, R; Wilkinson, ST, 2018) |
| "Ketamine treatment resulted in a general increase in circulating sphingomyelins, levels which were not correlated with response." | 2.87 | Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. ( Ferrucci, L; Gould, TD; Kadriu, B; Khadeer, M; Lovett, J; Moaddel, R; Morris, PJ; Ravichandran, S; Shardell, M; Thomas, CJ; Yuan, P; Zarate, CA, 2018) |
| "Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression." | 2.87 | Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Ketamine has been documented for its rapid antidepressant effects." | 2.87 | Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. ( Aubry, JM; Bancila, V; Dayer, A; Gex-Fabry, M; Jermann, F; Khan, N; Kosel, M; Michalopoulos, G; Schwartz, S; Sterpenich, V; Vidal, S; Vutskits, L; Warrot, D, 2018) |
| "Ketamine has shown rapid though short-lived antidepressant effects." | 2.84 | Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. ( Fasula, MK; Fenton, L; Griepp, M; Ostroff, RB; Sanacora, G; Wilkinson, ST; Wright, D, 2017) |
| "Ketamine was well tolerated." | 2.84 | Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. ( Brodaty, H; Gálvez, V; George, D; Glue, P; Hadzi-Pavlovic, D; Harper, S; Kumar, D; Leyden, J; Loo, CK; Martin, D; Mitchell, PB; Taylor, R, 2017) |
| " No changes in current psychotropic medication or dosage were permitted for 4weeks prior to trial entry and throughout the trial." | 2.84 | Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. ( Alonzo, A; Gálvez, V; Ho, KA; Loo, CK; Nikolin, S; Somogyi, AA, 2017) |
| "Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia." | 2.82 | The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. ( Ceban, F; Ho, R; Jasrai, AK; Kim, H; Lui, LMW; McIntyre, RS; Nasri, F; Nogo, D; Rosenblat, JD; Vinberg, M, 2022) |
| "After pooling data from seven randomized controlled trials, treatment with adjunctive IN esketamine vs IN placebo was safe overall, and more effective at decreasing depressive symptoms (d = -0." | 2.82 | The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. ( Alnafeesi, Y; Ceban, F; Di Vincenzo, JD; Gillissie, ES; Jaberi, S; Jawad, MY; Lui, LMW; McIntyre, RS; Rosenblat, JD, 2022) |
| " Finally, continuing to monitor research subjects and patients long-term for the emergence of adverse effects on cognition or other organ systems is critical." | 2.82 | Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. ( Kritzer, MD; Masand, PS; Pae, CU, 2022) |
| "Intravenous, subcutaneous, and possibly oral esketamine may offer an effective and safe addition to the depression treatment armamentarium." | 2.82 | The antidepressant effect and safety of non-intranasal esketamine: A systematic review. ( Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JK; Vischjager, M, 2022) |
| "Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine." | 2.82 | Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine. ( Javed, S; Kotra, M; Malathesh, BC; Nguyen, VS; Shoib, S, 2022) |
| "Ketamine has demonstrated at a lower dose a robust and rapid antidepressant effect due to a mechanism of action different from conventional treatments." | 2.82 | [Use of ketamine in psychiatry: an update]. ( Clerc, MT; Rosenhagen-Lapoirie, M; Von Gunten, A, 2022) |
| "Ketamine is a novel rapid-acting antidepressant with neuroplastic potential." | 2.82 | The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. ( Cubała, WJ; Wilkowska, A, 2022) |
| " In the twice-weekly dosing groups, the mean change in MADRS score at day 15 was -18." | 2.82 | A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. ( Cooper, K; Daly, EJ; De Boer, P; Drevets, WC; Fava, M; Fedgchin, M; Kurian, B; Lim, P; Manji, H; Murrough, JW; Pinter, C; Sanacora, G; Shelton, RC; Singh, JB; Van Nueten, L; Winokur, A, 2016) |
| "We gave 16 medication-free, major depressive disorder (MDD) patients a single, sub-anesthetic dose infusion of ketamine (0." | 2.80 | Hippocampal volume and the rapid antidepressant effect of ketamine. ( Abdallah, CG; Baldwin, P; Jackowski, A; Mathew, SJ; Salas, R; Sato, JR, 2015) |
| "Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists." | 2.80 | Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. ( Lally, N; Luckenbaugh, DA; Niciu, MJ; Nugent, AC; Roiser, JP; Zarate, CA, 2015) |
| "The ketamine ECT study is a multi-site randomised, placebo-controlled, double blind trial." | 2.80 | Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). ( Anderson, IM; Blamire, A; Branton, T; Clark, R; Downey, D; Dunn, G; Easton, A; Elliott, R; Ellwell, C; Hayden, K; Holland, F; Karim, S; Loo, C; Lowe, J; McAllister-Williams, RH; Nair, R; Oakley, T; Prakash, A; Sharma, PK; Trevithick, L; Williams, SR, 2015) |
| "Ketamine has a rapid antidepressant effect in treatment-resistant depression (TRD)." | 2.79 | Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. ( Atkinson, S; Cowen, PJ; Diamond, PR; Farmery, AD; Geddes, JR; Haldar, J; McShane, R; Williams, N, 2014) |
| "This is the first trial to present dose-response data of ketamine efficacy and psychomimetic effects in depressed subjects." | 2.79 | Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. ( Glue, P; Harper, S; Katalinic, N; Lai, R; Leyden, J; Loo, CK; Mitchell, PB; Somogyi, AA, 2014) |
| "Twenty-six inpatients with treatment-resistant major depressive disorder (MDD) (DSM-IV criteria) received a single infusion of ketamine (0." | 2.79 | Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. ( Brutsche, NE; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Slonena, EE; Vande Voort, JL; Zarate, CA, 2014) |
| "Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect." | 2.78 | Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. ( aan het Rot, M; Charney, DS; Collins, KA; Iosifescu, DV; Mathew, SJ; Murrough, JW; Parides, MK; Perez, AM; Pillemer, S; Stern, J, 2013) |
| "Twenty drug-free major depressive disorder patients received a single, open-label intravenous infusion of ketamine hydrochloride (." | 2.77 | Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. ( Brutsche, NE; Cornwell, BR; Furey, M; Grillon, C; Marquardt, CA; Salvadore, G; Zarate, CA, 2012) |
| "Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD)." | 2.72 | Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review. ( Buoli, M; Caldiroli, A; Capellazzi, M; Capuzzi, E; Clerici, M; Colmegna, F; Dakanalis, A; Marcatili, M; Tagliabue, I, 2021) |
| "Ketamine is an antagonist of the N-Methyl-D-aspartate receptor (NMDAR) and its main mechanism of action via NMDAR inhibition expressed in GABAergic (gamma-Aminobutyric acid, GABA) interneurons may be relayed to its antidepressant effects." | 2.72 | [Pharmacology of ketamine and esketamine as rapid-acting antidepressants]. ( Dalla, C; Kokras, N; Megalokonomou, A; Pavlidi, P; Sofron, A, 2021) |
| "Esketamine appears to be an effective therapy when combined with oral antidepressants in patients with TRD." | 2.72 | Esketamine: a glimmer of hope in treatment-resistant depression. ( Chakrabarti, SS; Kaur, U; Pathak, BK; Singh, A, 2021) |
| "Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe." | 2.72 | Are we repeating mistakes of the past? A review of the evidence for esketamine. ( Horowitz, MA; Moncrieff, J, 2021) |
| "Ketamine was initially used as an anesthetic which could induce cognitive impairment and psychomimetic effects." | 2.72 | Increased use of ketamine for the treatment of depression: Benefits and concerns. ( Kim, YK; Na, KS, 2021) |
| "Ketamine has demonstrated efficacy as a rapid-onset intervention for the treatment of depression." | 2.72 | The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. ( El-Halabi, S; Gill, B; Gill, H; Lee, Y; Lipsitz, O; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD, 2021) |
| "Ketamine has repeatedly shown to have rapid and robust antidepressant effects in patients with treatment resistant depression (TRD)." | 2.72 | Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. ( Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Spaans, HP; Veraart, JKE, 2021) |
| "One third among them will suffer from treatment resistant depression (TRD) which does not respond to two accepted treatment protocols." | 2.72 | [ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. ( Marom, A; Rosca, P, 2021) |
| "Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized." | 2.72 | Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. ( Bahji, A; Baldessarini, RJ; Tondo, L; Undurraga, J; Vázquez, GH, 2021) |
| "Nasal esketamine spray produces the adverse effects of dizziness, vertigo, and blurred vision severe enough to cause discontinuation in 4% of patients; it also can produce transient elevation of blood pressure (SOR: A, meta-analyses)." | 2.72 | Is ketamine effective and safe for treatment-resistant depression? ( Jenkinson, M; Kelsberg, G; Linn, S; Neher, JO; Safranek, S; Zorn, A, 2021) |
| " The literature shows that treatment with ketamine is efficacious and safe, and the majority of adverse drug reactions are mild and tend to mostly disappear within 30 min to 2 h of ketamine administration." | 2.66 | Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. ( Cubała, WJ; Włodarczyk, A, 2020) |
| "Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions." | 2.66 | Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. ( Borissova, A; Curran, HV; Grabski, M; Marsh, B; Morgan, CJA, 2020) |
| "Esketamine has a favorable risk-to-benefit profile, with demonstrated efficacy in reducing depressive symptoms more rapidly than monotherapy with traditional oral antidepressants." | 2.66 | Intranasal esketamine: A novel drug for treatment-resistant depression. ( Khorassani, F; Talreja, O, 2020) |
| "Major depressive disorder is one of the most important psychiatric issues worldwide, with important prevalence of treatment-resistant depression (TRD)." | 2.61 | Role of copper and ketamine in major depressive disorder - an update. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupska, A; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| " Our findings suggest a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing, despite these being reported in other patient groups exposed to ketamine (eg, those with chronic pain) and in recreational users." | 2.58 | Side-effects associated with ketamine use in depression: a systematic review. ( Fong, J; Galvez, V; Loo, CK; Shelker, W; Short, B, 2018) |
| "Nitrous oxide has also shown antidepressant efficacy." | 2.58 | Emerging evidence for antidepressant actions of anesthetic agents. ( Mickey, BJ; Tadler, SC, 2018) |
| "Ketamine treatment showed acute effectiveness in another 7 cases, especially in terms of reduction of suicidal ideation, albeit without significant long-term antidepressant effect." | 2.58 | Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior. ( Chan, LF; Chong, BTW; Eu, CL; Kahn, DA; Loo, JL; Loo, TH; Maniam, T; Ng, YP; Shahidii Kadir, Z; Sharip, S; Soh, SY; Wong, VCW, 2018) |
| "Ketamine is a racemic mixture of the enantiomers R-ketamine and S-ketamine (esketamine)." | 2.55 | Ketamine for Depression, 3: Does Chirality Matter? ( Andrade, C, 2017) |
| "Ketamine is a promising treatment for geriatric patients with TRD." | 2.55 | Use of Ketamine in Elderly Patients with Treatment-Resistant Depression. ( Medeiros da Frota Ribeiro, C; Riva-Posse, P, 2017) |
| "Ketamine is a psychoactive anesthetic agent, which has been approved and utilized for various forms of anesthesia over decades." | 2.53 | NMDA antagonist treatment of depression. ( Schatzberg, AF; Williams, NR, 2016) |
| "Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described." | 2.52 | Ketamine safety and tolerability in clinical trials for treatment-resistant depression. ( Brallier, JW; Chang, LC; Charney, DS; Foulkes, A; Iosifescu, DV; Levitch, CF; Mathew, SJ; Murrough, JW; Perez, AM; Wan, LB, 2015) |
| "Ketamine's efficacy was confirmed in MDD (resistant to previous pharmacological treatments or not) (SMD = -0." | 2.50 | Ketamine administration in depressive disorders: a systematic review and meta-analysis. ( Abbar, M; Boyer, L; Brittner, M; Courtet, P; Fond, G; Lançon, C; Leboyer, M; Loundou, A; Macgregor, A; Micoulaud-Franchi, JA; Rabu, C; Richieri, R; Roger, M, 2014) |
| "Ketamine for treatment-resistant MDD requires further evaluation before it can be considered a viable treatment option." | 2.48 | Intravenous ketamine for treatment-resistant major depressive disorder. ( Covvey, JR; Crawford, AN; Lowe, DK, 2012) |
| " Chronic administration of antidepressant drugs reverses the decreased sucrose intake and other behavioral changes in these subjects." | 1.91 | Models of Affective Illness: Chronic Mild Stress in the Rat. ( Papp, M; Willner, P, 2023) |
| " Response (≥50% improvement in total score from baseline for Montgomery-Åsberg Depression Rating Scale [MADRS] and Patient Health Questionnaire 9-item [PHQ-9]), remission (MADRS score ≤12; PHQ-9 total score <5), changes in depression rating scores (measured as mean change from baseline), and safety were evaluated (incidence of treatment-emergent and serious adverse events [AE])." | 1.91 | Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. ( Al Jurdi, RK; Borentain, S; Brown, B; Cabrera, P; Castro, M; Fu, DJ; Petrillo, MP; Sun, L; Turkoz, I; Wilkinson, ST; Zaki, N, 2023) |
| "Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications." | 1.91 | Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. ( Thase, ME, 2023) |
| " Beside adverse events that may be sought for abuse purpose (e." | 1.72 | Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market. ( Baudot, J; Mezaache, S; Micallef, J; Navarro, N; Soeiro, T; Tambon, M; Veyrac, G, 2022) |
| "Ketamine was proven to have short-term antidepressant effects." | 1.72 | Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. ( Lan, X; Li, W; Liu, H; Liu, W; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Ye, Y; Zhang, F; Zhang, Z; Zhou, Y, 2022) |
| "Ketamine has rapid and sustained antidepressant effects in patients with treatment-resistant depression (TRD)." | 1.72 | Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. ( Bevilacqua, L; Cathomas, F; Chan, KL; Charney, DS; Costi, S; Kronman, H; Li, L; Murrough, JW; Nestler, EJ; Ramakrishnan, A; Russo, SJ; Schneider, M; Shen, L, 2022) |
| "Ketamine has emerged as a rapid-acting antidepressant in treatment-resistant depression (TRD) increasingly used in non-research, clinical settings." | 1.72 | Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. ( Bolton, P; Boyle, B; Dai, D; Li, S; Meisner, R; Miller, C; Seiner, S; Valdivia, V, 2022) |
| "We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects." | 1.72 | The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. ( Bayes, A; Brunoni, AR; Fam, J; Galvez, V; Glue, P; Loo, CK; Martin, D; McLoughlin, DM; McShane, R; Murrough, JW; Parikh, S; Park, L; Riva-Posse, P; Schoevers, R; Short, B; Tor, PC; Veraart, J; Zarate, CA, 2022) |
| "Ketamine PK/PD data were collected from 21 treatment-refractory depressed participants who received ketamine (dose titration 0." | 1.72 | Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression. ( Abuhelwa, AY; Barratt, DT; Foster, DJR; Glue, P; Loo, CK; Somogyi, AA, 2022) |
| "Esketamine was safe and well tolerated." | 1.72 | Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. ( Abdo, GL; Barbosa, MG; de Oliveira Cerqueira, R; Del Porto, JA; Del Sant, LC; Delfino, RS; Fava, VAR; Grossi, JD; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2022) |
| "Ketamine was generally well tolerated, and we observed improvements in functional impairment, anhedonia, and psychiatric symptoms, with no increases in manic symptoms." | 1.72 | Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study. ( Kang, MJY; Vazquez, GH, 2022) |
| "Ketamine has been shown to provide rapid and significant efficacy in treating patients with TRD." | 1.62 | Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. ( Di Vincenzo, JD; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Mansur, R; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 1.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine has demonstrated rapid and robust efficacy in adults with TRD." | 1.62 | Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2021) |
| "Esketamine nasal spray is a novel, fast-acting agent that provides an additional treatment option for patients with TRD who have previously failed several therapies." | 1.62 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. ( Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH, 2021) |
| "Ketamine was associated with transient treatment-emergent hypertension." | 1.62 | Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. ( Cao, B; Cha, DS; Di Vincenzo, JD; Flint, AJ; Greenberg, D; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Clonidine was co-administered to reduce psychotomimetic effects." | 1.62 | Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. ( Ances, BM; Farber, NB; Kharasch, ED; Lenze, EJ; Nicol, GE; Palanca, BJA; Schweiger, JA; Siegel, JS; Snyder, AZ; Yingling, MD, 2021) |
| "Ketamine has been safely used as an anesthetic for over 50 years." | 1.62 | Compounded intranasal racemic ketamine for major depressive disorder: A case report. ( Halpape, K; Peters, E; Wanson, A; Ziegler, L, 2021) |
| "(S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression." | 1.62 | Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. ( Boehm, MA; Bonaventura, J; Carlton, M; Fredriksson, I; Gomez, JL; Lam, S; Michaelides, M; Morris, PJ; Sánchez-Soto, M; Shaham, Y; Sibley, DR; Solís, O; Thomas, CJ; Zarate, CA, 2021) |
| " The dose-response relationship calls for caution with higher doses of tranylcypromine." | 1.62 | Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. ( Bauer, M; Findeis, H; Ludwig, VM; Ritter, P; Rucker, J; Sauer, C; Young, AH, 2021) |
| "The safety psychometrics assessed dissociation and psychomimetic symptomatology with the Clinician-Administered Dissociative States Scale (CADSS) the Brief Psychiatric Rating Scale (BPRS)." | 1.62 | Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. ( Cubała, WJ; Gałuszko-Węgielnik, M; Szarmach, J; Włodarczyk, A, 2021) |
| " A numerical dose-response relationship was observed, with remitters/responders on ketamine 1." | 1.56 | Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2020) |
| "Treatment resistant depression is a significant source of morbidity and mortality." | 1.56 | Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series. ( Agapoff, JR; Goebert, D; Lu, BY; Olson, DJ; Roller, A; Williams, SR, 2020) |
| " For adverse events, odds ratio (OR) [95% confidence interval] for esketamine/antidepressant versus antidepressant/placebo was calculated." | 1.56 | Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. ( Doherty, T; Melkote, R; Miller, J; Singh, JB; Wajs, E; Weber, MA, 2020) |
| "Ketamine is a promising therapeutic for treatment-resistant depression (TRD) but is associated with an array of short-term psychomimetic side-effects." | 1.56 | Transient Dose-dependent Effects of Ketamine on Neural Oscillatory Activity in Wistar-Kyoto Rats. ( Manduca, JD; Perreault, ML; Rasmussen, DJ; Thériault, RK; Williams, OOF, 2020) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 1.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "esketamine injections were mild and well tolerated for doses up to 1 mg/kg." | 1.56 | Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression. ( Abdo, G; Barbosa, M; Cohrs, FM; de Jesus Mari, J; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VAR; Lacerda, ALT; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2020) |
| "Ketamine has shown rapid antidepressant effects in depressed patients." | 1.56 | A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. ( Lan, XF; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zhang, B; Zheng, W; Zhou, YL, 2020) |
| "Ketamine has rapid-acting antidepressant properties but also potentially concerning transient dissociative side effects (SEs)." | 1.56 | Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. ( Acevedo-Diaz, EE; Cavanaugh, GW; Greenstein, D; Kadriu, B; Kraus, C; Park, L; Zarate, CA, 2020) |
| "Forty-four patients with major depressive disorder received six intravenous ketamine (0." | 1.56 | Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. ( Deng, XR; Lan, XF; Ning, YP; Wang, CY; Wu, FC; Zheng, W; Zhou, YL, 2020) |
| "Major depression is one of the most frequent psychiatric conditions." | 1.51 | The immunomodulatory effect of ketamine in depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Lisowska, KA; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| " Optimal dosing schedules to best prolong the antidepressant effects of ketamine have yet to be determined." | 1.51 | Ketamine and Treatment-Resistant Depression. ( Arredondo, A; Austin, PN; Lent, JK; Pugh, MA, 2019) |
| "MRL/lpr mice, an established model of systemic lupus erythematosus, show depression-like behavior." | 1.51 | Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus. ( Adepu, B; Bristow, LJ; Das, ML; Dudhgaonkar, S; Kalidindi, N; Kuchibhotla, VK; Li, YW; Louis, JV; Nagar, J; Naidu, PS; Paschapur, M; Pieschl, RL; Prasad, DS; Ramarao, M; Sreedhara, MV; Srikumar, BN; Srivastava, R; Subramani, S; Vikramadithyan, RK, 2019) |
| " The site-based MADRS interviews were recorded at the baseline and 2 h post-dose assessments on the first intranasal dosing day." | 1.51 | Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. ( Cooper, K; Daly, E; Fedgchin, M; Singh, JB; Targum, SD, 2019) |
| "Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines." | 1.51 | Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective. ( López-Díaz, Á; Moreno-Mellado, E; Murillo-Izquierdo, M, 2019) |
| " Records were also screened for adverse medical events and changes in ketamine dosage over time." | 1.48 | Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. ( De Gioannis, A; Garrett-Walcott, S; Hartberg, J, 2018) |
| " Further research and large clinical trials are needed on the optimum KIT protocol, including dose, dosing interval, total number of treatments and when to stop." | 1.48 | Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up. ( Hong, JP; Kwon, JH; Lee, JY; Sim, WS; Song, IS, 2018) |
| "Current alternatives for the treatment of major depressive disorder lack efficacy and have a delayed onset of action." | 1.48 | Ketamine for Treatment-Resistant Depression: a New Advocate. ( Pérez-Esparza, R, 2018) |
| "Ketamine infusions were generally well tolerated; dissociative symptoms and hemodynamic symptoms were transient." | 1.48 | Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. ( Albott, CS; Amatya, P; Carstedt, P; Cullen, KR; Eberly, LE; Gunlicks-Stoessel, M; Horek, N; Klimes-Dougan, B; Lim, KO; Reigstad, K; Ren, Y; Roback, MG; Samikoglu, A; Tye, S; Westlund Schreiner, M, 2018) |
| " Etomidate, mean dosage (SD) = 0." | 1.46 | S -ketamine compared to etomidate during electroconvulsive therapy in major depression. ( Ahrens, K; Dannlowski, U; Dietsche, P; Kircher, T; Kluge, I; Köhnlein, B; Konrad, C; Wohltmann, T; Zavorotnyy, M, 2017) |
| "Ketamine infusions were well tolerated with occasional nausea or anxiety and mild hemodynamic effects during the infusion." | 1.46 | Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. ( Boggie, D; Feifel, D; Lee, K; Malcolm, B, 2017) |
| "Post-traumatic stress disorder (PTSD) displays high co-morbidity with major depression and treatment-resistant depression (TRD)." | 1.46 | Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. ( Brand, SJ; Harvey, BH, 2017) |
| "Ketamine and ECT treatment were both associated with significant reductions in depressive symptoms." | 1.42 | Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. ( Allen, AP; Clarke, G; Cryan, JF; Dinan, TG; Dowling, J; Ismail, F; McLoughlin, DM; Naughton, M; Scott, L; Shorten, G; Walsh, A, 2015) |
| "Ketamine has been showing high efficacy and rapid antidepressant effect." | 1.40 | Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. ( Albott, CS; Johns, B; Kuskowski, M; Lim, KO; Shiroma, PR; Thuras, P; Wels, J, 2014) |
| "Medication-free patients (n=19) with treatment-resistant major depressive disorder underwent positron emission tomography imaging at baseline and 230 minutes after an open-label ketamine infusion (0." | 1.40 | Neural correlates of suicidal ideation and its reduction in depression. ( Ballard, ED; Furey, ML; Lally, N; Luckenbaugh, DA; Nugent, AC; Zarate, CA, 2014) |
| "Ketamine (Ketalar®) is an anesthetic agent derived from the hallucinogenic drug phencyclidine (PCP)." | 1.39 | Ketamine for the treatment of depression. ( Howland, RH, 2013) |
| " We analysed the number of sessions until completion of ECT treatment (used as a surrogate parameter for outcome), psychopathology as assessed by pre- and post-ECT Mini-Mental State Examination (MMSE) and Hamilton Rating Scale for Depression (HAM-D) scores as well as ECT and seizure parameters (stimulation dose, seizure duration and concordance, urapidil dosage for post-seizure blood pressure management)." | 1.37 | Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. ( Hoyer, C; Kammerer-Ciernioch, J; Kranaster, L; Sartorius, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 223 (41.37) | 24.3611 |
| 2020's | 316 (58.63) | 2.80 |
| Authors | Studies |
|---|---|
| Capuzzi, E | 2 |
| Caldiroli, A | 2 |
| Capellazzi, M | 2 |
| Tagliabue, I | 2 |
| Marcatili, M | 3 |
| Colmegna, F | 2 |
| Clerici, M | 5 |
| Buoli, M | 2 |
| Dakanalis, A | 2 |
| Di Vincenzo, JD | 12 |
| Lipsitz, O | 24 |
| Rodrigues, NB | 28 |
| Lee, Y | 28 |
| Gill, H | 23 |
| Kratiuk, K | 21 |
| Subramaniapillai, M | 21 |
| Mansur, R | 4 |
| McIntyre, RS | 46 |
| Rosenblat, JD | 38 |
| White, PF | 1 |
| Zhou, Y | 10 |
| Wang, C | 8 |
| Lan, X | 6 |
| Li, H | 7 |
| Chao, Z | 3 |
| Ning, Y | 10 |
| Chen, MH | 27 |
| Lin, WC | 27 |
| Li, CT | 29 |
| Tsai, SJ | 21 |
| Wu, HJ | 16 |
| Bai, YM | 26 |
| Hong, CJ | 18 |
| Tu, PC | 26 |
| Su, TP | 27 |
| Singh, B | 9 |
| Vande Voort, JL | 15 |
| Kung, S | 4 |
| Mao, WC | 4 |
| Gee, SH | 1 |
| Wratten, C | 1 |
| Cairns, R | 1 |
| Santhouse, A | 1 |
| Taylor, D | 1 |
| Hara, H | 1 |
| Suzuki, A | 1 |
| Kunugi, A | 1 |
| Tajima, Y | 1 |
| Yamada, R | 1 |
| Kimura, H | 1 |
| Takahashi, N | 1 |
| Yamada, A | 1 |
| Shiraishi, A | 1 |
| Shimizu, H | 1 |
| Goto, R | 1 |
| Tominaga, Y | 1 |
| López-Díaz, Á | 3 |
| Rendón de Lope, L | 1 |
| de la Vega Sánchez, D | 1 |
| Zheng, W | 11 |
| Wu, K | 2 |
| Maraschin, JC | 1 |
| Frias, AT | 1 |
| Hernandes, PM | 1 |
| Batistela, MF | 1 |
| Martinez, LM | 1 |
| Joca, SRL | 2 |
| Graeff, FG | 1 |
| Audi, EA | 1 |
| Spera de Andrade, TGC | 1 |
| Zangrossi, H | 1 |
| Garakani, A | 1 |
| Andrade, C | 3 |
| Price, JB | 1 |
| Yates, CG | 1 |
| Morath, BA | 1 |
| Van De Wakker, SK | 1 |
| Yates, NJ | 1 |
| Butters, K | 1 |
| Frye, MA | 13 |
| McGee, SL | 1 |
| Tye, SJ | 5 |
| Moccia, L | 1 |
| Lanzotti, P | 1 |
| Pepe, M | 1 |
| Palumbo, L | 1 |
| Janiri, D | 1 |
| Camardese, G | 1 |
| Bentivoglio, AR | 1 |
| Di Nicola, M | 4 |
| Calabresi, P | 1 |
| Sani, G | 2 |
| Lijffijt, M | 4 |
| Murphy, N | 4 |
| Iqbal, S | 5 |
| Green, CE | 2 |
| Iqbal, T | 1 |
| Chang, LC | 9 |
| Haile, CN | 2 |
| Hirsch, LC | 1 |
| Ramakrishnan, N | 2 |
| Fall, DA | 1 |
| Swann, AC | 3 |
| Al Jurdi, RK | 5 |
| Mathew, SJ | 27 |
| Reus, VI | 1 |
| Schatzberg, AF | 8 |
| Mucci, F | 1 |
| Jones, BDM | 2 |
| Lui, LMW | 19 |
| Teopiz, KM | 13 |
| Ho, R | 18 |
| Lin, K | 11 |
| Nasri, F | 17 |
| Caliman-Fontes, AT | 5 |
| Leal, GC | 7 |
| Correia-Melo, FS | 8 |
| Paixão, CS | 2 |
| Carvalho, MS | 2 |
| Jesus-Nunes, AP | 8 |
| Vieira, F | 7 |
| Magnavita, G | 4 |
| Bandeira, ID | 6 |
| Mello, RP | 8 |
| Beanes, G | 2 |
| Silva, SS | 4 |
| Echegaray, M | 1 |
| Carvalho, LP | 2 |
| Machado, P | 1 |
| Sampaio, AS | 5 |
| Cardoso, TA | 1 |
| Kapczinski, F | 2 |
| Lacerda, ALT | 10 |
| Quarantini, LC | 8 |
| Baudot, J | 1 |
| Soeiro, T | 1 |
| Tambon, M | 1 |
| Navarro, N | 1 |
| Veyrac, G | 1 |
| Mezaache, S | 1 |
| Micallef, J | 1 |
| Li, W | 2 |
| Liu, W | 4 |
| Zhang, Z | 1 |
| Zhang, F | 2 |
| Ye, Y | 2 |
| Liu, H | 3 |
| de la Salle, S | 1 |
| Phillips, JL | 5 |
| Blier, P | 9 |
| Knott, V | 1 |
| Zhang, K | 2 |
| Yang, Y | 2 |
| Yuan, X | 1 |
| Zhang, W | 1 |
| Han, X | 2 |
| Lei, C | 1 |
| Tao, Z | 1 |
| Li, Y | 1 |
| Jones, RR | 1 |
| Freeman, MP | 6 |
| Kornstein, SG | 1 |
| Cooper, K | 7 |
| Daly, EJ | 18 |
| Canuso, CM | 3 |
| Nicholson, S | 1 |
| Özgen, MH | 1 |
| van den Brink, W | 4 |
| Goldberg, JF | 1 |
| Pavlidi, P | 1 |
| Megalokonomou, A | 1 |
| Sofron, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Christodoulakis, ΤΕ | 1 |
| Karakatsoulis, GN | 1 |
| Tsapakis, EM | 1 |
| Fountoulakis, KN | 1 |
| Kaliora, SC | 1 |
| Taillefer de Laportalière, T | 1 |
| Yrondi, A | 1 |
| Jullien, A | 1 |
| Cestac, P | 1 |
| Montastruc, F | 1 |
| Cathomas, F | 1 |
| Bevilacqua, L | 1 |
| Ramakrishnan, A | 1 |
| Kronman, H | 1 |
| Costi, S | 4 |
| Schneider, M | 1 |
| Chan, KL | 1 |
| Li, L | 1 |
| Nestler, EJ | 1 |
| Shen, L | 1 |
| Charney, DS | 11 |
| Russo, SJ | 2 |
| Murrough, JW | 22 |
| Ekstrand, J | 2 |
| Fattah, C | 1 |
| Persson, M | 1 |
| Cheng, T | 1 |
| Nordanskog, P | 1 |
| Åkeson, J | 1 |
| Tingström, A | 1 |
| Lindström, MB | 1 |
| Nordenskjöld, A | 1 |
| Movahed Rad, P | 1 |
| Chen, G | 2 |
| Chen, L | 4 |
| Zhang, Y | 3 |
| Li, X | 3 |
| Lane, R | 10 |
| Lim, P | 9 |
| Furey, ML | 6 |
| Fedgchin, M | 12 |
| Popova, V | 10 |
| Singh, JB | 21 |
| Drevets, WC | 21 |
| Horowitz, M | 1 |
| Moncrieff, J | 2 |
| Vanicek, T | 1 |
| Unterholzner, J | 1 |
| Lanzenberger, R | 2 |
| Naderi-Heiden, A | 3 |
| Kasper, S | 8 |
| Praschak-Rieder, N | 3 |
| Grabski, M | 2 |
| Waldron, J | 1 |
| Freeman, TP | 1 |
| van Laar, M | 1 |
| Curran, HV | 2 |
| Swainson, J | 7 |
| Klassen, LJ | 2 |
| Brennan, S | 1 |
| Chokka, P | 2 |
| Katzman, MA | 1 |
| Tanguay, RL | 1 |
| Khullar, A | 2 |
| Kritzer, MD | 2 |
| Mischel, NA | 1 |
| Young, JR | 1 |
| Lai, CS | 1 |
| Masand, PS | 3 |
| Szabo, ST | 1 |
| Evers, A | 1 |
| Klein, M | 1 |
| Aloysi, A | 1 |
| Murrough, J | 2 |
| Jha, MK | 6 |
| Echegaray, MVF | 4 |
| Marback, RF | 4 |
| Guerreiro-Costa, LNF | 4 |
| Souza-Marques, B | 4 |
| Santos-Lima, C | 3 |
| Souza, LS | 1 |
| Dai, D | 1 |
| Miller, C | 1 |
| Valdivia, V | 1 |
| Boyle, B | 1 |
| Bolton, P | 1 |
| Li, S | 1 |
| Seiner, S | 1 |
| Meisner, R | 1 |
| Nogo, D | 2 |
| Jasrai, AK | 1 |
| Kim, H | 1 |
| Ceban, F | 7 |
| Vinberg, M | 4 |
| Jawad, MY | 5 |
| Jaberi, S | 2 |
| Gillissie, ES | 1 |
| Alnafeesi, Y | 1 |
| Bayes, A | 4 |
| Short, B | 2 |
| Zarate, CA | 39 |
| Park, L | 4 |
| McLoughlin, DM | 4 |
| Riva-Posse, P | 4 |
| Schoevers, R | 2 |
| Veraart, J | 2 |
| Parikh, S | 1 |
| Glue, P | 7 |
| Fam, J | 1 |
| McShane, R | 5 |
| Galvez, V | 5 |
| Martin, D | 5 |
| Tor, PC | 1 |
| Brunoni, AR | 1 |
| Loo, CK | 8 |
| Nikayin, S | 3 |
| Murphy, E | 1 |
| Krystal, JH | 6 |
| Wilkinson, ST | 11 |
| Ballard, ED | 12 |
| Farmer, CA | 1 |
| Gerner, J | 1 |
| Bloomfield-Clagett, B | 1 |
| Park, LT | 5 |
| Pae, CU | 1 |
| Rosenman, S | 1 |
| Nazal, H | 1 |
| Song, Y | 1 |
| Rhee, TG | 2 |
| Cunningham, ME | 1 |
| de Fontnouvelle, CA | 1 |
| Ostroff, RB | 5 |
| Sanacora, G | 19 |
| Smith-Apeldoorn, SY | 6 |
| Vischjager, M | 1 |
| Veraart, JK | 2 |
| Kamphuis, J | 7 |
| Aan Het Rot, M | 5 |
| Schoevers, RA | 9 |
| Abuhelwa, AY | 1 |
| Somogyi, AA | 5 |
| Barratt, DT | 1 |
| Foster, DJR | 1 |
| Ohnishi, T | 1 |
| Wakamatsu, A | 1 |
| Kobayashi, H | 1 |
| Le, TT | 1 |
| Cordero, IP | 1 |
| Phan, L | 5 |
| Alnefeesi, Y | 2 |
| Chen-Li, D | 2 |
| Krane, E | 1 |
| Meshkat, S | 7 |
| Ho, RCM | 1 |
| Cao, B | 6 |
| Tham, JCW | 1 |
| Do, A | 2 |
| Fridfinnson, J | 1 |
| Rafizadeh, R | 1 |
| Siu, JTP | 1 |
| Budd, GP | 1 |
| Lam, RW | 3 |
| Camargo, A | 1 |
| Rodrigues, ALS | 1 |
| MahmoudianDehkordi, S | 1 |
| Voort, JLV | 2 |
| Port, JD | 2 |
| Kaddurah-Daouk, R | 2 |
| Borentain, S | 7 |
| Gogate, J | 2 |
| Williamson, D | 3 |
| Carmody, T | 1 |
| Trivedi, M | 3 |
| Jamieson, C | 4 |
| Cabrera, P | 2 |
| Wajs, E | 6 |
| DiBernardo, A | 2 |
| Medeiros, GC | 1 |
| Gould, TD | 3 |
| Prueitt, WL | 1 |
| Nanavati, J | 1 |
| Grunebaum, MF | 2 |
| Farber, NB | 3 |
| Selvaraj, S | 1 |
| Machado-Vieira, R | 8 |
| Achtyes, ED | 1 |
| Parikh, SV | 5 |
| Goes, FS | 4 |
| Yang, XH | 2 |
| Gu, LM | 2 |
| Tan, JQ | 1 |
| Zhou, YL | 5 |
| Wang, CY | 5 |
| Ning, YP | 6 |
| Rossi, GN | 1 |
| Hallak, JEC | 1 |
| Baker, G | 3 |
| Dursun, SM | 1 |
| Dos Santos, RG | 1 |
| Cook, J | 1 |
| Halaris, A | 1 |
| Shoib, S | 1 |
| Kotra, M | 1 |
| Javed, S | 1 |
| Nguyen, VS | 1 |
| Malathesh, BC | 1 |
| Joneborg, I | 1 |
| Fancy, F | 3 |
| Van Geel, A | 1 |
| Burhunduli, P | 1 |
| Vasudev, D | 1 |
| Batten, LA | 3 |
| Norris, S | 3 |
| Talbot, J | 4 |
| Ortiz, A | 3 |
| Owoeye, O | 3 |
| Cheng, CM | 11 |
| Zhang, JC | 1 |
| Yao, W | 1 |
| Hashimoto, K | 6 |
| Surjan, J | 3 |
| Grossi, JD | 1 |
| Del Porto, JA | 3 |
| Delfino, RS | 1 |
| de Oliveira Cerqueira, R | 1 |
| Lucchese, AC | 5 |
| Magalhães, E | 1 |
| Del Sant, LC | 3 |
| Tuena, MA | 5 |
| Nakahira, C | 5 |
| Fava, VAR | 2 |
| Steglich, MS | 1 |
| Abdo, GL | 1 |
| Barbosa, MG | 1 |
| Sarin, LM | 6 |
| Clerc, MT | 1 |
| Rosenhagen-Lapoirie, M | 1 |
| Von Gunten, A | 1 |
| Levinta, A | 1 |
| Ho, C | 1 |
| Mansur, RB | 21 |
| Kang, MJY | 2 |
| Vazquez, GH | 5 |
| Price, RB | 3 |
| Spotts, C | 1 |
| Panny, B | 1 |
| Griffo, A | 1 |
| Degutis, M | 1 |
| Cruz, N | 1 |
| Bell, E | 1 |
| Do-Nguyen, K | 1 |
| Wallace, ML | 1 |
| Howland, RH | 2 |
| Williamson, DJ | 1 |
| Gogate, JP | 1 |
| Kern Sliwa, JK | 1 |
| Manera, LS | 1 |
| Preskorn, SH | 1 |
| Winokur, A | 4 |
| Starr, HL | 3 |
| Martinotti, G | 5 |
| Vita, A | 3 |
| Fagiolini, A | 4 |
| Maina, G | 2 |
| Bertolino, A | 2 |
| Dell'Osso, B | 3 |
| Siracusano, A | 1 |
| Bellomo, A | 1 |
| d'Andrea, G | 5 |
| Chiaie, RD | 1 |
| Conca, A | 1 |
| Barlati, S | 3 |
| Di Lorenzo, G | 3 |
| De Fazio, P | 2 |
| De Filippis, S | 3 |
| Nicolò, G | 2 |
| Rosso, G | 2 |
| Valchera, A | 1 |
| Nucifora, D | 2 |
| Di Mauro, S | 2 |
| Bassetti, R | 3 |
| Martiadis, V | 1 |
| Olivola, M | 1 |
| Belletti, S | 1 |
| Andriola, I | 3 |
| Pettorruso, M | 5 |
| di Giannantonio, M | 2 |
| Bottemanne, H | 1 |
| Morlaas, O | 1 |
| Claret, A | 1 |
| Sharot, T | 1 |
| Fossati, P | 2 |
| Schmidt, L | 1 |
| Yuan, S | 1 |
| Luo, X | 1 |
| Chen, X | 2 |
| Wang, M | 2 |
| Hu, Y | 1 |
| Zhang, B | 5 |
| Gutiérrez, G | 2 |
| Vázquez, G | 2 |
| D Di Vincenzo, J | 1 |
| B Rodrigues, N | 1 |
| Mw Lui, L | 1 |
| Psiuk, D | 1 |
| Nowak, EM | 1 |
| Dycha, N | 1 |
| Łopuszańska, U | 1 |
| Kurzepa, J | 1 |
| Samardakiewicz, M | 1 |
| Spijker, J | 1 |
| Tao, Y | 1 |
| Xu, H | 1 |
| Huang, X | 2 |
| O'Brien, B | 3 |
| Lee, J | 2 |
| Kim, S | 2 |
| Nandra, GS | 1 |
| Pannu, P | 1 |
| Tamman, AJF | 2 |
| Amarneh, D | 2 |
| Averill, LA | 2 |
| Lan, XF | 4 |
| Badulescu, S | 1 |
| Tabassum, A | 3 |
| Mckenzie, A | 1 |
| Ho, RC | 6 |
| Lapidos, A | 2 |
| Lopez-Vives, D | 2 |
| Sera, CE | 2 |
| Ahearn, E | 2 |
| Vest, E | 2 |
| Senic, I | 2 |
| Frye, M | 2 |
| Achtyes, E | 3 |
| Greden, J | 2 |
| Wilkowska, A | 5 |
| Cubała, WJ | 11 |
| Turkoz, I | 5 |
| Bahji, A | 3 |
| Rosenblat, J | 1 |
| Schaffer, A | 1 |
| Karthikeyan, G | 1 |
| Ravindran, N | 1 |
| Giacobbe, P | 1 |
| Hawken, E | 1 |
| Milev, R | 1 |
| Ahmed, GK | 1 |
| Elserogy, YM | 1 |
| Elfadl, GMA | 1 |
| Ghada Abdelsalam, K | 1 |
| Ali, MA | 1 |
| Pompili, M | 1 |
| Sarli, G | 1 |
| Erbuto, D | 1 |
| Manfredi, G | 1 |
| Comparelli, A | 1 |
| Cavallotto, C | 1 |
| Chiappini, S | 2 |
| Zanardi, R | 1 |
| Sensi, SL | 1 |
| Pazdernik, VM | 1 |
| Taraku, B | 2 |
| Woods, RP | 3 |
| Boucher, M | 1 |
| Espinoza, R | 3 |
| Jog, M | 1 |
| Al-Sharif, N | 1 |
| Narr, KL | 4 |
| Zavaliangos-Petropulu, A | 2 |
| Wallner, MA | 1 |
| Eloge, JC | 1 |
| Mackey, IV | 1 |
| Zajecka, J | 2 |
| Mathai, DS | 1 |
| Nayak, SM | 1 |
| Yaden, DB | 1 |
| Garcia-Romeu, A | 1 |
| Kao, CF | 2 |
| Lineham, A | 1 |
| Avila-Quintero, VJ | 1 |
| Bloch, MH | 2 |
| Dwyer, J | 1 |
| Lugg, W | 1 |
| Lorenzo, GD | 1 |
| Mancusi, G | 1 |
| Danayan, K | 2 |
| Chisamore, N | 2 |
| Vincenzo, JDD | 1 |
| Doyle, Z | 2 |
| Chau, E | 2 |
| Arekapudi, A | 2 |
| Papp, M | 3 |
| Willner, P | 4 |
| Chen, LF | 2 |
| Li, WC | 2 |
| Yeung, A | 1 |
| Sapirstein, G | 1 |
| Crain, LD | 1 |
| Cramer, MA | 1 |
| Forcen, FE | 1 |
| McClintock, SM | 1 |
| Khalil, J | 1 |
| Joshi, SH | 3 |
| Al-Sharif, NB | 1 |
| Espinoza, RT | 1 |
| Payette, O | 1 |
| Lespérance, P | 2 |
| Desbeaumes Jodoin, V | 2 |
| Longpré-Poirier, C | 2 |
| Elkrief, L | 1 |
| Richard, M | 1 |
| Garel, N | 2 |
| Miron, JP | 2 |
| Swann, A | 1 |
| Sensi, S | 1 |
| Feeney, A | 2 |
| Papakostas, GI | 8 |
| Kamal, S | 1 |
| Radhakrishnan, R | 1 |
| Subramanian, S | 2 |
| Oughli, HA | 1 |
| Gebara, MA | 1 |
| Palanca, BJA | 2 |
| Lenze, EJ | 4 |
| Wu, Z | 1 |
| Gan, Y | 1 |
| Li, N | 2 |
| Hu, Z | 1 |
| Breeksema, JJ | 2 |
| Niemeijer, A | 1 |
| Kuin, B | 1 |
| Vermetten, E | 1 |
| Anand, A | 5 |
| Altinay, M | 4 |
| Aloysi, AS | 1 |
| Asghar-Ali, AA | 1 |
| Barnett, BS | 1 |
| Collins, KA | 5 |
| Krishnan, K | 2 |
| Malone, DA | 2 |
| Nissen, SE | 1 |
| Reti, IM | 1 |
| Wolski, K | 1 |
| Hu, B | 2 |
| Gonçalves, MAS | 1 |
| Leite, TRA | 1 |
| Júnior, EAB | 1 |
| Araújo, GAC | 1 |
| Bisol, LW | 3 |
| Gomes de Matos E Souza, F | 1 |
| van Amsterdam, J | 1 |
| Kavalali, ET | 2 |
| Monteggia, LM | 2 |
| Liu, YL | 1 |
| Greenway, KT | 1 |
| Dinh-Williams, LL | 1 |
| Thibault-Levesque, J | 1 |
| Jutras-Aswad, D | 1 |
| Turecki, G | 4 |
| Rej, S | 1 |
| Richard-Devantoy, S | 2 |
| Castro, M | 1 |
| Petrillo, MP | 1 |
| Zaki, N | 2 |
| Fu, DJ | 2 |
| Sun, L | 1 |
| Brown, B | 1 |
| Shafiee, A | 1 |
| Soltani Abhari, F | 1 |
| Jafarabady, K | 1 |
| Bakhtiyari, M | 1 |
| Thase, ME | 6 |
| Romani, S | 1 |
| Jacquet, B | 1 |
| Cohen, D | 1 |
| Curiale, V | 1 |
| Laurent, I | 1 |
| Louchart De La Chapelle, S | 1 |
| Jerath, AU | 1 |
| Oldak, SE | 1 |
| Parrish, MS | 1 |
| Zaydlin, M | 1 |
| Martin, S | 1 |
| Brown, K | 1 |
| Cara, V | 1 |
| Coffey, BJ | 1 |
| Reif, A | 1 |
| Bitter, I | 3 |
| Buyze, J | 1 |
| Cebulla, K | 1 |
| Frey, R | 1 |
| Ito, T | 1 |
| Kambarov, Y | 1 |
| Llorca, PM | 1 |
| Oliveira-Maia, AJ | 1 |
| Messer, T | 1 |
| Mulhern-Haughey, S | 1 |
| Rive, B | 1 |
| von Holt, C | 1 |
| Young, AH | 6 |
| Godinov, Y | 1 |
| Harris, E | 1 |
| Wang, Z | 2 |
| Chiang, CH | 3 |
| Hsia, YP | 1 |
| Niciu, MJ | 10 |
| Meisner, RC | 1 |
| Carr, BR | 1 |
| Farooqui, AA | 1 |
| Feifel, D | 2 |
| Kaplin, A | 2 |
| Kendrick, EJ | 1 |
| Kim, PM | 1 |
| Schneck, CD | 1 |
| Terao, I | 1 |
| Tsuge, T | 1 |
| Endo, K | 1 |
| Kodama, W | 1 |
| Lee, W | 1 |
| Sheehan, C | 1 |
| Chye, R | 1 |
| Chang, S | 1 |
| Loo, C | 8 |
| Draper, B | 1 |
| Agar, MR | 1 |
| Currow, DC | 1 |
| Lascelles, K | 1 |
| Marzano, L | 1 |
| Brand, F | 1 |
| Trueman, H | 1 |
| Hawton, K | 2 |
| Gueorguieva, R | 2 |
| Zhan, Y | 3 |
| Williams, NR | 3 |
| Heifets, BD | 2 |
| Bentzley, BS | 1 |
| Blasey, C | 2 |
| Sudheimer, KD | 1 |
| Hawkins, J | 2 |
| Lyons, DM | 2 |
| Xiong, Z | 2 |
| Su, B | 1 |
| Wang, L | 3 |
| Li, Z | 2 |
| Fang, J | 1 |
| Walter, M | 1 |
| Li, M | 2 |
| Li, MD | 1 |
| Szałach, ŁP | 3 |
| Lisowska, KA | 1 |
| Słupski, J | 4 |
| Włodarczyk, A | 7 |
| Górska, N | 4 |
| Szarmach, J | 6 |
| Jakuszkowiak-Wojten, K | 3 |
| Gałuszko-Węgielnik, M | 5 |
| Wiglusz, MS | 5 |
| Krysta, K | 1 |
| Słupska, A | 2 |
| Małyszko, A | 1 |
| Salloum, NC | 3 |
| Fava, M | 12 |
| Hock, RS | 4 |
| Flynn, M | 4 |
| Hoeppner, B | 4 |
| Cusin, C | 9 |
| Iosifescu, DV | 19 |
| Trivedi, MH | 7 |
| Debattista, C | 5 |
| Ionescu, DF | 15 |
| Veraart, JKE | 5 |
| Dale, RM | 4 |
| Bryant, KA | 1 |
| Finnegan, N | 3 |
| Cromer, K | 1 |
| Thompson, NR | 1 |
| Hough, D | 8 |
| Manji, H | 9 |
| Lent, JK | 1 |
| Arredondo, A | 1 |
| Pugh, MA | 1 |
| Austin, PN | 1 |
| Zhuo, C | 3 |
| Tian, H | 3 |
| Li, G | 2 |
| Chen, M | 2 |
| Jiang, D | 3 |
| Lin, X | 3 |
| Xu, Y | 1 |
| Wang, W | 2 |
| Kryst, J | 1 |
| Kawalec, P | 1 |
| Pilc, A | 1 |
| Cristea, IA | 2 |
| Naudet, F | 2 |
| Turner, EH | 2 |
| Lu, BY | 1 |
| Agapoff, JR | 1 |
| Olson, DJ | 1 |
| Williams, SR | 2 |
| Roller, A | 1 |
| Goebert, D | 1 |
| Bobo, WV | 4 |
| Rasmussen, KG | 4 |
| Stoppel, CJ | 1 |
| Rico, JA | 1 |
| Schak, KM | 3 |
| Biernacka, JM | 1 |
| Witt, K | 1 |
| Potts, J | 1 |
| Hubers, A | 1 |
| Cipriani, A | 1 |
| Lavretsky, H | 1 |
| Roose, SP | 1 |
| Ochs-Ross, R | 2 |
| Morrison, RL | 2 |
| Steffens, DC | 1 |
| Adler, C | 1 |
| Gaillard, R | 6 |
| Kaur, U | 1 |
| Pathak, BK | 1 |
| Singh, A | 1 |
| Chakrabarti, SS | 1 |
| Hatchard, T | 2 |
| Birmingham, M | 2 |
| Bolyós, C | 1 |
| Nagy, M | 1 |
| Réthelyi, J | 1 |
| Czobor, P | 1 |
| van Asselt, ADI | 1 |
| Touw, DJ | 1 |
| Cavalcanti, DE | 2 |
| Araújo-de-Freitas, L | 3 |
| Del-Porto, JA | 2 |
| Scheele, D | 1 |
| Zimbal, S | 1 |
| Feinstein, JS | 1 |
| Delis, A | 1 |
| Neumann, C | 1 |
| Mielacher, C | 1 |
| Philipsen, A | 1 |
| Hurlemann, R | 1 |
| Acevedo-Diaz, EE | 2 |
| Cavanaugh, GW | 2 |
| Greenstein, D | 2 |
| Kraus, C | 4 |
| Kadriu, B | 7 |
| Bozymski, KM | 1 |
| Crouse, EL | 1 |
| Titus-Lay, EN | 1 |
| Ott, CA | 1 |
| Nofziger, JL | 1 |
| Kirkwood, CK | 1 |
| Gastaldon, C | 2 |
| Papola, D | 2 |
| Ostuzzi, G | 2 |
| Barbui, C | 2 |
| Agboola, F | 1 |
| Atlas, SJ | 1 |
| Touchette, DR | 1 |
| Fazioli, K | 1 |
| Pearson, SD | 1 |
| Dadiomov, D | 1 |
| Chen, Q | 1 |
| Dong, J | 1 |
| Luo, J | 1 |
| Ren, L | 1 |
| Min, S | 1 |
| Hao, X | 1 |
| Luo, Q | 1 |
| Chen, J | 1 |
| Zimmermann, KS | 1 |
| Richardson, R | 1 |
| Baker, KD | 1 |
| Gilbert, JR | 4 |
| Basso, L | 2 |
| Bönke, L | 1 |
| Aust, S | 2 |
| Gärtner, M | 2 |
| Heuser-Collier, I | 2 |
| Otte, C | 2 |
| Wingenfeld, K | 2 |
| Bajbouj, M | 3 |
| Grimm, S | 2 |
| Doherty, T | 2 |
| Melkote, R | 3 |
| Miller, J | 1 |
| Weber, MA | 1 |
| Sakurai, H | 1 |
| Bentley, K | 1 |
| Pedrelli, P | 1 |
| Foster, S | 1 |
| Mischoulon, D | 4 |
| Sial, OK | 1 |
| Parise, EM | 1 |
| Parise, LF | 1 |
| Gnecco, T | 1 |
| Bolaños-Guzmán, CA | 2 |
| Carreno, FR | 1 |
| Lodge, DJ | 1 |
| Frazer, A | 1 |
| Wei, Y | 2 |
| Chang, L | 3 |
| Sahib, AK | 2 |
| Loureiro, JRA | 1 |
| Vasavada, MM | 2 |
| Kubicki, A | 2 |
| Wang, K | 1 |
| Congdon, E | 2 |
| Wang, DJJ | 1 |
| Boucher, ML | 1 |
| Kokane, SS | 1 |
| Armant, RJ | 1 |
| Perrotti, LI | 1 |
| Telles, M | 3 |
| Lima, CS | 2 |
| Marques, BLS | 1 |
| Bezerra, MLO | 1 |
| Dias-Neto, AL | 1 |
| Mathews, M | 3 |
| Jalloh, M | 1 |
| Zhang, J | 1 |
| Li, J | 2 |
| Ji, S | 1 |
| Chen, S | 1 |
| Zhu, J | 2 |
| Duman, RS | 2 |
| Nijs, M | 1 |
| Aluisio, L | 2 |
| Daly, E | 5 |
| Janik, A | 3 |
| Wiegand, F | 2 |
| Abdallah, CG | 3 |
| Holder, R | 1 |
| George, JE | 1 |
| Sulaiman, AH | 1 |
| Paik, JW | 1 |
| Grunfeld, J | 1 |
| Jeon, HJ | 1 |
| Heerlein, K | 1 |
| Canuso, C | 1 |
| Saad, Z | 1 |
| Hibar, D | 1 |
| Kolb, H | 1 |
| Rush, BS | 1 |
| Rice, TR | 1 |
| Fantasia, HC | 1 |
| Cha, DS | 13 |
| Malhi, GS | 1 |
| Suppes, T | 1 |
| Manduca, JD | 1 |
| Thériault, RK | 1 |
| Williams, OOF | 1 |
| Rasmussen, DJ | 1 |
| Perreault, ML | 1 |
| David, S | 1 |
| Horowitz, MA | 1 |
| Borissova, A | 1 |
| Marsh, B | 1 |
| Morgan, CJA | 1 |
| Dold, M | 2 |
| Bartova, L | 3 |
| Shiroma, PR | 5 |
| Thuras, P | 5 |
| Wels, J | 5 |
| Albott, CS | 6 |
| Erbes, C | 2 |
| Tye, S | 3 |
| Lim, KO | 6 |
| Kolar, D | 1 |
| Ji, F | 1 |
| Jia, F | 1 |
| Chen, C | 1 |
| Zhou, C | 1 |
| Magalhães, EJM | 2 |
| Delfino, R | 2 |
| Steiglich, MS | 2 |
| Barbosa, M | 2 |
| Abdo, G | 2 |
| Cohrs, FM | 2 |
| Liberatori, A | 2 |
| de Jesus Mari, J | 2 |
| Stultz, DJ | 1 |
| Stanley, N | 1 |
| Gills, T | 1 |
| Osburn, S | 1 |
| Burns, T | 1 |
| Moomaw, S | 1 |
| Pawlowska-Wajswol, S | 1 |
| Walton, R | 1 |
| Liu, WJ | 1 |
| Zhan, YN | 1 |
| Majeed, A | 3 |
| Senyk, O | 1 |
| Carvalho, IP | 2 |
| Siegel, A | 3 |
| Brietzke, E | 3 |
| Arekapudi, AK | 2 |
| Abrishami, A | 2 |
| Chau, EH | 2 |
| Szpejda, W | 2 |
| Sim, K | 2 |
| Xiang, YT | 1 |
| Luckenbaugh, DA | 16 |
| Pennybaker, SJ | 1 |
| Hopkins, MA | 1 |
| Henter, ID | 3 |
| Lener, MS | 1 |
| Chang, WC | 1 |
| Huang, WS | 1 |
| Khorassani, F | 1 |
| Talreja, O | 1 |
| Loureiro, JR | 1 |
| Wade, B | 1 |
| Fornaro, M | 1 |
| Carvalho, AF | 1 |
| Fusco, A | 1 |
| Anastasia, A | 1 |
| Solmi, M | 1 |
| Berk, M | 2 |
| Vieta, E | 3 |
| de Bartolomeis, A | 1 |
| Na, KS | 1 |
| Kim, YK | 1 |
| Crisanti, C | 1 |
| Enrico, P | 1 |
| Fiorentini, A | 1 |
| Delvecchio, G | 1 |
| Brambilla, P | 1 |
| Del Sant, L | 1 |
| Abell, J | 1 |
| Larish, A | 1 |
| Lewis, S | 1 |
| DeMuro, C | 1 |
| Kramer, M | 1 |
| Katz, EG | 1 |
| Singh, J | 4 |
| Levitan, B | 1 |
| Coles, AC | 1 |
| Tamura, JK | 1 |
| Iacobucci, M | 1 |
| Singhal, N | 1 |
| Wong, ER | 1 |
| Wu, FC | 1 |
| Deng, XR | 1 |
| Mkrtchian, A | 1 |
| Evans, JW | 2 |
| Yuan, P | 4 |
| Nugent, AC | 10 |
| Roiser, JP | 4 |
| Munkholm, K | 1 |
| Jørgensen, KJ | 1 |
| Kaster, TS | 1 |
| Teopiz, K | 2 |
| Shekotikhina, M | 3 |
| Lui, LM | 1 |
| Marcantoni, WS | 1 |
| Akoumba, BS | 1 |
| Wassef, M | 1 |
| Mayrand, J | 1 |
| Lai, H | 1 |
| Beauchamp, S | 1 |
| Lundin, NB | 2 |
| Sepe-Forrest, L | 1 |
| Carver, FW | 1 |
| Ramos-Quiroga, JA | 1 |
| Souery, D | 1 |
| Jelen, LA | 2 |
| Stone, JM | 2 |
| Rocha, FL | 1 |
| de Vasconcelos Cunha, UG | 1 |
| Paschoalin, RC | 1 |
| Hara, C | 1 |
| Thomaz, DP | 1 |
| Gill, B | 1 |
| El-Halabi, S | 1 |
| Rivas-Grajales, AM | 1 |
| Salas, R | 2 |
| Robinson, ME | 1 |
| Qi, K | 1 |
| Hudgens, S | 1 |
| Floden, L | 1 |
| Blackowicz, M | 1 |
| Machado, C | 1 |
| Bressan, RA | 1 |
| Noto, C | 1 |
| Simonson, K | 1 |
| Spaans, HP | 1 |
| Sydnor, VJ | 1 |
| Lyall, AE | 1 |
| Cetin-Karayumak, S | 1 |
| Cheung, JC | 1 |
| Felicione, JM | 1 |
| Akeju, O | 4 |
| Shenton, ME | 1 |
| Deckersbach, T | 1 |
| Pasternak, O | 1 |
| Kubicki, M | 1 |
| Kavakbasi, E | 1 |
| Hassan, A | 1 |
| Baune, BT | 1 |
| Kulcar, E | 1 |
| Chandrasena, R | 1 |
| Anjum, MR | 1 |
| Fairbairn, J | 1 |
| Hawken, ER | 1 |
| Hosanagar, A | 1 |
| Schmale, A | 1 |
| LeBlanc, A | 1 |
| B Puertas, C | 1 |
| Fava, VA | 1 |
| Lacerda, AL | 1 |
| B Andreoli, S | 1 |
| Khazaal, Y | 1 |
| Elowe, J | 1 |
| Kloucek, P | 1 |
| Preisig, M | 1 |
| Tadri, M | 1 |
| Vandeleur, C | 1 |
| Vandenberghe, F | 1 |
| Verloo, H | 1 |
| Ros, T | 1 |
| Von Guntenb, A | 1 |
| Cepeda, MS | 2 |
| Kern, DM | 1 |
| Greenberg, D | 1 |
| Flint, AJ | 1 |
| Siegel, JS | 1 |
| Ances, BM | 1 |
| Kharasch, ED | 1 |
| Schweiger, JA | 1 |
| Yingling, MD | 1 |
| Snyder, AZ | 1 |
| Nicol, GE | 1 |
| Ng, J | 3 |
| Xiong, J | 1 |
| Schlegel, M | 1 |
| Manji, HK | 2 |
| Sanders, B | 1 |
| Brula, AQ | 1 |
| Dwyer, JB | 1 |
| Landeros-Weisenberger, A | 1 |
| Johnson, JA | 1 |
| Londono Tobon, A | 1 |
| Flores, JM | 1 |
| Nasir, M | 1 |
| Couloures, K | 1 |
| Ziegler, L | 1 |
| Peters, E | 1 |
| Wanson, A | 1 |
| Halpape, K | 1 |
| Nemeroff, CB | 2 |
| Dodd, S | 1 |
| Gorwood, P | 1 |
| Lopez Jaramillo, C | 1 |
| Lee, JG | 2 |
| Thase, M | 1 |
| Stahl, S | 1 |
| Kim, YS | 1 |
| Wells, A | 1 |
| Parikh, T | 1 |
| Walkup, JT | 1 |
| Stocker, K | 1 |
| Hasler, G | 1 |
| Hartmann, M | 1 |
| Bonaventura, J | 1 |
| Lam, S | 1 |
| Carlton, M | 1 |
| Boehm, MA | 1 |
| Gomez, JL | 1 |
| Solís, O | 1 |
| Sánchez-Soto, M | 1 |
| Morris, PJ | 2 |
| Fredriksson, I | 1 |
| Thomas, CJ | 2 |
| Sibley, DR | 1 |
| Shaham, Y | 1 |
| Michaelides, M | 1 |
| McMullen, EP | 1 |
| Coombes, BJ | 1 |
| Geske, JR | 1 |
| Lanza, IR | 1 |
| Morgan, RJ | 2 |
| Magnavita, GM | 1 |
| Veldman, ER | 1 |
| Mamula, D | 1 |
| Jiang, H | 1 |
| Tiger, M | 2 |
| Ekman, CJ | 1 |
| Lundberg, J | 1 |
| Svenningsson, P | 1 |
| Wang, A | 1 |
| Fagerholm, ED | 1 |
| Leech, R | 1 |
| Williams, S | 1 |
| Moran, RJ | 1 |
| Cubala, WJ | 2 |
| Swiecicki, L | 1 |
| Newman-Tancredi, A | 1 |
| Mendonça-Filho, E | 1 |
| França, RJAF | 1 |
| Cardoso, TL | 1 |
| Marback, R | 1 |
| Teles, M | 1 |
| Echegaray, MV | 1 |
| Rabanea, T | 1 |
| Abreu, N | 1 |
| Marom, A | 1 |
| Rosca, P | 1 |
| Dogra, S | 1 |
| Conn, PJ | 1 |
| Doty, RL | 1 |
| Wylie, C | 1 |
| Undurraga, J | 1 |
| Tondo, L | 1 |
| Baldessarini, RJ | 1 |
| Galloway, MP | 1 |
| Wong, L | 1 |
| Roxas, N | 1 |
| Ahuja, C | 1 |
| Isom, J | 1 |
| Capurso, N | 1 |
| Ludwig, VM | 1 |
| Sauer, C | 1 |
| Rucker, J | 1 |
| Bauer, M | 1 |
| Findeis, H | 1 |
| Ritter, P | 1 |
| Salvadore, G | 3 |
| Zorn, A | 1 |
| Linn, S | 1 |
| Jenkinson, M | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Kelsberg, G | 1 |
| Ling, R | 1 |
| Gärde, M | 1 |
| Tateno, A | 1 |
| Matheson, GJ | 1 |
| Sakayori, T | 1 |
| Nogami, T | 1 |
| Moriya, H | 1 |
| Varnäs, K | 1 |
| Arakawa, R | 1 |
| Okubo, Y | 1 |
| da Costa, JPOM | 2 |
| Souza, FGME | 2 |
| Pennybaker, S | 1 |
| Roach, BJ | 1 |
| Fryer, SL | 1 |
| Badathala, A | 1 |
| Wallace, AW | 1 |
| Mathalon, DH | 1 |
| Marton, TF | 1 |
| Dong, V | 2 |
| Alonzo, A | 4 |
| Kabourakis, M | 1 |
| Lopez, D | 1 |
| Rico, J | 2 |
| Coryell, W | 1 |
| Goddard, A | 1 |
| Goes, F | 1 |
| Greden, JF | 1 |
| Maixner, D | 1 |
| Watson, B | 1 |
| Drake, K | 1 |
| Tarnal, V | 1 |
| Kiraly, DD | 1 |
| Horn, SR | 1 |
| Van Dam, NT | 1 |
| Schwartz, J | 3 |
| Kim-Schulze, S | 1 |
| Patel, M | 1 |
| Hodes, GE | 1 |
| Merad, M | 1 |
| Kellner, CH | 3 |
| Cullen, KR | 2 |
| Johns, B | 3 |
| Singh, I | 1 |
| Morgan, C | 1 |
| Curran, V | 1 |
| Nutt, D | 1 |
| Schlag, A | 1 |
| Zavorotnyy, M | 1 |
| Kluge, I | 1 |
| Ahrens, K | 1 |
| Wohltmann, T | 1 |
| Köhnlein, B | 1 |
| Dietsche, P | 1 |
| Dannlowski, U | 1 |
| Kircher, T | 1 |
| Konrad, C | 1 |
| Medlicott, NJ | 1 |
| Harland, S | 1 |
| Neehoff, S | 1 |
| Anderson-Fahey, B | 1 |
| Le Nedelec, M | 1 |
| Gray, A | 1 |
| McNaughton, N | 1 |
| Duncan, WC | 1 |
| Slonena, E | 1 |
| Hejazi, NS | 1 |
| Brutsche, N | 2 |
| Yu, KC | 1 |
| Wright, D | 1 |
| Fasula, MK | 1 |
| Fenton, L | 1 |
| Griepp, M | 1 |
| Al Shirawi, MI | 1 |
| Kennedy, SH | 1 |
| Ho, KT | 1 |
| Byrne, R | 1 |
| Downar, J | 1 |
| Weidenauer, A | 1 |
| Willeit, M | 2 |
| Malcolm, B | 1 |
| Boggie, D | 1 |
| Lee, K | 1 |
| Golzari, SEJ | 1 |
| Mahmoodpoor, A | 1 |
| George, D | 1 |
| Kumar, D | 1 |
| Leyden, J | 2 |
| Hadzi-Pavlovic, D | 1 |
| Harper, S | 2 |
| Brodaty, H | 1 |
| Taylor, R | 1 |
| Mitchell, PB | 4 |
| Fong, J | 1 |
| Shelker, W | 1 |
| Anderson, IM | 2 |
| McDaniel, W | 1 |
| Vyas, B | 1 |
| Laguerta, N | 1 |
| Iadarola, ND | 1 |
| Banerjee, D | 2 |
| Park, M | 2 |
| Lener, M | 1 |
| Brutsche, NE | 10 |
| Akula, N | 1 |
| McMahon, FJ | 1 |
| Gurnani, T | 1 |
| Khurshid, KA | 1 |
| Abbasi, J | 1 |
| Medeiros da Frota Ribeiro, C | 1 |
| Hartberg, J | 1 |
| Garrett-Walcott, S | 1 |
| De Gioannis, A | 2 |
| Shelton, RC | 4 |
| Van Nueten, L | 3 |
| Kwon, JH | 1 |
| Sim, WS | 1 |
| Hong, JP | 1 |
| Song, IS | 1 |
| Lee, JY | 1 |
| Allen, AP | 2 |
| Naughton, M | 3 |
| Dowling, J | 3 |
| Walsh, A | 3 |
| O'Shea, R | 1 |
| Shorten, G | 3 |
| Scott, L | 3 |
| Cryan, JF | 4 |
| Clarke, G | 4 |
| Dinan, TG | 4 |
| Moaddel, R | 4 |
| Shovestul, BJ | 1 |
| Jaso, BA | 1 |
| Farmer, C | 2 |
| Li, A | 2 |
| Huggins, C | 2 |
| Rodgers, A | 2 |
| Bergfeld, IO | 1 |
| Mantione, M | 1 |
| Figee, M | 1 |
| Schuurman, PR | 1 |
| Lok, A | 1 |
| Denys, D | 1 |
| Pérez-Esparza, R | 3 |
| Corona, T | 1 |
| Ruiz-García, RG | 1 |
| Oñate-Cadena, N | 1 |
| de la Fuente-Sandoval, C | 1 |
| Ramírez-Bermúdez, J | 1 |
| Lally, N | 4 |
| An, L | 1 |
| Snider, SL | 1 |
| Shen, J | 1 |
| Cobb, K | 1 |
| Nanda, M | 1 |
| Tadler, SC | 1 |
| Mickey, BJ | 1 |
| Shouan, A | 1 |
| Grover, S | 1 |
| Carspecken, CW | 1 |
| Borisovskaya, A | 1 |
| Lan, ST | 1 |
| Heller, K | 1 |
| Buchholz, J | 1 |
| Ruskin, D | 1 |
| Rozet, I | 1 |
| Archer, S | 3 |
| Chrenek, C | 3 |
| Vollmer, H | 1 |
| Amatya, P | 1 |
| Roback, MG | 1 |
| Westlund Schreiner, M | 1 |
| Ren, Y | 1 |
| Eberly, LE | 1 |
| Carstedt, P | 1 |
| Samikoglu, A | 1 |
| Gunlicks-Stoessel, M | 1 |
| Reigstad, K | 1 |
| Horek, N | 1 |
| Klimes-Dougan, B | 1 |
| Katz, RB | 1 |
| Toprak, M | 1 |
| Webler, R | 1 |
| Fernández-González, JL | 1 |
| Shardell, M | 1 |
| Khadeer, M | 1 |
| Lovett, J | 1 |
| Ravichandran, S | 1 |
| Ferrucci, L | 1 |
| Sudheimer, K | 1 |
| Pannu, J | 1 |
| Pankow, H | 1 |
| Birnbaum, J | 1 |
| Rodriguez, CI | 1 |
| Thomas, RK | 2 |
| Lind, J | 1 |
| Dursun, S | 2 |
| Gruca, P | 1 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 1 |
| Niemczyk, M | 1 |
| Ferreira, CBN | 1 |
| Vale, LAS | 1 |
| Argolo, FC | 1 |
| Cardoso, T | 1 |
| Souza, CDS | 1 |
| Fontes, ATC | 1 |
| Ferreira, MB | 1 |
| Abreu, JN | 1 |
| Machado, PRL | 1 |
| Domany, Y | 1 |
| Bleich-Cohen, M | 1 |
| Tarrasch, R | 1 |
| Meidan, R | 1 |
| Litvak-Lazar, O | 1 |
| Stoppleman, N | 1 |
| Schreiber, S | 1 |
| Bloch, M | 1 |
| Hendler, T | 1 |
| Sharon, H | 1 |
| Limandri, BJ | 2 |
| Judge, H | 2 |
| Hoeppner, BB | 1 |
| Bentley, KH | 1 |
| Eikermann, M | 2 |
| Taylor, N | 3 |
| Swee, MB | 3 |
| Pavone, KJ | 3 |
| Petrie, SR | 1 |
| Dording, C | 2 |
| Alpert, JE | 2 |
| Brown, EN | 3 |
| Baer, L | 2 |
| Nock, MK | 2 |
| Saligan, LN | 2 |
| Vidal, S | 2 |
| Gex-Fabry, M | 1 |
| Bancila, V | 2 |
| Michalopoulos, G | 2 |
| Warrot, D | 2 |
| Jermann, F | 1 |
| Dayer, A | 2 |
| Sterpenich, V | 2 |
| Schwartz, S | 2 |
| Vutskits, L | 2 |
| Khan, N | 1 |
| Aubry, JM | 2 |
| Kosel, M | 2 |
| Chan, LF | 1 |
| Eu, CL | 1 |
| Soh, SY | 1 |
| Maniam, T | 1 |
| Shahidii Kadir, Z | 1 |
| Chong, BTW | 1 |
| Loo, JL | 1 |
| Sharip, S | 1 |
| Wong, VCW | 1 |
| Loo, TH | 1 |
| Ng, YP | 1 |
| Kahn, DA | 1 |
| Musazzi, L | 1 |
| Graves, M | 1 |
| Popoli, M | 1 |
| Srikumar, BN | 1 |
| Naidu, PS | 1 |
| Kalidindi, N | 1 |
| Paschapur, M | 1 |
| Adepu, B | 1 |
| Subramani, S | 1 |
| Nagar, J | 1 |
| Srivastava, R | 1 |
| Sreedhara, MV | 1 |
| Prasad, DS | 1 |
| Das, ML | 1 |
| Louis, JV | 1 |
| Kuchibhotla, VK | 1 |
| Dudhgaonkar, S | 1 |
| Pieschl, RL | 1 |
| Li, YW | 1 |
| Bristow, LJ | 1 |
| Ramarao, M | 1 |
| Vikramadithyan, RK | 1 |
| Wills, KE | 1 |
| Asghar-Ali, A | 1 |
| Shao, M | 1 |
| Mazzone, E | 1 |
| Mathew, S | 1 |
| Iosifescu, D | 1 |
| Targum, SD | 1 |
| Chae, WR | 1 |
| Regen, F | 1 |
| Cosma, NC | 1 |
| van Hall, F | 1 |
| Lee, V | 1 |
| Gálvez Ortiz, V | 1 |
| Soleimani, L | 2 |
| Glasgow, A | 1 |
| Brallier, J | 1 |
| Spivack, J | 1 |
| Levitch, CF | 4 |
| Richards, S | 1 |
| Hoch, M | 1 |
| Stade, EC | 1 |
| Welch, A | 1 |
| Feder, A | 1 |
| Karne, H | 1 |
| Ghosh, P | 1 |
| Viswanath, O | 1 |
| Marton, T | 1 |
| Barnes, DE | 1 |
| Wallace, A | 1 |
| Woolley, JD | 1 |
| Lee, CW | 1 |
| Chen, YJ | 1 |
| Wu, HF | 1 |
| Chung, YJ | 1 |
| Lee, YC | 1 |
| Lin, HC | 1 |
| Hofmeister, J | 1 |
| Desseilles, M | 1 |
| Murillo-Izquierdo, M | 1 |
| Moreno-Mellado, E | 1 |
| Pu, Y | 1 |
| Qu, Y | 1 |
| Wang, SM | 1 |
| Ren, Q | 1 |
| Dong, C | 1 |
| Fujita, Y | 1 |
| Mazzucco, C | 1 |
| Molero, P | 2 |
| Duca, AR | 1 |
| Divacka, I | 1 |
| Pereira, VS | 1 |
| Harvey, BH | 2 |
| Elfving, B | 1 |
| Wegener, G | 1 |
| Aschenbrenner, DS | 1 |
| Kobayashi-Romero, LF | 1 |
| García-Mendoza, AM | 1 |
| Lamas-Aguilar, RM | 1 |
| Fonseca-Perezamador, A | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 3 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| MacKay, MA | 1 |
| Demas, ML | 1 |
| Vitagliano, D | 1 |
| Liebowitz, M | 1 |
| Ravindran, A | 1 |
| Ameele, HVD | 1 |
| Preskorn, S | 1 |
| Yang, C | 2 |
| Wardenaar, KJ | 1 |
| Bosker, FJ | 1 |
| Järventausta, K | 1 |
| Chrapek, W | 1 |
| Kampman, O | 1 |
| Tuohimaa, K | 1 |
| Björkqvist, M | 1 |
| Häkkinen, H | 1 |
| Yli-Hankala, A | 1 |
| Leinonen, E | 1 |
| Carlson, PJ | 1 |
| Diazgranados, N | 1 |
| Ibrahim, L | 1 |
| Herscovitch, P | 1 |
| Koike, H | 1 |
| Iijima, M | 1 |
| Chaki, S | 1 |
| D'Andrea, D | 1 |
| Andrew Sewell, R | 1 |
| Stahl, SM | 1 |
| Segmiller, F | 1 |
| Rüther, T | 1 |
| Linhardt, A | 1 |
| Padberg, F | 1 |
| Berger, M | 1 |
| Pogarell, O | 1 |
| Möller, HJ | 1 |
| Kohler, C | 1 |
| Schüle, C | 1 |
| Perez, AM | 4 |
| Pillemer, S | 2 |
| Foulkes, A | 4 |
| Shah, A | 2 |
| Rush, AJ | 1 |
| Mahoney, JJ | 1 |
| De La Garza, R | 1 |
| Newton, TF | 1 |
| Smith, MA | 1 |
| Pathak, S | 1 |
| Su, HL | 1 |
| Boeijinga, PH | 1 |
| McCarthy, DJ | 1 |
| Quirk, MC | 1 |
| Kuskowski, M | 1 |
| O'Leary, OF | 1 |
| Jay, T | 2 |
| Goncalvès, P | 2 |
| Lôo, H | 2 |
| De Leo, D | 1 |
| Clark, P | 1 |
| Szymkowicz, SM | 2 |
| Niemegeers, P | 1 |
| Schrijvers, D | 1 |
| Madani, Y | 1 |
| Sabbe, BG | 1 |
| Iqbal, SZ | 1 |
| Foulkes, AL | 1 |
| Villaseñor, A | 2 |
| Ramamoorthy, A | 2 |
| Silva dos Santos, M | 1 |
| Lorenzo, MP | 2 |
| Laje, G | 1 |
| Zarate, C | 1 |
| Barbas, C | 2 |
| Wainer, IW | 3 |
| Diamond, PR | 1 |
| Farmery, AD | 1 |
| Atkinson, S | 1 |
| Haldar, J | 1 |
| Williams, N | 1 |
| Cowen, PJ | 1 |
| Geddes, JR | 1 |
| Torjesen, I | 1 |
| Lai, R | 1 |
| Katalinic, N | 1 |
| Guevara, S | 1 |
| Richards, EM | 6 |
| Nolan, NM | 1 |
| Greenberg, RM | 1 |
| Ahle, GM | 1 |
| Liebman, LS | 1 |
| Fond, G | 2 |
| Loundou, A | 1 |
| Rabu, C | 1 |
| Macgregor, A | 1 |
| Lançon, C | 1 |
| Brittner, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Richieri, R | 1 |
| Courtet, P | 1 |
| Abbar, M | 1 |
| Roger, M | 1 |
| Leboyer, M | 1 |
| Boyer, L | 2 |
| Xie, Y | 1 |
| Garcia, A | 1 |
| Bernier, M | 2 |
| Torjman, MC | 1 |
| Yang, JJ | 1 |
| Wang, N | 1 |
| Shi, JY | 1 |
| Yu, HY | 1 |
| Jackowski, A | 1 |
| Baldwin, P | 1 |
| Sato, JR | 1 |
| McGirr, A | 1 |
| Berlim, MT | 1 |
| Wan, LB | 1 |
| Brallier, JW | 2 |
| Slonena, EE | 2 |
| Ameli, R | 1 |
| Singh, NS | 1 |
| Burdick, KE | 1 |
| Ostroff, R | 1 |
| Kothari, JS | 1 |
| Opler, LA | 1 |
| Opler, MG | 1 |
| Arnsten, AF | 1 |
| DeWilde, KE | 2 |
| Fields, J | 1 |
| Phillips, ML | 1 |
| Wong, E | 1 |
| Tang, CY | 1 |
| Köhler, S | 1 |
| Betzler, F | 1 |
| Ford, N | 1 |
| Ludbrook, G | 1 |
| Galletly, C | 1 |
| Kantrowitz, JT | 1 |
| Halberstam, B | 1 |
| Gangwisch, J | 1 |
| Xu, AJ | 1 |
| Miller, OH | 1 |
| Moran, JT | 1 |
| Hall, BJ | 1 |
| Kwak, S | 1 |
| Tiller, D | 1 |
| Tucker, P | 1 |
| Ismail, F | 2 |
| Belzung, C | 1 |
| Zhang, MW | 1 |
| Vogl, SE | 1 |
| Stamenkovic, M | 1 |
| Trevithick, L | 1 |
| McAllister-Williams, RH | 1 |
| Blamire, A | 1 |
| Branton, T | 1 |
| Clark, R | 1 |
| Downey, D | 1 |
| Dunn, G | 1 |
| Easton, A | 1 |
| Elliott, R | 1 |
| Ellwell, C | 1 |
| Hayden, K | 1 |
| Holland, F | 1 |
| Karim, S | 1 |
| Lowe, J | 1 |
| Nair, R | 1 |
| Oakley, T | 1 |
| Prakash, A | 1 |
| Sharma, PK | 1 |
| Syeda, K | 1 |
| Maruschak, NA | 1 |
| Wium-Andersen, IK | 1 |
| Woldeyohannes, HO | 1 |
| Xi, L | 1 |
| Melman, C | 1 |
| De Bruecker, G | 1 |
| Tadic, A | 1 |
| Sienaert, P | 1 |
| Kallmünzer, B | 1 |
| Volbers, B | 1 |
| Karthaus, A | 1 |
| Tektas, OY | 1 |
| Kornhuber, J | 1 |
| Müller, HH | 1 |
| Yang, BH | 1 |
| Liu, RS | 1 |
| Chaves, TV | 1 |
| Balukova, SM | 1 |
| Kortekaas, R | 1 |
| Cassano, P | 2 |
| Durham, K | 1 |
| Chang, T | 1 |
| Soskin, D | 1 |
| Kelley, J | 1 |
| Kucia, K | 1 |
| Merk, W | 1 |
| Kharasch, E | 1 |
| Schweiger, J | 1 |
| Yingling, M | 1 |
| Olney, J | 1 |
| Newcomer, JW | 1 |
| Johnson, EK | 1 |
| Leung, JG | 2 |
| Palmer, BA | 2 |
| Costemale-Lacoste, JF | 1 |
| Guilloux, JP | 1 |
| Rybakowski, JK | 2 |
| Bodnar, A | 1 |
| Krzywotulski, M | 1 |
| Chlopocka-Wozniak, M | 1 |
| Michalak, M | 1 |
| Rosada-Kurasinska, J | 1 |
| Bartkowska-Sniatkowska, A | 2 |
| Gold, PW | 2 |
| De Sousa, RT | 1 |
| De Boer, P | 1 |
| Pinter, C | 1 |
| Kurian, B | 1 |
| Croarkin, PE | 1 |
| Zhong, X | 1 |
| He, H | 1 |
| Zhang, C | 1 |
| Jiang, M | 1 |
| Li, Q | 1 |
| Zhang, M | 1 |
| Nyer, M | 1 |
| Gururajan, A | 1 |
| Naughton, ME | 1 |
| Scott, KA | 1 |
| O'Connor, RM | 1 |
| Moloney, G | 1 |
| Swiatek, KM | 1 |
| Jordan, K | 1 |
| Coffman, J | 1 |
| Romeo, B | 1 |
| Choucha, W | 1 |
| Rotge, JY | 1 |
| Rotroff, DM | 1 |
| Corum, DG | 1 |
| Motsinger-Reif, A | 1 |
| Fiehn, O | 1 |
| Bottrel, N | 1 |
| Ritter, MJ | 1 |
| Brand, SJ | 1 |
| Newman, LE | 1 |
| Nikolin, S | 1 |
| Ho, KA | 1 |
| Frere, M | 1 |
| Tepper, J | 1 |
| McDonald, W | 1 |
| Turner, MS | 1 |
| Summergrad, P | 1 |
| Permoda-Osip, A | 1 |
| Kranaster, L | 1 |
| Kammerer-Ciernioch, J | 1 |
| Hoyer, C | 1 |
| Sartorius, A | 1 |
| Covvey, JR | 1 |
| Crawford, AN | 1 |
| Lowe, DK | 1 |
| Lapidus, K | 1 |
| Clark, C | 1 |
| Jarun, N | 1 |
| Ostermeyer, B | 1 |
| Lauterbach, EC | 1 |
| Cornwell, BR | 1 |
| Furey, M | 1 |
| Marquardt, CA | 1 |
| Grillon, C | 1 |
| Stern, J | 1 |
| Parides, MK | 1 |
| Dowben, JS | 1 |
| Grant, JS | 1 |
| Keltner, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression[NCT02918318] | Phase 2 | 202 participants (Actual) | Interventional | 2016-12-12 | Completed | ||
| Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action[NCT01945047] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02417064] | Phase 3 | 346 participants (Actual) | Interventional | 2015-08-10 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02418585] | Phase 3 | 236 participants (Actual) | Interventional | 2015-08-07 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression[NCT02493868] | Phase 3 | 719 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD[NCT06036511] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression[NCT02497287] | Phase 3 | 802 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome[NCT05657860] | Phase 4 | 33 participants (Anticipated) | Interventional | 2020-12-17 | Recruiting | ||
| An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression[NCT05615948] | Phase 4 | 20 participants (Anticipated) | Interventional | 2022-12-06 | Recruiting | ||
| Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation in ICU: a Randomized Controlled Trial[NCT05718024] | Phase 4 | 174 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study[NCT06003218] | 88 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients[NCT06165848] | 67 participants (Actual) | Observational [Patient Registry] | 2020-07-09 | Completed | |||
| Effect of Intravenous Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth in Women With Prenatal Depression: 2-year Follow-up of a Randomized Controlled Trial[NCT05698394] | Phase 4 | 364 participants (Actual) | Interventional | 2020-06-19 | Active, not recruiting | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| [NCT02099630] | 40 participants (Actual) | Observational [Patient Registry] | 2014-03-31 | Completed | |||
| Translational Biomarkers of Fast Acting Therapies in Major Depression[NCT02165449] | Phase 1 | 60 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Effects of Different Concentrations of Esketamine on Postpartum Depression After Cesarean Section[NCT05229913] | Phase 4 | 500 participants (Anticipated) | Interventional | 2022-02-20 | Not yet recruiting | ||
| A Phase II, Randomised, Double-blind, Placebo- Controlled, Multi-site, Parallel Group Clinical Trial to Examine Ketamine as a Pharmacological Treatment for Alcohol Dependence in an Alcohol Dependent Population[NCT02649231] | Phase 2 | 96 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression[NCT02360280] | Phase 2 | 62 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression[NCT02782104] | Phase 3 | 1,148 participants (Actual) | Interventional | 2016-06-09 | Completed | ||
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression[NCT02422186] | Phase 3 | 139 participants (Actual) | Interventional | 2015-08-20 | Completed | ||
| A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of Excellence[NCT04209296] | 580 participants (Anticipated) | Observational | 2019-12-03 | Enrolling by invitation | |||
| Impact of Ketamine on Epigenetic Age (IKEA)[NCT05294835] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study[NCT05487885] | Phase 4 | 275 participants (Anticipated) | Interventional | 2022-07-22 | Recruiting | ||
| Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State[NCT06133309] | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)[NCT01920555] | Phase 2 | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders: Gdansk Depression Ketamine Project[NCT04226963] | 80 participants (Actual) | Observational [Patient Registry] | 2019-12-04 | Completed | |||
| The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.[NCT03156504] | Phase 4 | 75 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.[NCT03473431] | 90 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| A Study of Ketamine as an Antidepressant[NCT01441505] | Phase 2 | 42 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Effect of S-ketamine on Depressed Patients Undergoing Electroconvulsive Therapy-a Randomized, Double-blind, Controlled Clinical Study[NCT04399070] | 150 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | |||
| A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)[NCT01998958] | Phase 2 | 108 participants (Actual) | Interventional | 2014-01-27 | Completed | ||
| Long-term Observation of Participants With Mood Disorders[NCT04877977] | 1,000 participants (Anticipated) | Observational | 2021-08-17 | Recruiting | |||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| Double-Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)[NCT02911597] | Phase 1 | 16 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Effects of Ketamine Treatment on Suicidal Ideation, Drug-resistant Major Depression, and Negative Emotional Experience. Clinical and fMRI Study[NCT02037503] | Phase 3 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)[NCT03113968] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Nutritional Counselling Promoting Adherence to the Mediterranean Diet as Adjuvant in the Treatment of Major Depressive Disorder: A Randomized Open Controlled Trial Study[NCT05745194] | 190 participants (Anticipated) | Interventional | 2023-06-05 | Recruiting | |||
| Efficacy of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery: A Randomized, Double-blind Trial[NCT06062550] | Phase 4 | 312 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Impact of Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia on Long-term Outcomes After Scoliosis Correction Surgery: Follow-up of a Randomized Trial[NCT06087510] | Phase 4 | 312 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Patient-controlled Analgesia After Scoliosis Correction Surgery: a Randomized, Double-blind, Placebo-controlled Trial[NCT04791059] | Phase 4 | 200 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Effect of Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia on Long-term Outcomes Following Scoliosis Correction Surgery: 2-year Follow-up of a Randomized Controlled Trial[NCT05718544] | Phase 4 | 199 participants (Actual) | Interventional | 2023-01-30 | Active, not recruiting | ||
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression[NCT02610712] | Phase 4 | 20 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Optimization of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Placebo-Controlled, Triple-masked, Clinical Trial[NCT00768430] | Phase 2 | 73 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy[NCT02579642] | Phase 4 | 48 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Spreading Depolarization and Ketamine Suppression[NCT02501941] | Phase 1 | 10 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients[NCT00491686] | Phase 2 | 34 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo[NCT01130909] | Phase 1 | 36 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods) | ||
| A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants[NCT00781742] | Phase 2 | 152 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms[NCT02422303] | 12 participants (Actual) | Interventional | 2015-12-31 | Terminated | |||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial[NCT03272698] | Phase 4 | 62 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | ||
| Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial[NCT03666494] | Phase 4 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Effects of Low-dose S-Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression: A Randomized, Double-blind, Placebo-controlled Trial[NCT03927378] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention[NCT00548964] | Phase 1 | 36 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites[NCT04285684] | Early Phase 1 | 4 participants (Actual) | Interventional | 2019-12-20 | Completed | ||
| Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression[NCT00419003] | Phase 4 | 26 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant[NCT04656886] | 37 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression[NCT01640080] | Phase 2 | 30 participants (Actual) | Interventional | 2012-06-27 | Completed | ||
| A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue[NCT04141696] | Phase 1/Phase 2 | 59 participants (Anticipated) | Interventional | 2021-07-26 | Recruiting | ||
| N-methyl-D-aspartate Antagonist (Ketamine) Infusion for Treatment-resistant Major Depressive Disorder With Suicidal Ideation[NCT01582945] | 14 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt[NCT02094898] | Phase 2 | 12 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial[NCT02305394] | Phase 4 | 132 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Assessing the Effectiveness of Psychiatric Interventions on the Inpatient Unit[NCT03626142] | 200 participants (Anticipated) | Observational | 2018-07-09 | Enrolling by invitation | |||
| Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment-Resistant Depression[NCT01880593] | Phase 2 | 34 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction pahse)
| Intervention | Units on a scale (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | -1.0 |
| Esketamine 56 mg | -1.0 |
| Esketamine 84 mg | -1.0 |
| Placebo | -1.0 |
GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.2 |
| Esketamine 56 mg | -7.8 |
| Esketamine 84 mg | -8.1 |
| Placebo | -7.7 |
SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02918318)
Timeframe: Baseline (Day 1) to Day 28 (DB induction phase)
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -8.6 |
| Esketamine 56 mg | -7.9 |
| Esketamine 84 mg | -9.5 |
| Placebo | -7.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement. (NCT02918318)
Timeframe: Baseline (Day 1) up to Day 28 (DB phase) induction
| Intervention | Units on a scale (Mean) |
|---|---|
| Esketamine 28 Milligrams (mg) | -15.2 |
| Esketamine 56 mg | -14.5 |
| Esketamine 84 mg | -15.1 |
| Placebo | -15.3 |
Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 34.0 |
| Esketamine 56 mg | 52.0 |
| Esketamine 84 mg | 37.0 |
| Placebo | 30.0 |
Time to relapse in participants with response (>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score >= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score <=12. (NCT02918318)
Timeframe: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
| Intervention | Days (Median) |
|---|---|
| Esketamine 28 Milligrams (mg) | 32.0 |
| Esketamine 56 mg | 26.0 |
| Esketamine 84 mg | 79.5 |
| Placebo | 91.0 |
A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Day 2 up to Day 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of clinical response: Yes | Onset of clinical response: No | |
| Esketamine 28 Milligrams (mg) | 2.4 | 97.6 |
| Esketamine 56 mg | 2.6 | 97.4 |
| Esketamine 84 mg | 7.3 | 92.7 |
| Placebo | 6.3 | 93.7 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 9.8 | 2.4 | 7.5 | 10.3 | 23.1 |
| Esketamine 56 mg | 0 | 0 | 2.8 | 5.6 | 11.8 |
| Esketamine 84 mg | 7.5 | 4.9 | 10.0 | 7.7 | 23.1 |
| Placebo | 3.8 | 1.3 | 3.9 | 14.9 | 20.8 |
A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 2, 8, 15, 22 and 28 (DB induction phase)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine 28 Milligrams (mg) | 22.0 | 2.4 | 17.5 | 23.1 | 33.3 |
| Esketamine 56 mg | 13.2 | 2.6 | 8.3 | 13.9 | 35.3 |
| Esketamine 84 mg | 10.0 | 9.8 | 15.0 | 20.5 | 43.6 |
| Placebo | 9.0 | 3.8 | 18.2 | 29.7 | 37.5 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline | |
| Esketamine: Flexible Dose | 16.1 | -14.5 |
A participant was considered in remission at a given time point if the MADRS total score <=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02918318)
Timeframe: Days 8, 15, 22 and 28 (OL induction phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | Day 28 | |
| Esketamine: Flexible Dose | 14.6 | 23.4 | 31.9 | 42.6 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. (NCT02918318)
Timeframe: Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal, not at all ill:Baseline | Normal, not at all ill:Endpoint | Borderline mentally ill:Baseline | Borderline mentally ill:Endpoint | Mildly ill:Baseline | Mildly ill:Endpoint | Moderately ill:Baseline | Moderately ill:Endpoint | Markedly ill:Baseline | Markedly ill:Endpoint | Severely ill:Baseline | Severely ill:Endpoint | Among the most extremely ill patients:Baseline | Among the most extremely ill patients:Endpoint | |
| Esketamine: Flexible Dose | 0 | 14.6 | 0 | 16.7 | 4.2 | 43.8 | 75.0 | 20.8 | 14.6 | 4.2 | 4.2 | 0 | 2.1 | 0 |
SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase (NCT02918318)
Timeframe: Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
| Esketamine 28 Milligrams (mg) | -14.6 | -12.9 | -17.7 | -12.0 | -20.5 | -21.5 | -22.0 | -21.5 |
| Esketamine 56 mg | -8.1 | -8.3 | -11.0 | -13.3 | -13.0 | -17.5 | -18.0 | -16.0 |
| Esketamine 84 mg | -13.1 | -13.6 | -14.6 | -15.3 | -18.3 | -12.5 | -28.0 | -28.0 |
| Placebo | -11.2 | -9.8 | -12.0 | -11.4 | -14.8 | -15.8 | -14.0 | -14.8 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -2.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -2.0 |
| Oral AD Plus Intranasal Placebo | -1.0 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02417064)
Timeframe: Baseline up to end of Double-blind induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 20.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | 19.1 |
| Oral AD Plus Intranasal Placebo | 14.9 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). (NCT02417064)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 0.224 |
| Intranasal Esketamine 84 mg Plus Oral AD | 0.243 |
| Oral AD Plus Intranasal Placebo | 0.181 |
EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state. (NCT02417064)
Timeframe: Baseline up to end of Double-blind Induction phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -19.4 |
| Oral AD Plus Intranasal Placebo | -14.6 |
"GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -7.4 |
| Intranasal Esketamine 84 mg Plus Oral AD | -7.7 |
| Oral AD Plus Intranasal Placebo | -6.0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -19.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -18.8 |
| Oral AD Plus Intranasal Placebo | -14.8 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -18.3 |
| Intranasal Esketamine 84 mg Plus Oral AD | -17.4 |
| Oral AD Plus Intranasal Placebo | -14.3 |
PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.7 |
| Oral AD Plus Intranasal Placebo | -9.1 |
"PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.9 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.9 |
| Oral AD Plus Intranasal Placebo | -8.9 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment. (NCT02417064)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -11.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | -11.1 |
| Oral AD Plus Intranasal Placebo | -8.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: Baseline up to Double-blind Endpoint (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | -10.7 |
| Intranasal Esketamine 84 mg Plus Oral AD | -10.2 |
| Oral AD Plus Intranasal Placebo | -8.1 |
Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction Phase
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 36 |
| Intranasal Esketamine 84 mg Plus Oral AD | 38.8 |
| Oral AD Plus Intranasal Placebo | 30.6 |
"Participants who had a MADRS total score of less than or equal to (<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 34.8 |
| Intranasal Esketamine 84 mg Plus Oral AD | 35.4 |
| Oral AD Plus Intranasal Placebo | 29.2 |
A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: At Day 28 of Double-blind Induction phase
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 54.1 |
| Intranasal Esketamine 84 mg Plus Oral AD | 53.1 |
| Oral AD Plus Intranasal Placebo | 38.9 |
"A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as End Point for that phase." (NCT02417064)
Timeframe: At Day 28 (Double-blind Endpoint)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 53.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 47.8 |
| Oral AD Plus Intranasal Placebo | 37.2 |
A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02417064)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Day 2 up to Day 28 | Day 8 up to Day 28 | |
| Intranasal Esketamine 56 mg Plus Oral Antidepressant | 10.4 | 13.0 |
| Intranasal Esketamine 84 mg Plus Oral AD | 8.8 | 11.4 |
| Oral AD Plus Intranasal Placebo | 1.8 | 3.5 |
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -2.0 |
| Intranasal Placebo Plus Oral AD | -2.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 29.1 |
| Intranasal Placebo Plus Oral AD | 20.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -23.2 |
| Intranasal Placebo Plus Oral AD | -17.1 |
"European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health)." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 0.288 |
| Intranasal Placebo Plus Oral AD | 0.231 |
"GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -7.9 |
| Intranasal Placebo Plus Oral AD | -6.8 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -21.4 |
| Intranasal Placebo Plus Oral AD | -17.0 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -19.6 |
| Intranasal Placebo Plus Oral AD | -16.3 |
PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.0 |
| Intranasal Placebo Plus Oral AD | -10.2 |
"PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.2 |
| Intranasal Placebo Plus Oral AD | -10.1 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.6 |
| Intranasal Placebo Plus Oral AD | -9.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.5 |
| Intranasal Placebo Plus Oral AD | -9.3 |
"Remission was defined as participants who had a MADRS total score of less than or equal to (=<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 48.2 |
| Intranasal Placebo Plus Oral AD | 30.3 |
Remission defined as SDS total score <= 6 and individual item scores each <= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 (End of Double-blind Induction Phase)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 39.5 |
| Intranasal Placebo Plus Oral AD | 20.9 |
Response defined as SDS total score <= 12 and individual item scores each <= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 [end of Double-blind Induction Phase]
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 57.0 |
| Intranasal Placebo Plus Oral AD | 39.5 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 63.4 |
| Intranasal Placebo Plus Oral AD | 49.5 |
A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders. (NCT02418585)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of Clinical response on Day 2 | Onset of Clinical response on Day 8 | |
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 7.9 | 10.5 |
| Intranasal Placebo Plus Oral AD | 4.6 | 6.4 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 0.0 |
| Oral AD+ Intranasal Placebo | 1.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -10.4 |
| Oral AD+ Intranasal Placebo | -16.1 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -1.3 |
| Oral AD+ Intranasal Placebo | -13.8 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.067 |
| Oral AD+ Intranasal Placebo | -0.096 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health)." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | -0.023 |
| Oral AD+ Intranasal Placebo | -0.073 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 10.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.0 |
| Oral AD+ Intranasal Placebo | 8.4 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 4.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.4 |
| Oral AD+ Intranasal Placebo | 2.6 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (last observation carried forward [LOCF] data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 7.5 |
| Oral AD+ Intranasal Placebo | 12.5 |
MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.4 |
| Oral AD+ Intranasal Placebo | 11.4 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 3.3 |
| Oral AD+ Intranasal Placebo | 5.9 |
PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 1.7 |
| Oral AD+ Intranasal Placebo | 4.7 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 4.7 |
| Oral AD+ Intranasal Placebo | 7.2 |
The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores <= 4 for each item and <= 12 for the total score are considered response. Scores <= 2 for each item and <= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint. (NCT02493868)
Timeframe: Baseline and Endpoint (Up to 92 Weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral AD | 2.2 |
| Oral AD+ Intranasal Placebo | 6.8 |
Relapse is defined as any of following: Montgomery-asberg depression rating scale (MADRS) total score greater than or equal to (>=) 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable remission: MADRS total score less than or equal to (<=) 12 for at least 3 of last 4 weeks of OP phase, with 1 excursion total score greater than (>) 12 or one missing assessment at OP week 13 or 14. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | NA |
| Oral AD+ Intranasal Placebo | 273.0 |
Relapse is defined as any of following: MADRS total score >= 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable response is defined as >= 50 percent (%) reduction in MADRS total score from baseline (Day 1 of induction phase, prior to first intranasal dose) in each of the last 2 weeks of the OP phase, but without meeting criteria for stable remission. (NCT02493868)
Timeframe: Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)
| Intervention | Days (Median) |
|---|---|
| Intranasal Esketamine + Oral AD | 635.0 |
| Oral AD+ Intranasal Placebo | 88.0 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of participants (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranges from 2 to 3.3 log 10 milliseconds (msec). Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of Optimization/Maintenance [OP/MA] Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0028 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranges from 0 to 999 number of errors. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of Errors (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 6.9 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranges from 2 to 3.3 log 10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.0083 |
The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranges from 2 to 3.54 log10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | log10 msec (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0177 |
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicates better performance. Higher change from baseline indicates better performance. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Arcsine ([sqrt] of proportion of [CR]) (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0502 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.8 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number of words recalled (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Number of words (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.5 |
Hopkins Verbal Learning Test (HVLT) measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Number correct (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 2.8 |
"SDS was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, (3) family life/home responsibilities using a 0 to 10 rating scale. Score for the first three items are summed to create a total score of 0 to 30, higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -9.3 |
"SDS was a participant-reported outcome measure and was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0 to 10 rating scale. The score for the first three items are summed to create a total score of 0 to 30 where a higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -1.6 |
"The CGI-S measures the severity of the participant's illness that include knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.0 |
"CGI-S measures severity of participant's illness that include knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on a scale range from 0 - 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Median) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -2.0 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.190 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health)." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.009 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 17.0 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 1.6 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -15.3 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.7 |
"GAD-7 is brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.2 |
"GAD-7 is brief, validated 7-item self-reported assessment of overall anxiety. Participant's responded to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of GAD-7 is categorized as: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method, last post baseline observation during the phase was carried forward as Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -5.9 |
"MADRS measure depression severity, detects changes due to AD treatment. It evaluates 10 items: apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 0.3 |
"MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method, last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -16.4 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Unit on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -8.9 |
"PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | -0.2 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of OP/MA phase [Week 52])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 86.1 |
"The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = Not at all, 1 = Mild, 2 = Moderate, 3 = 'Severe and 4 = Extreme). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition." (NCT02497287)
Timeframe: Predose, up to 1.5 hours postdose (up to end of IND phase [Week 4])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 92.0 |
An adverse event is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an event that was new in onset or increased in severity following treatment initiation. (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine + Oral Antidepressant | 90.1 |
"Percentage of participants with cystitis, urinary tract infections, renal and urinary tract symptoms, renal and urinary disorders were evaluated. Cystitis and urinary tract infections are selected MedDRA preferred terms, renal and urinary tract symptoms refers to any preferred term (PT) in the group of selected PTs; and renal and urinary disorders refers to a MedDRA System Organ Class (SOC)." (NCT02497287)
Timeframe: Up to End of Follow up Phase (Week 56)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cystitis | Urinary tract infections | Renal and urinary disorders | Renal and urinary tract symptoms | |
| Intranasal Esketamine + Oral Antidepressant | 0.6 | 8.1 | 10.5 | 17.0 |
"Remission is defined as MADRS total score less than or equal to (<=) 12. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 7.3 | 15.6 | 27.2 | 47.2 |
"Remission is defined as PHQ-9 total score <= 4. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | Endpoint | |
| Intranasal Esketamine + Oral Antidepressant | 12.7 | 26.9 |
"Response is defined as greater than or equal to (>=) 50 % reduction from baseline in the MADRS total score. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Days 8, 15, 22 and Endpoint (last post-baseline assessment during 4 weeks of IND phase)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 11.6 | 25.0 | 42.8 | 78.4 |
"Response is defined as >= 50 % reduction from baseline (IND phase) in PHQ-9 total score. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the Endpoint." (NCT02497287)
Timeframe: Day 15 and Endpoint (last post-baseline assessment value during 4 Week IND phase)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Day 15 | End point | |
| Intranasal Esketamine + Oral Antidepressant | 37.2 | 62.0 |
Percentage of participants with treatment-emergent acute hypertension (Systolic Blood Pressure >=180 millimeters of mercury [mm Hg] or Diastolic Blood Pressure >= 110 mm Hg) during IND and OP/MA Phases were evaluated. (NCT02497287)
Timeframe: Up to End of OP/MA phase (Week 52)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Systolic BP >=180 | Diastolic BP >=110 | Acute hypertension | |
| Intranasal Esketamine + Oral Antidepressant | 2.2 | 2.4 | 4.1 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | percentage of days abstinent (Mean) |
|---|---|
| Ketamine+Psychological Therapy | 86.4 |
| Ketamine+Education | 82.5 |
| Placebo+Psychological Therapy | 78.3 |
| Placebo+Education | 70.7 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine+Psychological Therapy | 13 |
| Ketamine+Education | 15 |
| Placebo+Psychological Therapy | 14 |
| Placebo+Education | 18 |
Comparing the number of subjects that achieve response between groups as defined above. (NCT02360280)
Timeframe: 13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Six Ketamine Infusions | 19 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 20 |
Average difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score change between groups. The MADRS has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT02360280)
Timeframe: 13 days
| Intervention | units on a scale (Mean) |
|---|---|
| Six Ketamine Infusions | 21.0 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 17.2 |
Comparing the number of subjects that achieve remission between groups as defined above (NCT02360280)
Timeframe: 13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Six Ketamine Infusions | 12 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 11 |
The length of time from post-infusion response until relapse (defined as >50% of MADRS baseline score) assessed for up to 6 months. (NCT02360280)
Timeframe: 6 months
| Intervention | weeks (Median) |
|---|---|
| Six Ketamine Infusions | 6.00 |
| Single Ketamine Infusion Preceded by 5 Midazolam Infusions | 2.00 |
"CGI-S provides an overall clinician-determined summary measure of the severity of the participants illness including participants history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participants ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Missing data was imputed using LOCF method and last post baseline observation during the double-blind induction phase was carried forward as the End Point for that phase." (NCT02422186)
Timeframe: Baseline and Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | -1.0 |
| Oral AD Plus Intranasal Placebo | 0.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02422186)
Timeframe: Baseline and Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | 6.2 |
| Oral AD Plus Intranasal Placebo | 4.4 |
"EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a health status index (HSI). HSI ranges from -0.148 (health state value equal to dead) and 0.949 (full health), is anchored at 0 (dead) and 1 (full health)." (NCT02422186)
Timeframe: Baseline and Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | 0.081 |
| Oral AD Plus Intranasal Placebo | 0.026 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 (health state value equal to dead) and 0.949 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02422186)
Timeframe: Baseline and Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | -6.6 |
| Oral AD Plus Intranasal Placebo | -1.6 |
"The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items (to evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel [interest level], pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0-60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during the double-blind induction phase was carried forward as the End Point for that phase." (NCT02422186)
Timeframe: Baseline and Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | -9.3 |
| Oral AD Plus Intranasal Placebo | -5.6 |
The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items (to evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel [interest level], pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0-60. Higher scores represent a more severe condition. Negative change in score indicates improvement. (NCT02422186)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase[Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | -10.0 |
| Oral AD Plus Intranasal Placebo | -6.3 |
"Remission was defined as participants who had a MADRS total score of less than or equal to (=<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and last post baseline observation during the double-blind induction phase was carried forward as the End Point for that phase." (NCT02422186)
Timeframe: At Endpoint-Double-blind Induction Phase [Day 28]
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | 15.5 |
| Oral AD Plus Intranasal Placebo | 6.3 |
"Percentage of participants with greater than or equal to (>=50) percent (%) reduction from baseline are reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and last post baseline observation during the double-blind induction phase was carried forward as the End Point for that phase." (NCT02422186)
Timeframe: At Endpoint-Double-blind Induction Phase [Day 28]
| Intervention | Percentage of Participants (Number) |
|---|---|
| Intranasal Esketamine Plus Oral Antidepressant (AD) | 23.9 |
| Oral AD Plus Intranasal Placebo | 12.5 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
"The CGI-I is a clinician rated single-item scale: Compared to the patient's condition at admission, how much has the patient changed?, rated on a 7-point response scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse. In this case, admission referred to the CGI-S screening assessments performed between Day -28 an -7, one conducted during the screening visit, and a second rating conducted by a remote, independent rater." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.8888889 | 3.0625000 | 2.9333333 |
| Ketamine 0.2mg | 4.0500000 | 3.3684211 | 2.8421053 |
| Ketamine 0.5mg | 4.1363636 | 2.6363636 | 2.5714286 |
| Ketamine 1.0mg | 4.0000000 | 3.0500000 | 2.5500000 |
| Midazolam 0.045mg | 4.1578947 | 3.6111111 | 3.1666667 |
"The CGI-S is a clinician rated single-item scale: How depressed is the patient at this time?, rated on a 7-point response scale: 1 = Normal, not at all depressed, 2 = Borderline depressed, 3 = Mildly depressed, 4 = Moderately depressed. 5 = Markedly depressed, 6 = severely depressed, 7 = Among the most severely depressed patients. When rating patients, clinicians were asked to consider the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 5.0000000 | 3.5625000 | 3.4000000 |
| Ketamine 0.2mg | 5.2000000 | 4.2631579 | 3.7368421 |
| Ketamine 0.5mg | 4.8636364 | 3.2727273 | 3.1428571 |
| Ketamine 1.0mg | 5.2000000 | 3.5000000 | 3.3000000 |
| Midazolam 0.045mg | 5.000000 | 4.555556 | 4.1666667 |
"The CPAS is a 16-item self-report scale to assess the level to which participants experience persistent distress due to feeling that they have not returned to their normal or premorbid state. Items (e.g., I look forward to things) are rated on a 5-point scale (0=not at all, 1=very much less than normal, 2=much less than normal, 3=slightly less than normal, 4=same as best or normal self). The possible scale range is 0 to 64, with higher scores indicating greater recovery from depression. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 19.3333333 | 35.2500000 | 38.8666667 |
| Ketamine 0.2mg | 20.5000000 | 27.0526316 | 28.3888889 |
| Ketamine 0.5mg | 20.6363636 | 40.8696964 | 39.7619048 |
| Ketamine 1.0mg | 21.2500000 | 33.0000000 | 37.4500000 |
| Midazolam 0.045mg | 21.2631579 | 24.4444444 | 33.3750000 |
"The CADSS is a 23-item self-report scale for the assessment of dissociative states. It is a reliable, valid self-report instrument. The severity of each dissociative symptom ranges from 0 (not present) to 4 (extreme). The total score is calculated by summing across items, with a total possible range of 0-92. The CADSS was administered right before infusion, and 40, 80 minute and 120 minutes after the start of infusion. The timeframe is at this moment." (NCT01920555)
Timeframe: Day 0/baseline at 0, 40, 80, and 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Minute 0 | Minute 40 | Minute 80 | Minute 120 | |
| Ketamine 0.1mg | 0.1111111 | 3.0000000 | 0.4444444 | 0.0555556 |
| Ketamine 0.2mg | 0.1000000 | 4.0500000 | 0.1000000 | 0 |
| Ketamine 0.5mg | 0 | 14.2727273 | 0.7727273 | 0.1363636 |
| Ketamine 1.0mg | 0.1000000 | 24.6842105 | 1.8000000 | 0.6500000 |
| Midazolam 0.045mg | 0.4210526 | 2.6842105 | 1.1578947 | 0.5789474 |
The HAMD6 is a 6-item clinician-rated scale, where clinicians rate the presence of depression symptoms (i.e., depressed mood, guilt, work and interests, psychomotor retardation, psychic anxiety, somatic symptoms) on a 5-point scale, where 0 = not present, and 1-4 represent increasingly severe symptoms. One item (i.e., somatic symptoms) is rated on only a 3-point scale, ranging from 0-2. The possible scale range is 0-22, where higher values represent more severe depression. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. In this study, the HAMD6 was used to assess symptoms occurring in the past 24 hours. (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1, & 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 12.5555556 | 7.5000000 | 6.8000000 |
| Ketamine 0.2mg | 12.7500000 | 9.2631579 | 8.4736842 |
| Ketamine 0.5mg | 12.5909091 | 5.8636364 | 5.9047619 |
| Ketamine 1.0mg | 12.6315789 | 6.9000000 | 7.2000000 |
| Midazolam 0.045mg | 13.0526316 | 10.6666667 | 9.0555556 |
"The MADRS is a 10-item clinician-rated scale measuring depression severity. Symptoms are rated on a 7-point scale, where 0 = not present, and 1-6 represent increasing severity. Values 2, 4, and 6 have specific anchoring text (e.g., 2=Difficulties in starting activities. 4=Difficulties in starting simple routine activities which are carried out with effort, 6=Complete lassitude. Unable to do anything without help.) Values 1, 3, and 5 do not have specific text. The possible scale range is 0-60, where higher values represent higher severity. In this study, the MADRS was used to rate symptoms occurring in the past 3 days." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0 and 3.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Day 3 | |
| Ketamine 0.1mg | 33.8333333 | 19.6666667 |
| Ketamine 0.2mg | 34.4500000 | 22.6315789 |
| Ketamine 0.5mg | 31.5909091 | 14.7619048 |
| Ketamine 1.0mg | 32.6500000 | 17.1000000 |
| Midazolam 0.045mg | 33.6315789 | 24.8333333 |
The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale. (NCT01920555)
Timeframe: Screening Visit and Days 0, 1, 3, 5, 7, 14 and 30 combined
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Screening: # with suicidal ideation/behavior | Follow-Up: # with suicidal ideation/behavior | |
| Ketamine 0.1mg | 17 | 15 |
| Ketamine 0.2mg | 15 | 9 |
| Ketamine 0.5mg | 17 | 10 |
| Ketamine 1.0mg | 14 | 6 |
| Midazolam 0.045mg | 17 | 13 |
"CBC~Chemistry (Total bilirubin, AST, ALT, GGT, ALK Phosphatase, Creatinine, BUN/Urea, Glucose, Uric Acid)~Testing was performed by study site laboratories and used institutional normal lab value ranges." (NCT01920555)
Timeframe: Day 3 and Early Termination Visit (approximately 3 weeks following intervention)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Chemistry ALT(SGPT) | Chemistry AST(SGOT) | Chemistry Total Bilirubin | Chemistry Remaining Tests | CBC | |
| Ketamine 0.1mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 0.2mg | 1 | 1 | 1 | 0 | 0 |
| Ketamine 0.5mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 1.0mg | 0 | 0 | 0 | 0 | 0 |
| Midazolam 0.045mg | 0 | 0 | 0 | 0 | 0 |
"The SHAPS is a 14-item self-report scale to measure hedonic tone. Items (e.g., I would enjoy reading a book, magazine, or newspaper.) are rated on a 4-point scale (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree). Either of the 'disagree' responses scores 1 point, and either of the 'agree' responses scores 0 points, for a total scale range of 0-14. Higher scores indicate greater inability to experience pleasure. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 7.2222222 | 3.9375000 | 3.5333333 |
| Ketamine 0.2mg | 7.5500000 | 5.7368421 | 6.3888889 |
| Ketamine 0.5mg | 6.5909091 | 2.22727273 | 3.0000000 |
| Ketamine 1.0mg | 7.3500000 | 4.3000000 | 3.6500000 |
| Midazolam 0.045mg | 6.4736842 | 5.0000000 | 4.2500000 |
"The SDQ is a 44-item self-report scale, which aims to measure depression more comprehensively by including the assessment of symptoms in the anxiety-depression spectrum, including symptoms of irritability, anger attacks, and anxiety. Items are rated on an 6-point Likert scale, where participants are asked to rate if a specific symptom (e.g. How has your mood been over the past 24 hours?) is normal for him or her (score = 2), what is better than normal (score = 1), and what is worse than normal (scores = 3-6). The total scale score is calculated by averaging across the items, resulting in a possible range from 1 to 6. Higher scores indicate greater depression severity. When rating, patients were asked to consider their symptoms during the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.5164141 | 2.5752843 | 2.5106061 |
| Ketamine 0.2mg | 3.4636364 | 2.9096195 | 2.7828283 |
| Ketamine 0.5mg | 3.5392562 | 2.3109504 | 2.5573593 |
| Ketamine 1.0mg | 3.4113636 | 2.6113636 | 2.5909091 |
| Midazolam 0.045mg | 3.4264507 | 2.9200573 | 2.8751353 |
Total number of subjects with ≤ 9 MADRS score 24 hours post Ketamine infusion #3. The Montgomery Åsberg Depression Scale (MÅDRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT03156504)
Timeframe: 24 hours post infusion #3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 39 |
Total number of subjects to have a reduction of suicidality, as defined by a 50% reduction on the Beck Scale for Suicidal Ideation (BSS) 24 hours post Ketamine infusion #3. The Beck Scale for Suicidal Ideation consists of 19 items which can be used to evaluate a patient's suicidal intentions. Each of the 19 items is rated on a 0-3 point scale (range 0-38, with higher scores indicating greater suicidal ideations or risk), and includes specific items that assess wish to live, wish to die, desire to make an active suicide attempt, passive suicidal desire, duration of suicidal ideations, frequency of suicidal ideations, and subjective level of control over suicidal actions. (NCT03156504)
Timeframe: 24 hours post infusion #3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 42 |
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Units on a scale (Median) |
|---|---|
| Panel A: Period 1 Placebo | 5.0 |
| Panel A: Period 1 Esketamine 28 mg | 4.0 |
| Panel A: Period 1 Esketamine 56 mg | 4.0 |
| Panel A: Period 1 Esketamine 84 mg | 4.0 |
| Panel B: Period 1 Placebo | 4.0 |
| Panel B: Period 1 Esketamine 14 mg | 4.0 |
| Panel B: Period 1 Esketamine 56 mg | 3.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -1.7 |
| Panel A: Period 1 Esketamine 28 mg | -1.5 |
| Panel A: Period 1 Esketamine 56 mg | -3.1 |
| Panel A: Period 1 Esketamine 84 mg | -5.1 |
| Panel B: Period 1 Placebo | -1.7 |
| Panel B: Period 1 Esketamine 14 mg | -1.9 |
| Panel B: Period 1 Esketamine 56 mg | -3.2 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -4.9 |
| Panel A: Period 1 Esketamine 28 mg | -9.8 |
| Panel A: Period 1 Esketamine 56 mg | -12.4 |
| Panel A: Period 1 Esketamine 84 mg | -15.3 |
| Panel B: Period 1 Placebo | -6.6 |
| Panel B: Period 1 Esketamine 14 mg | -4.8 |
| Panel B: Period 1 Esketamine 56 mg | -10.3 |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Median) |
|---|---|
| Panel A: Period 1 Placebo | 3.0 |
| Panel A: Period 1 Esketamine 28 mg | 3.0 |
| Panel A: Period 1 Esketamine 56 mg | 3.0 |
| Panel A: Period 1 Esketamine 84 mg | 3.0 |
| Panel B: Period 1 Placebo | 3.0 |
| Panel B: Period 1 Esketamine 14 mg | 3.0 |
| Panel B: Period 1 Esketamine 56 mg | 3.0 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3. (NCT01998958)
Timeframe: Baseline (Day 1) and Endpoint (Day 8) of Period 1
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 1 Placebo | -1.8 |
| Panel A: Period 1 Esketamine 28 mg | -4.0 |
| Panel A: Period 1 Esketamine 56 mg | -4.4 |
| Panel A: Period 1 Esketamine 84 mg | -4.2 |
| Panel B: Period 1 Placebo | -1.1 |
| Panel B: Period 1 Esketamine 14 mg | -0.6 |
| Panel B: Period 1 Esketamine 56 mg | -3.0 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Units on a scale (Median) |
|---|---|
| Panel A: Period 2 Placebo | 5.0 |
| Panel A: Period 2 Esketamine 28 mg | 4.0 |
| Panel A: Period 2 Esketamine 56 mg | 5.0 |
| Panel A: Period 2 Esketamine 84 mg | 4.0 |
| Panel B: Period 2 Placebo | 4.0 |
| Panel B: Period 2 Esketamine 14 mg | 3.0 |
| Panel B: Period 2 Esketamine 56 mg | 4.0 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | 0.4 |
| Panel A: Period 2 Esketamine 28 mg | -1.6 |
| Panel A: Period 2 Esketamine 56 mg | 1.0 |
| Panel A: Period 2 Esketamine 84 mg | -0.9 |
| Panel B: Period 2 Placebo | -2.7 |
| Panel B: Period 2 Esketamine 14 mg | -6.6 |
| Panel B: Period 2 Esketamine 56 mg | -0.7 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | -4.5 |
| Panel A:Period 2 Esketamine 28 mg | -7.6 |
| Panel A: Period 2 Esketamine 56 mg | -8.9 |
| Panel A: Period 2 Esketamine 84 mg | -11.4 |
| Panel B: Period 2 Placebo | -0.7 |
| Panel B: Period 2 Esketamine 14 mg | -6.6 |
| Panel B:Period 2 Esketamine 56 mg | -1.2 |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Median) |
|---|---|
| Panel A: Period 2 Placebo | 3.0 |
| Panel A: Period 2 Esketamine 28 mg | 3.0 |
| Panel A: Period 2 Esketamine 56 mg | 4.0 |
| Panel A: Period 2 Esketamine 84 mg | 3.0 |
| Panel B: Period 2 Placebo | 3.0 |
| Panel B: Period 2 Esketamine 14 mg | 3.0 |
| Panel B: Period 2 Esketamine 56 mg | 3.0 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3. (NCT01998958)
Timeframe: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Panel A: Period 2 Placebo | -2.0 |
| Panel A: Period 2 Esketamine 28 mg | -3.1 |
| Panel A: Period 2 Esketamine 56 mg | -2.0 |
| Panel A: Period 2 Esketamine 84 mg | -3.3 |
| Panel B: Period 2 Placebo | -2.1 |
| Panel B: Period 2 Esketamine 14 mg | -5.7 |
| Panel B: Period 2 Esketamine 56 mg | -1.5 |
Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Day 2 Up to Day 15
| Intervention | Percentage of participants (Number) |
|---|---|
| Panel A: Placebo (Period 1 and 2) | 0 |
| Panel A: Esketamine 28 mg (Period 1 and 2) | 12.5 |
| Panel A: Esketamine 56 mg (Period 1 and 2) | 9.1 |
| Panel A: Esketamine 84 mg (Period 1 and 2) | 30.0 |
| Panel B: Placebo (Period 1 and 2) | 15.4 |
| Panel B: Esketamine 14 mg (Period 1 and 2) | 18.2 |
| Panel B: Esketamine 56 mg (Period 1 and 2) | 22.2 |
Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Day 2 Up to Day 15
| Intervention | Percentage of participants (Number) |
|---|---|
| Panel A: Placebo (Period 1 and 2) | 0 |
| Panel A: Esketamine 28 mg (Period 1 and 2) | 12.5 |
| Panel A: Esketamine 56 mg (Period 1 and 2) | 9.1 |
| Panel A: Esketamine 84 mg (Period 1 and 2) | 25.0 |
| Panel B: Placebo (Period 1 and 2) | 15.4 |
| Panel B: Esketamine 14 mg (Period 1 and 2) | 18.2 |
| Panel B: Esketamine 56 mg (Period 1 and 2) | 22.2 |
Participants who had a MADRS total score of <=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Days 1, 2 and 8 of Double-blind Phase of Period 1
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 8 | |
| Panel A: Period 1 Esketamine 28 mg | 27.3 | 36.4 | 9.1 |
| Panel A: Period 1 Esketamine 84 mg | 25.0 | 25.0 | 25.0 |
| Panel A: Period 1: Esketamine 56 mg | 18.2 | 18.2 | 9.1 |
| Panel A: Period 1: Placebo | 3.0 | 0 | 3.0 |
| Panel B: Period 1 Esketamine 14 mg | 36.4 | 27.3 | 18.2 |
| Panel B: Period 1 Esketamine 56 mg | 33.3 | 33.3 | 22.2 |
| Panel B: Period 1 Placebo | 19.0 | 19.0 | 14.3 |
Participants who had a MADRS total score of less than or equal to (<=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement. (NCT01998958)
Timeframe: Days 1, 2 and 8 of Double-blind Phase of Period 2
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 8 | |
| Panel A: Period 2 Esketamine 28 mg | 12.5 | 0 | 12.5 |
| Panel A: Period 2 Esketamine 56 mg | 0 | 0 | 0 |
| Panel A: Period 2 Esketamine 84 mg | 40.0 | 20.0 | 20.0 |
| Panel A: Period 2 Placebo | 16.7 | 0 | 0 |
| Panel B: Period 2 Esketamine 14 mg | 60.0 | 80.0 | 0 |
| Panel B: Period 2 Esketamine 56 mg | 0 | 0 | 0 |
| Panel B: Period 2 Placebo | 0 | 0 | 0 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is >=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Period 2: Days 1 (2 hour), 2 and 8 of Double-blind Phase
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 (2 hour) | Day 2 | Day 8 | |
| Panel A: Period 2 Esketamine 28 mg | 12.5 | 0 | 12.5 |
| Panel B: Period 2 Placebo | 0 | 0 | 0 |
| Panel A: Period 2 Esketamine 56 mg | 22.2 | 11.1 | 0 |
| Panel A: Period 2 Esketamine 84 mg | 40.0 | 40.0 | 20.0 |
| Panel A: Period 2 Placebo | 16.7 | 0 | 0 |
| Panel B: Period 2 Esketamine 14 mg | 60.0 | 80.0 | 0 |
| Panel B: Period 2 Esketamine 56 mg | 0 | 0 | 33.3 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (>=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT01998958)
Timeframe: Period 1: Days 1 (2 hour), 2 and 8 of Double-blind Phase
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Day 1 (2 hour) | Day 2 | Day 8 | |
| Panel A: Period 1 Esketamine 28 mg | 54.5 | 36.4 | 9.1 |
| Panel A: Period 1 Esketamine 84 mg | 58.3 | 41.7 | 41.7 |
| Panel A: Period 1 Placebo | 18.2 | 3.0 | 6.1 |
| Panel B: Period 1 Esketamine 14 mg | 36.4 | 36.4 | 18.2 |
| Panel B: Period 1 Esketamine 56 mg | 44.4 | 44.4 | 22.2 |
| Panel B: Period 1 Placebo | 33.3 | 28.6 | 23.8 |
| Panel A: Period 1 Esketamine 56 mg | 36.4 | 27.3 | 18.2 |
Response is defined as at least a 50% improvement in the QIDS-SR-16 scale from baseline to the End of Treatment visit. The End of Treatment visit will occur 3-5 weeks after the Baseline visit. (NCT03113968)
Timeframe: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroconvulsive Therapy (ECT) | 70 |
| Ketamine Infusion | 108 |
The outcome measure was the percentage of responders at the end-of-treatment visit, defined as a ≥50% decrease in MADRS score from the baseline visit (i.e., first treatment visit) to the end-of-treatment visit (within 3 days of last treatment). (NCT03113968)
Timeframe: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroconvulsive Therapy (ECT) | 70 |
| Ketamine Infusion | 99 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. (NCT00768430)
Timeframe: 24 hours post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 14.77 |
| Midazolam | 22.72 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | .3 | .3 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | .56 | .55 | .45 | .21 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 2.0 | 1.9 | 1.4 | 1.1 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 30.5 | 13.9 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 29.9 | 28.3 | 25.6 | 17.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 64.1 | 66.9 | 54.6 | 41.6 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 4.9 | 6.4 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 51.2 | 22.6 | 10.6 | 4.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 125.0 | 48.2 | 21.6 | 18.5 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 24 and 30 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 24 and 30 hour collections
| Intervention | ng/mL (Mean) | |
|---|---|---|
| 24 Hours | 30 Hours | |
| Ketamine During Lactation | 10.3 | 9.9 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 42.6 | 28.6 | 18.8 | 8.7 |
"Quantitative analysis of the concentration of ketamine and its metabolites in breast milk (collected by pumping breast milk into containers at 3, 6, 9, and 12 hours post ketamine IM administration) was performed at the Clinical Medicine and Toxicology Laboratory at UCSF School of Medicine. Sample aliquots were frozen in our conventional freezer at the clinic where the sessions took place, labelled with a HIPAA compliant code which blinded the lab to all patient data.~The limits of sensitivity for the quantification of each substance were:~Ketamine: 0.25 ng Norketamine: 0.25 ng Dehydronorketamine: 0.1 ng Hydroxynorketamine: 0.25 ng" (NCT04285684)
Timeframe: 3, 6, 9, and 12 hour collections
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| 3 Hours | 6 Hours | 9 Hours | 12 Hours | |
| Ketamine During Lactation | 92.7 | 62.4 | 37.3 | 32.3 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. The primary outcome for the initial phase of the trial was the 24-h MADRS score, which included all 10 MADRS items. (NCT00419003)
Timeframe: 24 Hours
| Intervention | scores on a scale (Mean) |
|---|---|
| Riluzole Group | 24.4 |
| Placebo | 22.0 |
Patients will be assessed with HAMD-28 weekly for the first 8 weeks, then every two weeks for another 8 weeks. Participants were considered as responders if there was a ⩾50% improvement on the HAM-D28. (NCT01582945)
Timeframe: Weekly for total duration of 4 months
| Intervention | participants who met response criteria (Number) |
|---|---|
| Ketamine IV | 5 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -29.4 |
| Remission | -50.7 |
| Non-Remission | -14.3 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -50.3 |
| Remission | -83.6 |
| Non-Remission | -26.5 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (negative thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -37.0 |
| Remission | -65.4 |
| Non-Remission | -16.7 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -40.2 |
| Remission | -84.3 |
| Non-Remission | -8.9 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (neurovegetative symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -36.0 |
| Remission | -84.3 |
| Non-Remission | -8.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -26.7 |
| Remission | -50.0 |
| Non-Remission | -7.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -41.5 |
| Remission | -79.1 |
| Non-Remission | -14.5 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 5.6 | 3.9 |
| Non-Remission | 5.7 | 4.9 |
| Remission | 5.4 | 2.6 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 7.4 | 3.5 |
| Non-Remission | 7.4 | 5.1 |
| Remission | 7.4 | 1.2 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (Negative Thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.0 | 3.4 |
| Non-Remission | 5.9 | 4.6 |
| Remission | 6.2 | 1.8 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (Detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 9.5 | 4.9 |
| Non-Remission | 9.3 | 7.4 |
| Remission | 9.8 | 1.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (Neurovegetative Symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.5 | 3.8 |
| Non-Remission | 6.9 | 5.9 |
| Remission | 6.0 | 1.0 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 2.9 | 1.7 |
| Non-Remission | 2.7 | 2.2 |
| Remission | 3.2 | 1.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 29.4 | 15.9 |
| Non-Remission | 29.4 | 23.4 |
| Remission | 29.4 | 5.4 |
BECK Scale for Suicidal Ideation (BSS) - 0-13 Minimal; 14-19 Mild; 20-28 Moderate; 29-63 Severe (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | 4.94 |
| Ketamine and Placebo | 2.69 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | 3.83 |
| Ketamine and Placebo | 3.875 |
Columbia Suicide Severity Rating Scale (CSSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation). (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | .833 |
| Ketamine and Placebo | .44 |
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | 13.5 |
| Ketamine and Placebo | 11.13 |
The Montgomery Asberg Depression Rating Scale (MADRS-S) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | 22.56 |
| Ketamine and Placebo | 23 |
Number of Participants with PRISE (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine and Lithium | 3 |
| Ketamine and Placebo | 2 |
Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 (no depression) to 3 (severe depression), for a total score range of 0 (no depression) to 27 (severe depression). (NCT01880593)
Timeframe: 2 weeks after last ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine and Lithium | 9.89 |
| Ketamine and Placebo | 10.13 |
118 reviews available for ketamine and Refractory Depression
| Article | Year |
|---|---|
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2021 |
Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.
Topics: Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Second-Generation; Buspirone; Central | 2021 |
[Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamin | 2021 |
[The role of ketamine in the treatment of treatment-resistant bipolar depression].
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Drug- | 2021 |
[Electroconvulsive therapy in treatment resistant depression: What is new?]
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; | 2021 |
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Meta-Analysi | 2022 |
The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.
Topics: Anhedonia; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Motivation; Reward | 2022 |
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Long-term safety of ketamine and esketamine in treatment of depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2022 |
A review of potential neuropathological changes associated with ketamine.
Topics: Adult; Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Excitat | 2022 |
The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
The abuse liability of ketamine: A scoping review of preclinical and clinical studies.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2022 |
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treat | 2022 |
Guanosine as a promising target for fast-acting antidepressant responses.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Glutamic Acid; Guanosin | 2022 |
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment | 2022 |
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Treatment-Resistant; Hallucinoge | 2023 |
Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Active mechanisms of ketamine-assisted psychotherapy: A systematic review.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Psychotherapy; Receptors, N-Methy | 2022 |
Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
[Use of ketamine in psychiatry: an update].
Topics: Administration, Intravenous; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans | 2022 |
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis.
Topics: Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resistant; Electroconv | 2022 |
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; | 2022 |
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Letter to the editor about "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis".
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.
Topics: Anhedonia; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2023 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder | 2023 |
Pharmacotherapy: Ketamine and Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
Role of Psychedelics in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2023 |
Treatment-Resistant Late-Life Depression: A Review of Clinical Features, Neuropsychology, Neurobiology, and Treatment.
Topics: Aged; Alzheimer Disease; Anxiety; Depressive Disorder, Treatment-Resistant; Diagnosis, Differential; | 2023 |
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2024 |
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Tr | 2024 |
Role of copper and ketamine in major depressive disorder - an update.
Topics: Antidepressive Agents; Copper; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cardiovascular System; Depression; Depressive Disord | 2019 |
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Dis | 2020 |
Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Suicidal Ideation | 2020 |
Esketamine: a glimmer of hope in treatment-resistant depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant | 2021 |
Esketamine: a glimmer of hope in treatment-resistant depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant | 2021 |
Esketamine: a glimmer of hope in treatment-resistant depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant | 2021 |
Esketamine: a glimmer of hope in treatment-resistant depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant | 2021 |
Esketamine: A Novel Option for Treatment-Resistant Depression.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Blood Pressure; Depr | 2020 |
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
Topics: Animals; Antidepressive Agents; Biomarkers; Depressive Disorder, Treatment-Resistant; Gamma Rhythm; | 2020 |
Ketamine: The final frontier or another depressing end?
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamin | 2020 |
Ketamine: Leading us into the future for development of antidepressants.
Topics: Allosteric Regulation; Animals; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2020 |
A historical review of antidepressant effects of ketamine and its enantiomers.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2020 |
Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Topics: Administration, Intravenous; Administration, Oral; Antidepressive Agents; Bipolar Disorder; Comorbid | 2020 |
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder, | 2020 |
Esketamine (Spravato) for Treatment-Resistant Depression.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treatment Outcome | 2020 |
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Topics: Adolescent; Adult; Antidepressive Agents; Bipolar Disorder; Child; Depressive Disorder, Treatment-Re | 2021 |
Are we repeating mistakes of the past? A review of the evidence for esketamine.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Suicide | 2021 |
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2020 |
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
Topics: Administration, Intranasal; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; | 2020 |
Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; K | 2020 |
Intranasal esketamine: A novel drug for treatment-resistant depression.
Topics: Administration, Intranasal; Administration, Oral; Antidepressive Agents; Depressive Disorder, Treatm | 2020 |
The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Ketam | 2020 |
Increased use of ketamine for the treatment of depression: Benefits and concerns.
Topics: Antidepressive Agents; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2021 |
Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2020 |
[Ketamine as an anesthetic, analgesic and anti-depressant].
Topics: Analgesics; Anesthetics; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ke | 2020 |
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine | 2020 |
Ketamine: A tale of two enantiomers.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Intern | 2021 |
The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
Esketamine for treatment-resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive | 2020 |
Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; | 2021 |
[Psychiatry].
Topics: COVID-19; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Neurofeedback; Pandemics; Psyc | 2021 |
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disor | 2021 |
Ketamine for depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2021 |
Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-R | 2021 |
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Recep | 2022 |
Perspectives for therapy of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Ketamine | 2022 |
[ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT].
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2021 |
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Topics: Allosteric Regulation; Animals; Anxiety Disorders; Brain; Depressive Disorder, Major; Depressive Dis | 2021 |
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatm | 2021 |
Is ketamine effective and safe for treatment-resistant depression?
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depression; Depressi | 2021 |
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Off-L | 2017 |
Ketamine for Depression, 3: Does Chirality Matter?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Stereois | 2017 |
Side-effects associated with ketamine use in depression: a systematic review.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Res | 2018 |
Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treatment O | 2017 |
New medications for treatment-resistant depression: a brief review of recent developments.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Oligopeptides; Tr | 2017 |
Treatment-resistant depression and suicidality.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Deep Brain Stimulation; Depressive Disorder, Tr | 2018 |
Ketamine and electroconvulsive therapy: so happy together?
Topics: Anesthesia; Anesthetics, Dissociative; Combined Modality Therapy; Depressive Disorder, Treatment-Res | 2018 |
Emerging evidence for antidepressant actions of anesthetic agents.
Topics: Anesthesiologists; Anesthetics; Antidepressive Agents; Cerebral Cortex; Depressive Disorder, Treatme | 2018 |
Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2018 |
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; | 2019 |
Esketamine for treatment resistant depression.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2019 |
Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review.
Topics: Adult; Antidepressive Agents; Biomarkers; C-Reactive Protein; Depressive Disorder, Treatment-Resista | 2019 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
[Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Treatment-Resistant; Elongation Factor 2 | 2014 |
[Ketamine's antidepressant effect: literature review on clinical use].
Topics: Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Huma | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2015 |
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2015 |
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.
Topics: Administration, Intranasal; Animals; Cerebral Cortex; Depressive Disorder, Treatment-Resistant; Exci | 2016 |
The promise of ketamine for treatment-resistant depression: current evidence and future directions.
Topics: Anhedonia; Antidepressive Agents; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatm | 2015 |
[Ketamine--a new treatment option for therapy-resistant depression].
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Resistance; Excitatory Amino A | 2015 |
Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.
Topics: Administration, Intranasal; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mental Disor | 2015 |
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Re | 2016 |
Treatment-resistant depression: are animal models of depression fit for purpose?
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Disea | 2015 |
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.
Topics: Adult; Cognition; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Human | 2016 |
NMDA antagonist treatment of depression.
Topics: Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resi | 2016 |
Oral ketamine for the treatment of pain and treatment-resistant depression†.
Topics: Administration, Oral; Analgesics; Antidepressive Agents; Chronic Pain; Depressive Disorder, Treatmen | 2016 |
The use of ketamine in electroconvulsive therapy.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroc | 2015 |
The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Enzyme Inhibitors; Glycogen Synthas | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
Ketamine for treatment-resistant depression: recent developments and clinical applications.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2016 |
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2016 |
[Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Gene Ex | 2017 |
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Topics: Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Evide | 2017 |
Intravenous ketamine for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Tr | 2012 |
Ketamine as a novel antidepressant: from synapse to behavior.
Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depressive Disorder, Treatment-Resi | 2012 |
Ketamine for treatment-resistant unipolar depression: current evidence.
Topics: Antidepressive Agents; Cognition; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Dru | 2012 |
Ketamine as an alternative treatment for treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Depressive Disorder, Tre | 2013 |
135 trials available for ketamine and Refractory Depression
| Article | Year |
|---|---|
Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine.
Topics: Case-Control Studies; Cytokines; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketam | 2021 |
Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Memory, Short-Term; Treatmen | 2022 |
Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2021 |
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.
Topics: Bayes Theorem; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hu | 2022 |
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Topics: Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ket | 2023 |
Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
Topics: Adult; Analgesics; Anesthetics, Intravenous; Brain Waves; Cross-Over Studies; Depressive Disorder, T | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Comb | 2022 |
Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depre | 2022 |
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blin | 2022 |
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; | 2022 |
Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2022 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; H | 2023 |
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinations; Humans; Ketamine; P | 2023 |
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinations; Humans; Ketamine; P | 2023 |
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinations; Humans; Ketamine; P | 2023 |
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinations; Humans; Ketamine; P | 2023 |
Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Hu | 2023 |
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Depressive | 2023 |
Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Topics: Borderline Personality Disorder; Canada; Depression; Depressive Disorder, Treatment-Resistant; Human | 2023 |
A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusion | 2023 |
Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine; Retr | 2023 |
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Topics: Antidepressive Agents; Biomarkers; Depression; Depressive Disorder, Treatment-Resistant; Electroence | 2023 |
Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dorsolateral Prefrontal Cortex; Dou | 2023 |
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Topics: Administration, Intravenous; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2023 |
Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treat | 2023 |
Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Matri | 2023 |
Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Topics: Antidepressive Agents; Delayed-Action Preparations; Depression; Depressive Disorder, Treatment-Resis | 2023 |
Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.
Topics: Adolescent; Adult; Antidepressive Agents; Australia; Depressive Disorder, Major; Depressive Disorder | 2023 |
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cycloserine; Depressive Disorder, Major; Depressive | 2019 |
Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, | 2019 |
Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Topics: Adolescent; Adult; Aged; Brain; Circadian Rhythm; Depressive Disorder, Major; Depressive Disorder, T | 2019 |
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disord | 2020 |
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disord | 2020 |
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disord | 2020 |
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disord | 2020 |
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Dru | 2020 |
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
Topics: Administration, Oral; Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Majo | 2019 |
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2020 |
Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients.
Topics: Antidepressive Agents; Cognition; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therap | 2020 |
Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2021 |
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Clinical Tri | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Co | 2020 |
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Doub | 2020 |
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Doub | 2020 |
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Doub | 2020 |
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Doub | 2020 |
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Hu | 2020 |
Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketam | 2020 |
The effects of ketamine on typical and atypical depressive symptoms.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Functional Dysconnectivity of Frontal Cortex to Striatum Predicts Ketamine Infusion Response in Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Connectome; Corpus Striatum; Depressive Disorder, Treatment-Resistant; | 2020 |
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Ma | 2020 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment | 2021 |
Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
Topics: Antidepressive Agents; Cognition; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Hum | 2020 |
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Emotion | 2021 |
Happiness During Low-Dose Ketamine Infusion Predicts Treatment Response: Reexploring the Adjunctive Ketamine Study of Taiwanese Patients With Treatment-Resistant Depression.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Female; Follow-U | 2020 |
Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials.
Topics: Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intrave | 2021 |
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cerebral Cortex; Connectome; Depressive D | 2021 |
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resi | 2021 |
A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
Topics: Anesthetics; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dissociative Diso | 2021 |
Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Rel | 2021 |
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Topics: Adolescent; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disord | 2021 |
Effects of treatment refractoriness and brain-derived neurotrophic factor Val66Met polymorphism on antidepressant response to low-dose ketamine infusion.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resistant; | 2021 |
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
Topics: Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Infusions, Intravenous; Ketam | 2021 |
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2021 |
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Topics: Adult; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Ther | 2021 |
The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzodiazepines; Depressive Disorder, Treatment-Resi | 2017 |
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cognition; Cognitive Behavioral Therapy; | 2017 |
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Asian People; Blood Pressure; Brain-Derived Neurotrophic Factor; Depre | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Topics: Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Admini | 2017 |
Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.
Topics: Adult; Antidepressive Agents; Brain; Depressive Disorder, Treatment-Resistant; Female; Gyrus Cinguli | 2018 |
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
Topics: Adolescent; Adult; Aged; Amygdala; Antidepressive Agents; Atrophy; Brain-Derived Neurotrophic Factor | 2017 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2018 |
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depersonalization; Depressive Diso | 2018 |
Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Analgesics; Antidepressive Agents; D | 2018 |
Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Synergism; Excitatory A | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
7T
Topics: Adult; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; Depressive Diso | 2018 |
Ketamine Anesthesia Does Not Improve Depression Scores in Electroconvulsive Therapy: A Randomized Clinical Trial.
Topics: Adult; Anesthesia; Anesthetics, Dissociative; Anesthetics, Intravenous; Brain-Derived Neurotrophic F | 2018 |
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Treatment-Re | 2018 |
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Topics: Adult; Amino Acids, Essential; Antidepressive Agents; Biogenic Amines; Carnitine; Cross-Over Studies | 2018 |
Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, | 2018 |
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-B | 2018 |
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.
Topics: Anesthetics, Dissociative; Brazil; Depression; Depressive Disorder, Treatment-Resistant; Female; Hum | 2018 |
Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
Topics: Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Administration Schedule; Excitat | 2019 |
Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Di | 2018 |
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Disentangling the association of depression on the anti-fatigue effects of ketamine.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, T | 2019 |
Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2018 |
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
Topics: Adult; Aged; Antidepressive Agents; Cognition; Depressive Disorder, Treatment-Resistant; Electroconv | 2019 |
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Topics: Adult; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Hu | 2019 |
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Topics: Antidepressive Agents; Anxiety; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2019 |
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.
Topics: Adult; Anesthetics; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Me | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Topics: Adult; Ambulatory Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double | 2019 |
Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
Topics: Adult; Antidepressive Agents; Asian People; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressi | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, | 2019 |
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Antidepressive Agents; Citalopr | 2019 |
Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Anesthesia; Anesthesia Recovery Period; Anest | 2013 |
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Treatment-Resistant; Female | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Repeated S-ketamine infusions in therapy resistant depression: a case series.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, In | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
Topics: Adult; Aged; Animals; Antidepressive Agents; Brain; Cross-Over Studies; Depressive Disorder, Major; | 2014 |
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
Topics: Adult; Analgesics; Anti-Anxiety Agents; Cognition; Depressive Disorder, Treatment-Resistant; Double- | 2014 |
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.
Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Bipolar Disorder; Cross-Over Studies; Dep | 2014 |
Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Topics: Adult; Affect; Antidepressive Agents; Brain; Depressive Disorder, Treatment-Resistant; Drug Administ | 2014 |
Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.
Topics: Adult; Aged; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Dose-Response Relationshi | 2014 |
Clinical predictors of ketamine response in treatment-resistant major depression.
Topics: Adult; Bipolar Disorder; Body Mass Index; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Biomarkers; Chromatography, Liquid; Depressive Disorder, Treatment-Res | 2015 |
Hippocampal volume and the rapid antidepressant effect of ketamine.
Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Depressive Disorder, Treatment | 2015 |
Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Excitatory Amino | 2014 |
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Depressive Disord | 2015 |
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Antidepressive Agents; Depressive Disorder, Majo | 2014 |
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2015 |
Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
Topics: Adult; Bipolar Disorder; Cycloserine; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combin | 2015 |
Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Depressive Disorder, Treatment-R | 2015 |
Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).
Topics: Adolescent; Adult; Aged; Cognition; Cognition Disorders; Combined Modality Therapy; Depressive Disor | 2015 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind | 2016 |
The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Topics: Adult; Amygdala; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-R | 2016 |
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Topics: Adult; Antidepressive Agents; Clonidine; Depressive Disorder, Treatment-Resistant; Double-Blind Meth | 2016 |
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Topics: Adult; Antidepressive Agents; Clonidine; Depressive Disorder, Treatment-Resistant; Double-Blind Meth | 2016 |
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Topics: Adult; Antidepressive Agents; Clonidine; Depressive Disorder, Treatment-Resistant; Double-Blind Meth | 2016 |
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Topics: Adult; Antidepressive Agents; Clonidine; Depressive Disorder, Treatment-Resistant; Double-Blind Meth | 2016 |
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Topics: Adolescent; Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Doubl | 2016 |
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression.
Topics: Adolescent; Adult; Affect; Aged; Anesthetics, Intravenous; Cognition Disorders; Combined Modality Th | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Biomarkers; Bipolar Disorder; Cytokines; Depressive Disorder, Major; D | 2017 |
Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial.
Topics: Administration, Intranasal; Adolescent; Adult; Affect; Antidepressive Agents; Depressive Disorder, T | 2017 |
Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatm | 2017 |
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cerebral Cortex; Depressive Disor | 2012 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2013 |
286 other studies available for ketamine and Refractory Depression
| Article | Year |
|---|---|
Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hum | 2021 |
Ketamine and depression: An old drug in search of a clinical indication.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pharm | 2021 |
Ketamine for treatment-resistant bipolar depression-need for more data!
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Infusions | 2021 |
Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2022 |
Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital.
Topics: Administration, Intravenous; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; D | 2021 |
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Depre | 2021 |
Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Regis | 2022 |
The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
Topics: Adult; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2021 |
Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia.
Topics: Analgesics, Opioid; Animals; Anti-Anxiety Agents; Antidepressive Agents; Buprenorphine; Depressive D | 2022 |
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
Topics: Adult; Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Elect | 2021 |
Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depres | 2021 |
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Recommendations for the Usage of Ketamine and Esketamine.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Mechanisms of Action of Ketamine and Esketamine.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
Topics: Adult; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Infusio | 2022 |
Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketami | 2022 |
Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Follow-Up Studies; Humans; Infusions, In | 2022 |
Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine | 2022 |
[Ketamine self-medication in a patient with autism spectrum disorder and comorbid treatment-resistant depression].
Topics: Autism Spectrum Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Res | 2021 |
Ketamine and Cognitive Function in Depression: Detrimental, Neutral, or Advantageous?
Topics: Cognition; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
[Ketamine infusion therapy in treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2021 |
How to deprescribe esketamine in resistant depression? A point of view after first clinical uses.
Topics: Deprescriptions; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ket | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatme | 2022 |
Esketamine: uncertain safety and efficacy data in depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depr | 2022 |
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees.
Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depression; Depressive Disorder, | 2022 |
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood | 2022 |
Antidepressant effect of prolonged twice-weekly intranasal esketamine treatments after nonresponse to electroconvulsive therapy in a patient with treatment-resistant depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2022 |
The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamin | 2022 |
Can ketamine be a safe option for treatment-resistant bipolar depression?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2022 |
Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ket | 2022 |
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug-Re | 2022 |
Prospective association of psychological pain and hopelessness with suicidal thoughts.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pain; Suicid | 2022 |
Intranasal esketamine for depression: Not so special K.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression.
Topics: Biological Availability; Depressive Disorder, Treatment-Resistant; Heart Rate; Humans; Iatrogenic Di | 2022 |
Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2022 |
Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot | 2022 |
Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
Topics: Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methy | 2022 |
Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Topics: Cognition; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2022 |
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dep | 2022 |
Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depression; Depressive | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; | 2022 |
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Bias; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
Functional connectivity differences in the amygdala are related to the antidepressant efficacy of ketamine in patients with anxious depression.
Topics: Amygdala; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infus | 2023 |
Pros and cons of esketamine treatment in psychiatry.
Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Psychiatry | 2022 |
Replication of distinct trajectories of antidepressant response to intravenous ketamine.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
Topics: Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; P | 2023 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Dis | 2023 |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2023 |
Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression.
Topics: Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2023 |
Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression.
Topics: Adult; Brain; Depressive Disorder, Treatment-Resistant; Diffusion Tensor Imaging; Female; Humans; Ke | 2023 |
Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double- | 2023 |
Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression.
Topics: Adiponectin; Antidepressive Agents; Cytokines; Depression; Depressive Disorder, Treatment-Resistant; | 2023 |
The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia.
Topics: Australia; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Models of Affective Illness: Chronic Mild Stress in the Rat.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2023 |
Ketamine for Treatment-Resistant bipolar depression-A reality check!
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Human | 2023 |
Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression: A Patient With Lifelong Self-Doubt and Self-Criticism.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Male; | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disord | 2023 |
Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression.
Topics: Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2023 |
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Topics: Adolescent; Adult; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intraven | 2023 |
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Patie | 2023 |
Giovanni Martinotti: Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine and bipolar × unipolar treatment resistant depression.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intr | 2023 |
Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report.
Topics: Benzodiazepines; Cohort Studies; Deprescriptions; Depression; Depressive Disorder, Treatment-Resista | 2023 |
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Topics: Adolescent; Adult; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Treatment-R | 2023 |
Ketamine versus electroconvulsive therapy for treatment-resistant depression: An updated meta-analysis of randomized clinical trials.
Topics: Anesthetics, Dissociative; Depression; Depressive Disorder, Treatment-Resistant; Electroconvulsive T | 2023 |
Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Halluci | 2023 |
Esketamine for resistant depression in older people with cognitive impairment: A case report.
Topics: Aged; Antidepressive Agents; Cognitive Dysfunction; Depression; Depressive Disorder, Treatment-Resis | 2023 |
Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.
Topics: Bridge Therapy; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression.
Topics: Adolescent; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Transcranial Mag | 2023 |
Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Queti | 2023 |
Ketamine versus electroconvulsive therapy for major depressive disorder: A deeper dive into the data.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Hum | 2024 |
Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine?
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive | 2023 |
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Infusions, | 2024 |
Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Female; Humans; | 2019 |
Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Female; Humans; Inf | 2019 |
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
Topics: Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-B | 2019 |
Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Sy | 2020 |
Association between depression subtypes and response to repeated-dose intravenous ketamine.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2019 |
The immunomodulatory effect of ketamine in depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Suicidality in treatment resistant depression: perspective for ketamine use.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2019 |
Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.
Topics: Central Nervous System; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2019 |
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.
Topics: Adult; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusio | 2020 |
[Off-label ketamine treatment for treatment-resistant depression: win-win?]
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Off-L | 2019 |
The NEO-FFI domain of openness to experience moderates ketamine response in treatment resistant depression.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Extraversion, Psychological; Female; Humans; Infusi | 2020 |
Comment on a Word to the Wise About Intranasal Esketamine.
Topics: Administration, Intranasal; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2019 |
More Thoughts on Intranasal Esketamine: Response to Drevets et al.
Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2019 |
Ketamine for chronic depression: two cautionary tales
Topics: Adult; Chronic Disease; Depressive Disorder, Treatment-Resistant; Duration of Therapy; Excitatory Am | 2019 |
Ketamine and Treatment-Resistant Depression.
Topics: Anesthetics, Dissociative; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; | 2019 |
US Food and Drug Administration approval of esketamine and brexanolone.
Topics: Antidepressive Agents; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Treatment-Re | 2019 |
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.
Topics: Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treatment Outc | 2019 |
Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug The | 2020 |
The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
Topics: Adult; Bipolar Disorder; Body Mass Index; Clinical Trials as Topic; Depressive Disorder, Treatment-R | 2019 |
The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2020 |
[How we see the development of clinical trials from the investigators' side?]
Topics: Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; | 2019 |
Treatment-Resistant Depression and Ketamine Response in a Patient With Bilateral Amygdala Damage.
Topics: Adult; Amygdala; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Am | 2019 |
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2020 |
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Drug Approval; E | 2019 |
The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Affect; Aged; Antidepressive Agents; Compar | 2020 |
Dissociating the Clinical Role and Economic Value of Intranasal Esketamine.
Topics: Administration, Intranasal; Aerosols; Affect; Antidepressive Agents; Cost-Benefit Analysis; Depressi | 2020 |
Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy.
Topics: Adult; Anesthetics, Dissociative; Anesthetics, Intravenous; Antidepressive Agents; Combined Modality | 2020 |
Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Clini | 2020 |
Drs Rosenblat and McIntyre Reply.
Topics: Administration, Oral; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketam | 2020 |
Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?
Topics: Anesthetics, Dissociative; Antidepressive Agents; Biological Availability; Depressive Disorder, Trea | 2020 |
All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment.
Topics: Administration, Intranasal; Adult; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid A | 2020 |
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change.
Topics: Alcoholism; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Midazolam; Pilot Projects | 2020 |
Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder.
Topics: Adult; Affect; Anhedonia; Apathy; Brain Mapping; Cerebrovascular Circulation; Depressive Disorder, M | 2020 |
Approval of esketamine for treatment-resistant depression.
Topics: beta-Cyclodextrins; Depression; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; | 2020 |
Approval of esketamine for treatment-resistant depression - Authors' reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Approval of esketamine for treatment-resistant depression - Author's reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Pregnancy; Suicide, | 2020 |
Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression.
Topics: Adult; Anesthetics, Intravenous; Antidepressive Agents; Brain; Combined Modality Therapy; Depressive | 2020 |
A New Rapid-Acting Antidepressant.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Approval; GABAergic Neurons; H | 2020 |
(2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?
Topics: Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Major; Depressive Disorder, Treatmen | 2020 |
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui.
Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Esketamine clinical trials: reply to Maju
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug and Narcotic Control; Drug App | 2020 |
Esketamine Nasal Spray for Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Ma | 2020 |
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Transient Dose-dependent Effects of Ketamine on Neural Oscillatory Activity in Wistar-Kyoto Rats.
Topics: Animals; Depressive Disorder, Treatment-Resistant; Ketamine; Nucleus Accumbens; Rats; Rats, Inbred W | 2020 |
Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Female; Humans; Inf | 2021 |
Response to a recently published systematic review on intranasal esketamine for major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double- | 2020 |
"Remote Monitoring of Intranasal Ketamine Self-Administration as Maintenance Therapy in Treatment-Resistant Depression (TRD): A Novel Strategy for Vulnerable and At-Risk Populations to COVID-19?"
Topics: Administration, Intranasal; Betacoronavirus; Coronavirus Infections; COVID-19; Depressive Disorder, | 2020 |
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2020 |
Long-term treatment of depression with intranasal esketamine: Is it justified?
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Blood Pressure; Cohort Studies; Depressive Disorder, Treatment-Resista | 2020 |
Three Months of Treatment With Esketamine: Effects on Depression, Insomnia, and Weight.
Topics: Administration, Intranasal; Antidepressive Agents; Body Weight; Depressive Disorder, Treatment-Resis | 2020 |
A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Infusions | 2020 |
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Bipolar Disorder; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies - Authors' reply.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; K | 2020 |
Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2020 |
Short - Term Ketamine Administration in Treatment - Resistant Depression: Focus on Cardiovascular Safety.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Metho | 2020 |
Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hippoca | 2020 |
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fem | 2021 |
A new indication for esketamine nasal spray (Spravato).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; | 2020 |
No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, I | 2021 |
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Administration, Intravenous; Adult; Anxiety; Anxiety Disorders; Bipolar Disorder; Canada; Depressive | 2021 |
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer's disease.
Topics: Alzheimer Disease; Depressive Disorder, Treatment-Resistant; Humans; Injections, Subcutaneous; Ketam | 2021 |
Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Topics: Copper; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ke | 2020 |
Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Body Mass Index; Canada; Depressive Disorder, Major; | 2022 |
Esketamine for Postpartum Suicidality.
Topics: Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Postpartum Period; Suicide | 2021 |
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
Topics: Adult; Anhedonia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2022 |
Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot Projects; W | 2020 |
Combination of Electroconvulsive Therapy Alternating With Intravenous Esketamine Can Lead to Rapid Remission of Treatment Resistant Depression.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; | 2021 |
Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Topics: Adult; Analgesics; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
Topics: Antidepressive Agents; Buprenorphine; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Su | 2021 |
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disord | 2021 |
At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.
Topics: Antidepressive Agents; Cost of Illness; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2021 |
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Huma | 2021 |
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Clonidine; Depressive Disorder, Treatment-Resistant; | 2021 |
Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clozapine; D | 2021 |
Ketamine for Depression in Older Adults.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Comments to Drs. Bahji, Vazquez, and Zarate.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
Letter to the editor - Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; | 2021 |
Compounded intranasal racemic ketamine for major depressive disorder: A case report.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, | 2021 |
Distinct trajectories of antidepressant response to intravenous ketamine.
Topics: Adult; Antidepressive Agents; Child; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
The Future of Ketamine in the Treatment of Teen Depression.
Topics: Adolescent; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ket | 2021 |
Letter to the editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of lightness are not the same - A comment on Acevedo-Diaz et al.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2021 |
The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2021 |
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Ketamine; Mice | 2021 |
A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration.
Topics: Depression; Depressive Disorder, Treatment-Resistant; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus | 2021 |
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment | 2021 |
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
Topics: Adult; Bipolar Disorder; Canada; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatme | 2021 |
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitatory Amino A | 2021 |
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Resting-State Functional Magnetic Resonance Imaging Reveals Neuroplasticity After Repeated Treatment With Ketamine in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Magnetic Resonance Imaging; | 2021 |
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Topics: Adult; COVID-19; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; H | 2021 |
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hum | 2021 |
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Topics: Administration, Intravenous; Adult; Aged; Antidepressive Agents; Blood Pressure; Cohort Studies; Dep | 2021 |
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Human | 2021 |
A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Hum | 2021 |
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?
Topics: Demography; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?
Topics: Demography; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Infant; Infant, Newbo | 2021 |
Ketamine treatment for depression: A model of care.
Topics: Antidepressive Agents; Australia; Depression; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2021 |
Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anesthetics, Dissociative; Depressive Disorder | 2021 |
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.
Topics: Adult; Case-Control Studies; Chemokines; Cytokines; Depressive Disorder, Major; Depressive Disorder, | 2017 |
Ketamine and ECT: better alone than together?
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
S -ketamine compared to etomidate during electroconvulsive therapy in major depression.
Topics: Aged; Anesthetics, Intravenous; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2017 |
Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
Topics: Actigraphy; Adult; Affect; Aged; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressi | 2017 |
Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series.
Topics: Administration, Oral; Adult; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagon | 2017 |
Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.
Topics: Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Electroc | 2017 |
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Topics: Academic Medical Centers; Adult; Aged; Depressive Disorder, Major; Depressive Disorder, Treatment-Re | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine-ECT Study - Author's reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
Ketamine-ECT Study.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Electroconvulsive Therapy | 2017 |
What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?
Topics: Aged; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Keta | 2017 |
Role of Ketamine in Severe Depression with suicidal ideation - Insights from a Case Study.
Topics: Aged; Anesthetics, Dissociative; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2017 |
Ketamine Minus the Trip: New Hope for Treatment-Resistant Depression.
Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Off-Label Use; Receptors, N-Methyl-D-Asp | 2017 |
Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anesthetics, Dissociative; Antidepressive | 2018 |
Can we confidently use ketamine as a clinical treatment for depression?
Topics: Anesthetics, Dissociative; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Res | 2018 |
Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; | 2018 |
Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.
Topics: Adult; Antidepressive Agents; Biomarkers; Cytokines; Depressive Disorder, Treatment-Resistant; Elect | 2018 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Cross-Over Studies; Depression; Depressive Disor | 2019 |
Ketamine for Treatment-Resistant Depression: a New Advocate.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2018 |
Adjunctive Intranasal Esketamine in Treatment-Resistant Depression-Reply.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2018 |
Adjunctive Intranasal Esketamine in Treatment-Resistant Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resist | 2018 |
Maintenance Ketamine Therapy for Treatment-Resistant Depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketami | 2018 |
[In process].
Topics: Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Huma | 2016 |
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
Topics: Administration, Intravenous; Adolescent; Child; Depressive Disorder, Treatment-Resistant; Dose-Respo | 2018 |
Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Topics: Adult; Antidepressive Agents; Attention; Cognition; Depressive Disorder, Treatment-Resistant; Excita | 2018 |
Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink?
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, Intraven | 2018 |
Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Topics: Adult; Aged; Anhedonia; Antidepressive Agents; Databases, Factual; Depressive Disorder, Treatment-Re | 2018 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.
Topics: Administration, Intravenous; Analgesics; Antidepressive Agents; Depressive Disorder, Treatment-Resis | 2018 |
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met | 2020 |
Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus.
Topics: Animals; Antidepressive Agents; Corticosterone; Depressive Disorder, Treatment-Resistant; Disease Mo | 2019 |
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Topics: Adult; Anesthetics, Dissociative; Antidepressive Agents; Cross-Over Studies; Depressive Disorder, Ma | 2019 |
Ethical Reasoning in Prescribing and Monitoring Psychotropic Medications.
Topics: Advanced Practice Nursing; Depressive Disorder, Treatment-Resistant; Ethics, Nursing; Humans; Ketami | 2019 |
Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; | 2019 |
A response to: Repeated intranasal ketamine for treatment resistant depression: The way to go? Results from a pilot randomised controlled trial.
Topics: Analgesics; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot Projects | 2019 |
A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial.
Topics: Analgesics; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Pilot Projects | 2019 |
Promoting the Discussion of the Beneficial Effects of Ketamine to Treat Refractory Depression.
Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2019 |
Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
Topics: Adult; Aged; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Treatmen | 2019 |
Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Topics: Amygdala; Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, | 2019 |
Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder.
Topics: Administration, Intravenous; Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Depressiv | 2019 |
Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Europe; Humans; Ketamine; Off-Label | 2019 |
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive | 2019 |
Esketamine nasal spray (Spravato) for treatment-resistant depression.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Rec | 2019 |
Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depre | 2019 |
New Nasal Spray for Treatment-Resistant Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; | 2019 |
Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Topics: Administration, Intranasal; Anesthetics, Dissociative; Antidepressive Agents; Brain-Derived Neurotro | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Considerations for use of ketamine to treat depression in Australia and New Zealand.
Topics: Australia; Depression; Depressive Disorder, Treatment-Resistant; Drug and Narcotic Control; Excitato | 2019 |
Ketamine for the treatment of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2013 |
Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats.
Topics: Amino Acids; Animals; Corticosterone; Depressive Disorder, Treatment-Resistant; Disease Models, Anim | 2013 |
Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion.
Topics: Depressive Disorder, Treatment-Resistant; Drug Resistance; Humans; Infusions, Intravenous; Ketamine; | 2013 |
Mechanism of action of ketamine.
Topics: Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Humans; Ketamine; Recep | 2013 |
Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2013 |
Ketamine for treatment-resistant depression: ready or not for clinical use?
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2013 |
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relation | 2014 |
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relation | 2014 |
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relation | 2014 |
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dose-Response Relation | 2014 |
Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
Topics: Administration, Oral; Adult; Anesthetics, Dissociative; Antidepressive Agents; Chronic Disease; Depr | 2014 |
Treatment-refractory depression: a case of successful treatment with intranasal ketamine 10%.
Topics: Administration, Intranasal; Adult; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid A | 2014 |
Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.
Topics: Aged; Aging; Depressive Disorder, Treatment-Resistant; Female; Humans; Infusions, Intravenous; Ketam | 2014 |
A word to the wise about ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2014 |
Remission of treatment-resistant depression with electroconvulsive therapy and ketamine.
Topics: Aged; Anesthetics, Dissociative; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant | 2014 |
Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
Topics: Administration, Intravenous; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, T | 2014 |
Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Excitat | 2014 |
Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Topics: Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Depressive Disorder, | 2015 |
A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine's effectiveness in unipolar versus bipolar depression.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
What is hydroxynorketamine and what can it bring to neurotherapeutics?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Rats | 2014 |
Neural correlates of suicidal ideation and its reduction in depression.
Topics: Brain; Brain Mapping; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; | 2014 |
Reversal of non-suppression of cortisol levels in a patient with refractory depression receiving ketamine.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Hydrocortisone; Hypothalamo | 2015 |
The Effect of Repeated Ketamine Infusion Over Facial Emotion Recognition in Treatment-Resistant Depression: A Preliminary Report.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Treatment-Resistant; Emotions; Excitatory Amino Acid A | 2015 |
Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
Topics: Adult; Brain; Case-Control Studies; Caudate Nucleus; Depressive Disorder, Major; Depressive Disorder | 2015 |
Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.
Topics: Antidepressive Agents; Benzodiazepines; Clinical Trials as Topic; Depression; Depressive Disorder, T | 2015 |
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De | 2015 |
Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge.
Topics: Cycloserine; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male | 2015 |
Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Primary Health Ca | 2015 |
Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; D | 2015 |
Ketamine's potential as a rapid antidepressant was overplayed.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Prescription Drug | 2015 |
Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antidepressive Agents; Depressive Di | 2015 |
Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Ex | 2016 |
Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Synergism; Female; Huma | 2017 |
Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.
Topics: Alcohol-Related Disorders; Analgesics; Antidepressive Agents; Depressive Disorder, Major; Depressive | 2016 |
Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression.
Topics: Adult; Aged; Anesthesia; Anesthetics, Dissociative; Anesthetics, Intravenous; Cognition; Depressive | 2016 |
The role of adipokines in the rapid antidepressant effects of ketamine.
Topics: Adipokines; Adiponectin; Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; | 2017 |
Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose- | 2016 |
MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2016 |
New use for an old drug: oral ketamine for treatment-resistant depression.
Topics: Administration, Oral; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Excitatory Am | 2016 |
Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Topics: Adult; Arginine; Citrulline; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; E | 2016 |
Detrimental Side Effects of Repeated Ketamine Infusions in the Brain.
Topics: Brain; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Hu | 2016 |
Antidepressant Efficacy and Dosing Comparisons of Ketamine Enantiomers: Response to Hashimoto.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2016 |
Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depressive Disorder, Treatment-Re | 2017 |
Ketamine: Future Treatment For Unresponsive Depression?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ireland; Ketami | 2016 |
Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study.
Topics: Aged; Anesthetics, Dissociative; Anesthetics, Intravenous; Antihypertensive Agents; Cognition Disord | 2011 |
An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dextromethorphan; Dextrorphan; Huma | 2012 |
A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2013 |